#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Impact of schizophrenia on anterior and posterior hippocampus during memory for complex scenes
#Text=Objectives
#Text=Hippocampal dysfunction has been proposed as a mechanism for memory deficits in schizophrenia.
1-1	0-6	Impact	_	
1-2	7-9	of	_	
1-3	10-23	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-4	24-26	on	_	
1-5	27-35	anterior	_	
1-6	36-39	and	_	
1-7	40-49	posterior	_	
1-8	50-61	hippocampus	_	
1-9	62-68	during	_	
1-10	69-75	memory	_	
1-11	76-79	for	_	
1-12	80-87	complex	_	
1-13	88-94	scenes	_	
1-14	95-105	Objectives	_	
1-15	106-117	Hippocampal	_	
1-16	118-129	dysfunction	_	
1-17	130-133	has	_	
1-18	134-138	been	_	
1-19	139-147	proposed	_	
1-20	148-150	as	_	
1-21	151-152	a	_	
1-22	153-162	mechanism	_	
1-23	163-166	for	_	
1-24	167-173	memory	_	
1-25	174-182	deficits	_	
1-26	183-185	in	_	
1-27	186-199	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-28	199-200	.	_	

#Text=Available evidence suggests that the anterior and posterior hippocampus could be differentially affected.
2-1	201-210	Available	_	
2-2	211-219	evidence	_	
2-3	220-228	suggests	_	
2-4	229-233	that	_	
2-5	234-237	the	_	
2-6	238-246	anterior	_	
2-7	247-250	and	_	
2-8	251-260	posterior	_	
2-9	261-272	hippocampus	_	
2-10	273-278	could	_	
2-11	279-281	be	_	
2-12	282-296	differentially	_	
2-13	297-305	affected	_	
2-14	305-306	.	_	

#Text=Accordingly, we used fMRI to test the hypothesis that activity in posterior hippocampus is disproportionately reduced in schizophrenia, particularly during spatial memory retrieval.
3-1	307-318	Accordingly	_	
3-2	318-319	,	_	
3-3	320-322	we	_	
3-4	323-327	used	_	
3-5	328-332	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
3-6	333-335	to	_	
3-7	336-340	test	_	
3-8	341-344	the	_	
3-9	345-355	hypothesis	_	
3-10	356-360	that	_	
3-11	361-369	activity	_	
3-12	370-372	in	_	
3-13	373-382	posterior	_	
3-14	383-394	hippocampus	_	
3-15	395-397	is	_	
3-16	398-416	disproportionately	_	
3-17	417-424	reduced	_	
3-18	425-427	in	_	
3-19	428-441	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
3-20	441-442	,	_	
3-21	443-455	particularly	_	
3-22	456-462	during	_	
3-23	463-470	spatial	_	
3-24	471-477	memory	_	
3-25	478-487	retrieval	_	
3-26	487-488	.	_	

#Text=Methods
#Text=26 healthy participants and 24 patients with schizophrenia from the UC Davis Early Psychosis Program were studied while fMRI was acquired on a 3 Tesla Siemens scanner.
4-1	489-496	Methods	_	
4-2	497-499	26	_	
4-3	500-507	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
4-4	508-520	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
4-5	521-524	and	_	
4-6	525-527	24	_	
4-7	528-536	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
4-8	537-541	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
4-9	542-555	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]	
4-10	556-560	from	_	
4-11	561-564	the	_	
4-12	565-567	UC	_	
4-13	568-573	Davis	_	
4-14	574-579	Early	_	
4-15	580-589	Psychosis	_	
4-16	590-597	Program	_	
4-17	598-602	were	_	
4-18	603-610	studied	_	
4-19	611-616	while	_	
4-20	617-621	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
4-21	622-625	was	_	
4-22	626-634	acquired	_	
4-23	635-637	on	_	
4-24	638-639	a	_	
4-25	640-641	3	_	
4-26	642-647	Tesla	_	
4-27	648-655	Siemens	_	
4-28	656-663	scanner	_	
4-29	663-664	.	_	

#Text=During encoding, participants were oriented to critical items through questions about item features (e.g., “Does the lamp have a square shade?”)
5-1	665-671	During	_	
5-2	672-680	encoding	_	
5-3	680-681	,	_	
5-4	682-694	participants	_	
5-5	695-699	were	_	
5-6	700-708	oriented	_	
5-7	709-711	to	_	
5-8	712-720	critical	_	
5-9	721-726	items	_	
5-10	727-734	through	_	
5-11	735-744	questions	_	
5-12	745-750	about	_	
5-13	751-755	item	_	
5-14	756-764	features	_	
5-15	765-766	(	_	
5-16	766-769	e.g	_	
5-17	769-770	.	_	
5-18	770-771	,	_	
5-19	772-773	“	_	
5-20	773-777	Does	_	
5-21	778-781	the	_	
5-22	782-786	lamp	_	
5-23	787-791	have	_	
5-24	792-793	a	_	
5-25	794-800	square	_	
5-26	801-806	shade	_	
5-27	806-807	?	_	
5-28	807-808	”	_	
5-29	808-809	)	_	

#Text=or spatial location (e.g., “Is the lamp on the table next to the couch?”).
6-1	810-812	or	_	
6-2	813-820	spatial	_	
6-3	821-829	location	_	
6-4	830-831	(	_	
6-5	831-834	e.g	_	
6-6	834-835	.	_	
6-7	835-836	,	_	
6-8	837-838	“	_	
6-9	838-840	Is	_	
6-10	841-844	the	_	
6-11	845-849	lamp	_	
6-12	850-852	on	_	
6-13	853-856	the	_	
6-14	857-862	table	_	
6-15	863-867	next	_	
6-16	868-870	to	_	
6-17	871-874	the	_	
6-18	875-880	couch	_	
6-19	880-881	?	_	
6-20	881-882	”	_	
6-21	882-883	)	_	
6-22	883-884	.	_	

#Text=At test, participants determined whether scenes were changed or unchanged. fMRI analyses contrasted activation in a priori regions of interest (ROI) in anterior and posterior hippocampus during correct recognition of item changes and spatial changes.
7-1	885-887	At	_	
7-2	888-892	test	_	
7-3	892-893	,	_	
7-4	894-906	participants	_	
7-5	907-917	determined	_	
7-6	918-925	whether	_	
7-7	926-932	scenes	_	
7-8	933-937	were	_	
7-9	938-945	changed	_	
7-10	946-948	or	_	
7-11	949-958	unchanged	_	
7-12	958-959	.	_	
7-13	960-964	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
7-14	965-973	analyses	_	
7-15	974-984	contrasted	_	
7-16	985-995	activation	_	
7-17	996-998	in	_	
7-18	999-1000	a	_	
7-19	1001-1007	priori	_	
7-20	1008-1015	regions	_	
7-21	1016-1018	of	_	
7-22	1019-1027	interest	_	
7-23	1028-1029	(	_	
7-24	1029-1032	ROI	_	
7-25	1032-1033	)	_	
7-26	1034-1036	in	_	
7-27	1037-1045	anterior	_	
7-28	1046-1049	and	_	
7-29	1050-1059	posterior	_	
7-30	1060-1071	hippocampus	_	
7-31	1072-1078	during	_	
7-32	1079-1086	correct	_	
7-33	1087-1098	recognition	_	
7-34	1099-1101	of	_	
7-35	1102-1106	item	_	
7-36	1107-1114	changes	_	
7-37	1115-1118	and	_	
7-38	1119-1126	spatial	_	
7-39	1127-1134	changes	_	
7-40	1134-1135	.	_	

#Text=Results
#Text=As predicted, patients with schizophrenia exhibited reduced activation in the posterior hippocampus during detection of spatial changes but not during detection of item changes.
8-1	1136-1143	Results	_	
8-2	1144-1146	As	_	
8-3	1147-1156	predicted	_	
8-4	1156-1157	,	_	
8-5	1158-1166	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-6	1167-1171	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-7	1172-1185	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[3]	
8-8	1186-1195	exhibited	_	
8-9	1196-1203	reduced	_	
8-10	1204-1214	activation	_	
8-11	1215-1217	in	_	
8-12	1218-1221	the	_	
8-13	1222-1231	posterior	_	
8-14	1232-1243	hippocampus	_	
8-15	1244-1250	during	_	
8-16	1251-1260	detection	_	
8-17	1261-1263	of	_	
8-18	1264-1271	spatial	_	
8-19	1272-1279	changes	_	
8-20	1280-1283	but	_	
8-21	1284-1287	not	_	
8-22	1288-1294	during	_	
8-23	1295-1304	detection	_	
8-24	1305-1307	of	_	
8-25	1308-1312	item	_	
8-26	1313-1320	changes	_	
8-27	1320-1321	.	_	

#Text=Unexpectedly, patients exhibited increased activation of anterior hippocampus during detection of item changes.
9-1	1322-1334	Unexpectedly	_	
9-2	1334-1335	,	_	
9-3	1336-1344	patients	_	
9-4	1345-1354	exhibited	_	
9-5	1355-1364	increased	_	
9-6	1365-1375	activation	_	
9-7	1376-1378	of	_	
9-8	1379-1387	anterior	_	
9-9	1388-1399	hippocampus	_	
9-10	1400-1406	during	_	
9-11	1407-1416	detection	_	
9-12	1417-1419	of	_	
9-13	1420-1424	item	_	
9-14	1425-1432	changes	_	
9-15	1432-1433	.	_	

#Text=Whole brain analyses revealed reduced fronto-parietal and striatal activation in patients for spatial but not for item change trials.
10-1	1434-1439	Whole	_	
10-2	1440-1445	brain	_	
10-3	1446-1454	analyses	_	
10-4	1455-1463	revealed	_	
10-5	1464-1471	reduced	_	
10-6	1472-1487	fronto-parietal	_	
10-7	1488-1491	and	_	
10-8	1492-1500	striatal	_	
10-9	1501-1511	activation	_	
10-10	1512-1514	in	_	
10-11	1515-1523	patients	_	
10-12	1524-1527	for	_	
10-13	1528-1535	spatial	_	
10-14	1536-1539	but	_	
10-15	1540-1543	not	_	
10-16	1544-1547	for	_	
10-17	1548-1552	item	_	
10-18	1553-1559	change	_	
10-19	1560-1566	trials	_	
10-20	1566-1567	.	_	

#Text=Conclusions
#Text=Results suggest a gradient of hippocampal dysfunction in which posterior hippocampus – which is necessary for processing fine-grained spatial relationships – is underactive, and anterior hippocampus – which may process context more globally - is overactive.
11-1	1568-1579	Conclusions	_	
11-2	1580-1587	Results	_	
11-3	1588-1595	suggest	_	
11-4	1596-1597	a	_	
11-5	1598-1606	gradient	_	
11-6	1607-1609	of	_	
11-7	1610-1621	hippocampal	_	
11-8	1622-1633	dysfunction	_	
11-9	1634-1636	in	_	
11-10	1637-1642	which	_	
11-11	1643-1652	posterior	_	
11-12	1653-1664	hippocampus	_	
11-13	1665-1666	–	_	
11-14	1667-1672	which	_	
11-15	1673-1675	is	_	
11-16	1676-1685	necessary	_	
11-17	1686-1689	for	_	
11-18	1690-1700	processing	_	
11-19	1701-1713	fine-grained	_	
11-20	1714-1721	spatial	_	
11-21	1722-1735	relationships	_	
11-22	1736-1737	–	_	
11-23	1738-1740	is	_	
11-24	1741-1752	underactive	_	
11-25	1752-1753	,	_	
11-26	1754-1757	and	_	
11-27	1758-1766	anterior	_	
11-28	1767-1778	hippocampus	_	
11-29	1779-1780	–	_	
11-30	1781-1786	which	_	
11-31	1787-1790	may	_	
11-32	1791-1798	process	_	
11-33	1799-1806	context	_	
11-34	1807-1811	more	_	
11-35	1812-1820	globally	_	
11-36	1821-1822	-	_	
11-37	1823-1825	is	_	
11-38	1826-1836	overactive	_	
11-39	1836-1837	.	_	

#Text=Highlights
#Text=Patients with schizophrenia show impaired memory for spatial relationships amongst objects in scenes.
12-1	1838-1848	Highlights	_	
12-2	1849-1857	Patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
12-3	1858-1862	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
12-4	1863-1876	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
12-5	1877-1881	show	_	
12-6	1882-1890	impaired	_	
12-7	1891-1897	memory	_	
12-8	1898-1901	for	_	
12-9	1902-1909	spatial	_	
12-10	1910-1923	relationships	_	
12-11	1924-1931	amongst	_	
12-12	1932-1939	objects	_	
12-13	1940-1942	in	_	
12-14	1943-1949	scenes	_	
12-15	1949-1950	.	_	

#Text=Patients have less posterior hippocampal activation during spatial memory and more anterior hippocampal activation during item memory.
13-1	1951-1959	Patients	_	
13-2	1960-1964	have	_	
13-3	1965-1969	less	_	
13-4	1970-1979	posterior	_	
13-5	1980-1991	hippocampal	_	
13-6	1992-2002	activation	_	
13-7	2003-2009	during	_	
13-8	2010-2017	spatial	_	
13-9	2018-2024	memory	_	
13-10	2025-2028	and	_	
13-11	2029-2033	more	_	
13-12	2034-2042	anterior	_	
13-13	2043-2054	hippocampal	_	
13-14	2055-2065	activation	_	
13-15	2066-2072	during	_	
13-16	2073-2077	item	_	
13-17	2078-2084	memory	_	
13-18	2084-2085	.	_	

#Text=This gradient of hippocampal dysfunction in schizophrenia, suggests that it should not be examined as a unitary structure in future studies.
14-1	2086-2090	This	_	
14-2	2091-2099	gradient	_	
14-3	2100-2102	of	_	
14-4	2103-2114	hippocampal	_	
14-5	2115-2126	dysfunction	_	
14-6	2127-2129	in	_	
14-7	2130-2143	schizophrenia	_	
14-8	2143-2144	,	_	
14-9	2145-2153	suggests	_	
14-10	2154-2158	that	_	
14-11	2159-2161	it	_	
14-12	2162-2168	should	_	
14-13	2169-2172	not	_	
14-14	2173-2175	be	_	
14-15	2176-2184	examined	_	
14-16	2185-2187	as	_	
14-17	2188-2189	a	_	
14-18	2190-2197	unitary	_	
14-19	2198-2207	structure	_	
14-20	2208-2210	in	_	
14-21	2211-2217	future	_	
14-22	2218-2225	studies	_	
14-23	2225-2226	.	_	

#Text=Introduction
#Text=Episodic memory impairment is a core symptom of psychotic disorders such as schizophrenia, and this deficit is likely related to impaired hippocampal function.
15-1	2227-2239	Introduction	_	
15-2	2240-2248	Episodic	_	
15-3	2249-2255	memory	_	
15-4	2256-2266	impairment	_	
15-5	2267-2269	is	_	
15-6	2270-2271	a	_	
15-7	2272-2276	core	_	
15-8	2277-2284	symptom	_	
15-9	2285-2287	of	_	
15-10	2288-2297	psychotic	_	
15-11	2298-2307	disorders	_	
15-12	2308-2312	such	_	
15-13	2313-2315	as	_	
15-14	2316-2329	schizophrenia	_	
15-15	2329-2330	,	_	
15-16	2331-2334	and	_	
15-17	2335-2339	this	_	
15-18	2340-2347	deficit	_	
15-19	2348-2350	is	_	
15-20	2351-2357	likely	_	
15-21	2358-2365	related	_	
15-22	2366-2368	to	_	
15-23	2369-2377	impaired	_	
15-24	2378-2389	hippocampal	_	
15-25	2390-2398	function	_	
15-26	2398-2399	.	_	

#Text=Basic behavioral and cognitive neuroscience research reveals important functional differences across the longitudinal extent of the anterior and posterior hippocampus.
16-1	2400-2405	Basic	_	
16-2	2406-2416	behavioral	_	
16-3	2417-2420	and	_	
16-4	2421-2430	cognitive	_	
16-5	2431-2443	neuroscience	_	
16-6	2444-2452	research	_	
16-7	2453-2460	reveals	_	
16-8	2461-2470	important	_	
16-9	2471-2481	functional	_	
16-10	2482-2493	differences	_	
16-11	2494-2500	across	_	
16-12	2501-2504	the	_	
16-13	2505-2517	longitudinal	_	
16-14	2518-2524	extent	_	
16-15	2525-2527	of	_	
16-16	2528-2531	the	_	
16-17	2532-2540	anterior	_	
16-18	2541-2544	and	_	
16-19	2545-2554	posterior	_	
16-20	2555-2566	hippocampus	_	
16-21	2566-2567	.	_	

#Text=However, it is unclear whether the anterior and posterior hippocampus is differentially affected in schizophrenia.
17-1	2568-2575	However	_	
17-2	2575-2576	,	_	
17-3	2577-2579	it	_	
17-4	2580-2582	is	_	
17-5	2583-2590	unclear	_	
17-6	2591-2598	whether	_	
17-7	2599-2602	the	_	
17-8	2603-2611	anterior	_	
17-9	2612-2615	and	_	
17-10	2616-2625	posterior	_	
17-11	2626-2637	hippocampus	_	
17-12	2638-2640	is	_	
17-13	2641-2655	differentially	_	
17-14	2656-2664	affected	_	
17-15	2665-2667	in	_	
17-16	2668-2681	schizophrenia	_	
17-17	2681-2682	.	_	

#Text=Research in rodents demonstrates that the dorsal (corresponding to posterior in humans) and ventral hippocampus (corresponding to anterior in humans) differ in terms of anatomical connectivity and gene expression.
18-1	2683-2691	Research	_	
18-2	2692-2694	in	_	
18-3	2695-2702	rodents	_	
18-4	2703-2715	demonstrates	_	
18-5	2716-2720	that	_	
18-6	2721-2724	the	_	
18-7	2725-2731	dorsal	_	
18-8	2732-2733	(	_	
18-9	2733-2746	corresponding	_	
18-10	2747-2749	to	_	
18-11	2750-2759	posterior	_	
18-12	2760-2762	in	_	
18-13	2763-2769	humans	_	
18-14	2769-2770	)	_	
18-15	2771-2774	and	_	
18-16	2775-2782	ventral	_	
18-17	2783-2794	hippocampus	_	
18-18	2795-2796	(	_	
18-19	2796-2809	corresponding	_	
18-20	2810-2812	to	_	
18-21	2813-2821	anterior	_	
18-22	2822-2824	in	_	
18-23	2825-2831	humans	_	
18-24	2831-2832	)	_	
18-25	2833-2839	differ	_	
18-26	2840-2842	in	_	
18-27	2843-2848	terms	_	
18-28	2849-2851	of	_	
18-29	2852-2862	anatomical	_	
18-30	2863-2875	connectivity	_	
18-31	2876-2879	and	_	
18-32	2880-2884	gene	_	
18-33	2885-2895	expression	_	
18-34	2895-2896	.	_	

#Text=Furthermore, lesions to the dorsal hippocampus in rats impair performance on spatial memory tasks, whereas ventral hippocampal lesions often have no effect on spatial learning.
19-1	2897-2908	Furthermore	_	
19-2	2908-2909	,	_	
19-3	2910-2917	lesions	_	
19-4	2918-2920	to	_	
19-5	2921-2924	the	_	
19-6	2925-2931	dorsal	_	
19-7	2932-2943	hippocampus	_	
19-8	2944-2946	in	_	
19-9	2947-2951	rats	_	
19-10	2952-2958	impair	_	
19-11	2959-2970	performance	_	
19-12	2971-2973	on	_	
19-13	2974-2981	spatial	_	
19-14	2982-2988	memory	_	
19-15	2989-2994	tasks	_	
19-16	2994-2995	,	_	
19-17	2996-3003	whereas	_	
19-18	3004-3011	ventral	_	
19-19	3012-3023	hippocampal	_	
19-20	3024-3031	lesions	_	
19-21	3032-3037	often	_	
19-22	3038-3042	have	_	
19-23	3043-3045	no	_	
19-24	3046-3052	effect	_	
19-25	3053-3055	on	_	
19-26	3056-3063	spatial	_	
19-27	3064-3072	learning	_	
19-28	3072-3073	.	_	

#Text=Studies of place cells in rats complement lesion findings by suggesting that place cells in dorsal hippocampus exhibit specific place fields, whereas place cells in ventral hippocampus are often large, sometimes extending across an entire spatial context.
20-1	3074-3081	Studies	_	
20-2	3082-3084	of	_	
20-3	3085-3090	place	_	
20-4	3091-3096	cells	_	
20-5	3097-3099	in	_	
20-6	3100-3104	rats	_	
20-7	3105-3115	complement	_	
20-8	3116-3122	lesion	_	
20-9	3123-3131	findings	_	
20-10	3132-3134	by	_	
20-11	3135-3145	suggesting	_	
20-12	3146-3150	that	_	
20-13	3151-3156	place	_	
20-14	3157-3162	cells	_	
20-15	3163-3165	in	_	
20-16	3166-3172	dorsal	_	
20-17	3173-3184	hippocampus	_	
20-18	3185-3192	exhibit	_	
20-19	3193-3201	specific	_	
20-20	3202-3207	place	_	
20-21	3208-3214	fields	_	
20-22	3214-3215	,	_	
20-23	3216-3223	whereas	_	
20-24	3224-3229	place	_	
20-25	3230-3235	cells	_	
20-26	3236-3238	in	_	
20-27	3239-3246	ventral	_	
20-28	3247-3258	hippocampus	_	
20-29	3259-3262	are	_	
20-30	3263-3268	often	_	
20-31	3269-3274	large	_	
20-32	3274-3275	,	_	
20-33	3276-3285	sometimes	_	
20-34	3286-3295	extending	_	
20-35	3296-3302	across	_	
20-36	3303-3305	an	_	
20-37	3306-3312	entire	_	
20-38	3313-3320	spatial	_	
20-39	3321-3328	context	_	
20-40	3328-3329	.	_	

#Text=Dissociations between anterior and posterior hippocampal functions have also been observed in humans with fMRI.
21-1	3330-3343	Dissociations	_	
21-2	3344-3351	between	_	
21-3	3352-3360	anterior	_	
21-4	3361-3364	and	_	
21-5	3365-3374	posterior	_	
21-6	3375-3386	hippocampal	_	
21-7	3387-3396	functions	_	
21-8	3397-3401	have	_	
21-9	3402-3406	also	_	
21-10	3407-3411	been	_	
21-11	3412-3420	observed	_	
21-12	3421-3423	in	_	
21-13	3424-3430	humans	_	
21-14	3431-3435	with	_	
21-15	3436-3440	fMRI	_	
21-16	3440-3441	.	_	

#Text=Functional dissociations between anterior and posterior hippocampus have been attributed to processing of; novel versus repeated stimuli, emotional versus non-emotional material and encoding versus retrieval.
22-1	3442-3452	Functional	_	
22-2	3453-3466	dissociations	_	
22-3	3467-3474	between	_	
22-4	3475-3483	anterior	_	
22-5	3484-3487	and	_	
22-6	3488-3497	posterior	_	
22-7	3498-3509	hippocampus	_	
22-8	3510-3514	have	_	
22-9	3515-3519	been	_	
22-10	3520-3530	attributed	_	
22-11	3531-3533	to	_	
22-12	3534-3544	processing	_	
22-13	3545-3547	of	_	
22-14	3547-3548	;	_	
22-15	3549-3554	novel	_	
22-16	3555-3561	versus	_	
22-17	3562-3570	repeated	_	
22-18	3571-3578	stimuli	_	
22-19	3578-3579	,	_	
22-20	3580-3589	emotional	_	
22-21	3590-3596	versus	_	
22-22	3597-3610	non-emotional	_	
22-23	3611-3619	material	_	
22-24	3620-3623	and	_	
22-25	3624-3632	encoding	_	
22-26	3633-3639	versus	_	
22-27	3640-3649	retrieval	_	
22-28	3649-3650	.	_	

#Text=Work has also linked posterior hippocampus to retrieving memories based on spatial context information, and anterior hippocampus to more global and less context-dependent relational memory processes.
23-1	3651-3655	Work	_	
23-2	3656-3659	has	_	
23-3	3660-3664	also	_	
23-4	3665-3671	linked	_	
23-5	3672-3681	posterior	_	
23-6	3682-3693	hippocampus	_	
23-7	3694-3696	to	_	
23-8	3697-3707	retrieving	_	
23-9	3708-3716	memories	_	
23-10	3717-3722	based	_	
23-11	3723-3725	on	_	
23-12	3726-3733	spatial	_	
23-13	3734-3741	context	_	
23-14	3742-3753	information	_	
23-15	3753-3754	,	_	
23-16	3755-3758	and	_	
23-17	3759-3767	anterior	_	
23-18	3768-3779	hippocampus	_	
23-19	3780-3782	to	_	
23-20	3783-3787	more	_	
23-21	3788-3794	global	_	
23-22	3795-3798	and	_	
23-23	3799-3803	less	_	
23-24	3804-3821	context-dependent	_	
23-25	3822-3832	relational	_	
23-26	3833-3839	memory	_	
23-27	3840-3849	processes	_	
23-28	3849-3850	.	_	

#Text=Moreover, when processing spatial information, a distinction exists between retrieval of fine-grained spatial details (posterior hippocampus) versus more global gist-like information (anterior hippocampus).
24-1	3851-3859	Moreover	_	
24-2	3859-3860	,	_	
24-3	3861-3865	when	_	
24-4	3866-3876	processing	_	
24-5	3877-3884	spatial	_	
24-6	3885-3896	information	_	
24-7	3896-3897	,	_	
24-8	3898-3899	a	_	
24-9	3900-3911	distinction	_	
24-10	3912-3918	exists	_	
24-11	3919-3926	between	_	
24-12	3927-3936	retrieval	_	
24-13	3937-3939	of	_	
24-14	3940-3952	fine-grained	_	
24-15	3953-3960	spatial	_	
24-16	3961-3968	details	_	
24-17	3969-3970	(	_	
24-18	3970-3979	posterior	_	
24-19	3980-3991	hippocampus	_	
24-20	3991-3992	)	_	
24-21	3993-3999	versus	_	
24-22	4000-4004	more	_	
24-23	4005-4011	global	_	
24-24	4012-4021	gist-like	_	
24-25	4022-4033	information	_	
24-26	4034-4035	(	_	
24-27	4035-4043	anterior	_	
24-28	4044-4055	hippocampus	_	
24-29	4055-4056	)	_	
24-30	4056-4057	.	_	

#Text=This has contributed to a “granularity gradient” model in which the head of the hippocampus retrieves course, large-scale representations; the hippocampal body retrieves medium sized spatial representations; and the tail of the hippocampus retrieves fine-grained local representations.
25-1	4058-4062	This	_	
25-2	4063-4066	has	_	
25-3	4067-4078	contributed	_	
25-4	4079-4081	to	_	
25-5	4082-4083	a	_	
25-6	4084-4085	“	_	
25-7	4085-4096	granularity	_	
25-8	4097-4105	gradient	_	
25-9	4105-4106	”	_	
25-10	4107-4112	model	_	
25-11	4113-4115	in	_	
25-12	4116-4121	which	_	
25-13	4122-4125	the	_	
25-14	4126-4130	head	_	
25-15	4131-4133	of	_	
25-16	4134-4137	the	_	
25-17	4138-4149	hippocampus	_	
25-18	4150-4159	retrieves	_	
25-19	4160-4166	course	_	
25-20	4166-4167	,	_	
25-21	4168-4179	large-scale	_	
25-22	4180-4195	representations	_	
25-23	4195-4196	;	_	
25-24	4197-4200	the	_	
25-25	4201-4212	hippocampal	_	
25-26	4213-4217	body	_	
25-27	4218-4227	retrieves	_	
25-28	4228-4234	medium	_	
25-29	4235-4240	sized	_	
25-30	4241-4248	spatial	_	
25-31	4249-4264	representations	_	
25-32	4264-4265	;	_	
25-33	4266-4269	and	_	
25-34	4270-4273	the	_	
25-35	4274-4278	tail	_	
25-36	4279-4281	of	_	
25-37	4282-4285	the	_	
25-38	4286-4297	hippocampus	_	
25-39	4298-4307	retrieves	_	
25-40	4308-4320	fine-grained	_	
25-41	4321-4326	local	_	
25-42	4327-4342	representations	_	
25-43	4342-4343	.	_	

#Text=Based on this granularity model, we predict that manipulation of spatial locations during the current memory task will produce maximal activation in the posterior hippocampus, whereas the anterior hippocampus will be most sensitive to global changes in item identity.
26-1	4344-4349	Based	_	
26-2	4350-4352	on	_	
26-3	4353-4357	this	_	
26-4	4358-4369	granularity	_	
26-5	4370-4375	model	_	
26-6	4375-4376	,	_	
26-7	4377-4379	we	_	
26-8	4380-4387	predict	_	
26-9	4388-4392	that	_	
26-10	4393-4405	manipulation	_	
26-11	4406-4408	of	_	
26-12	4409-4416	spatial	_	
26-13	4417-4426	locations	_	
26-14	4427-4433	during	_	
26-15	4434-4437	the	_	
26-16	4438-4445	current	_	
26-17	4446-4452	memory	_	
26-18	4453-4457	task	_	
26-19	4458-4462	will	_	
26-20	4463-4470	produce	_	
26-21	4471-4478	maximal	_	
26-22	4479-4489	activation	_	
26-23	4490-4492	in	_	
26-24	4493-4496	the	_	
26-25	4497-4506	posterior	_	
26-26	4507-4518	hippocampus	_	
26-27	4518-4519	,	_	
26-28	4520-4527	whereas	_	
26-29	4528-4531	the	_	
26-30	4532-4540	anterior	_	
26-31	4541-4552	hippocampus	_	
26-32	4553-4557	will	_	
26-33	4558-4560	be	_	
26-34	4561-4565	most	_	
26-35	4566-4575	sensitive	_	
26-36	4576-4578	to	_	
26-37	4579-4585	global	_	
26-38	4586-4593	changes	_	
26-39	4594-4596	in	_	
26-40	4597-4601	item	_	
26-41	4602-4610	identity	_	
26-42	4610-4611	.	_	

#Text=This distinction between anterior and posterior hippocampal function has received minimal attention in the schizophrenia literature.
27-1	4612-4616	This	_	
27-2	4617-4628	distinction	_	
27-3	4629-4636	between	_	
27-4	4637-4645	anterior	_	
27-5	4646-4649	and	_	
27-6	4650-4659	posterior	_	
27-7	4660-4671	hippocampal	_	
27-8	4672-4680	function	_	
27-9	4681-4684	has	_	
27-10	4685-4693	received	_	
27-11	4694-4701	minimal	_	
27-12	4702-4711	attention	_	
27-13	4712-4714	in	_	
27-14	4715-4718	the	_	
27-15	4719-4732	schizophrenia	_	
27-16	4733-4743	literature	_	
27-17	4743-4744	.	_	

#Text=The most consistent story comes from resting-state studies supporting a model of tonic hyperactivity of the anterior hippocampus in patients versus healthy controls According to this view, increased activity of the ventral/anterior hippocampus leads to disinhibition of the ventral tegmental area, and this, in turn, contributes to increased dopaminergic activity and disordered cognition in schizophrenia.
28-1	4745-4748	The	_	
28-2	4749-4753	most	_	
28-3	4754-4764	consistent	_	
28-4	4765-4770	story	_	
28-5	4771-4776	comes	_	
28-6	4777-4781	from	_	
28-7	4782-4795	resting-state	_	
28-8	4796-4803	studies	_	
28-9	4804-4814	supporting	_	
28-10	4815-4816	a	_	
28-11	4817-4822	model	_	
28-12	4823-4825	of	_	
28-13	4826-4831	tonic	_	
28-14	4832-4845	hyperactivity	_	
28-15	4846-4848	of	_	
28-16	4849-4852	the	_	
28-17	4853-4861	anterior	_	
28-18	4862-4873	hippocampus	_	
28-19	4874-4876	in	_	
28-20	4877-4885	patients	_	
28-21	4886-4892	versus	_	
28-22	4893-4900	healthy	_	
28-23	4901-4909	controls	_	
28-24	4910-4919	According	_	
28-25	4920-4922	to	_	
28-26	4923-4927	this	_	
28-27	4928-4932	view	_	
28-28	4932-4933	,	_	
28-29	4934-4943	increased	_	
28-30	4944-4952	activity	_	
28-31	4953-4955	of	_	
28-32	4956-4959	the	_	
28-33	4960-4967	ventral	_	
28-34	4967-4968	/	_	
28-35	4968-4976	anterior	_	
28-36	4977-4988	hippocampus	_	
28-37	4989-4994	leads	_	
28-38	4995-4997	to	_	
28-39	4998-5011	disinhibition	_	
28-40	5012-5014	of	_	
28-41	5015-5018	the	_	
28-42	5019-5026	ventral	_	
28-43	5027-5036	tegmental	_	
28-44	5037-5041	area	_	
28-45	5041-5042	,	_	
28-46	5043-5046	and	_	
28-47	5047-5051	this	_	
28-48	5051-5052	,	_	
28-49	5053-5055	in	_	
28-50	5056-5060	turn	_	
28-51	5060-5061	,	_	
28-52	5062-5073	contributes	_	
28-53	5074-5076	to	_	
28-54	5077-5086	increased	_	
28-55	5087-5099	dopaminergic	_	
28-56	5100-5108	activity	_	
28-57	5109-5112	and	_	
28-58	5113-5123	disordered	_	
28-59	5124-5133	cognition	_	
28-60	5134-5136	in	_	
28-61	5137-5150	schizophrenia	_	
28-62	5150-5151	.	_	

#Text=Consistent with this idea, a series of resting-state studies of cerebral blood volume (CBV), found that CBV was increased in patients relative to healthy controls specifically within the CA1 region of the anterior hippocampus [for review, see ].
29-1	5152-5162	Consistent	_	
29-2	5163-5167	with	_	
29-3	5168-5172	this	_	
29-4	5173-5177	idea	_	
29-5	5177-5178	,	_	
29-6	5179-5180	a	_	
29-7	5181-5187	series	_	
29-8	5188-5190	of	_	
29-9	5191-5204	resting-state	_	
29-10	5205-5212	studies	_	
29-11	5213-5215	of	_	
29-12	5216-5224	cerebral	_	
29-13	5225-5230	blood	_	
29-14	5231-5237	volume	_	
29-15	5238-5239	(	_	
29-16	5239-5242	CBV	_	
29-17	5242-5243	)	_	
29-18	5243-5244	,	_	
29-19	5245-5250	found	_	
29-20	5251-5255	that	_	
29-21	5256-5259	CBV	_	
29-22	5260-5263	was	_	
29-23	5264-5273	increased	_	
29-24	5274-5276	in	_	
29-25	5277-5285	patients	_	
29-26	5286-5294	relative	_	
29-27	5295-5297	to	_	
29-28	5298-5305	healthy	_	
29-29	5306-5314	controls	_	
29-30	5315-5327	specifically	_	
29-31	5328-5334	within	_	
29-32	5335-5338	the	_	
29-33	5339-5342	CA1	_	
29-34	5343-5349	region	_	
29-35	5350-5352	of	_	
29-36	5353-5356	the	_	
29-37	5357-5365	anterior	_	
29-38	5366-5377	hippocampus	_	
29-39	5378-5379	[	_	
29-40	5379-5382	for	_	
29-41	5383-5389	review	_	
29-42	5389-5390	,	_	
29-43	5391-5394	see	_	
29-44	5395-5396	]	_	
29-45	5396-5397	.	_	

#Text=It is unclear how this tonic hyperactivity would relate to specific episodic memory functions, although an early study suggested that a hyperactive baseline state could help explain the reduced responsivity of the hippocampus to memory demands.
30-1	5398-5400	It	_	
30-2	5401-5403	is	_	
30-3	5404-5411	unclear	_	
30-4	5412-5415	how	_	
30-5	5416-5420	this	_	
30-6	5421-5426	tonic	_	
30-7	5427-5440	hyperactivity	_	
30-8	5441-5446	would	_	
30-9	5447-5453	relate	_	
30-10	5454-5456	to	_	
30-11	5457-5465	specific	_	
30-12	5466-5474	episodic	_	
30-13	5475-5481	memory	_	
30-14	5482-5491	functions	_	
30-15	5491-5492	,	_	
30-16	5493-5501	although	_	
30-17	5502-5504	an	_	
30-18	5505-5510	early	_	
30-19	5511-5516	study	_	
30-20	5517-5526	suggested	_	
30-21	5527-5531	that	_	
30-22	5532-5533	a	_	
30-23	5534-5545	hyperactive	_	
30-24	5546-5554	baseline	_	
30-25	5555-5560	state	_	
30-26	5561-5566	could	_	
30-27	5567-5571	help	_	
30-28	5572-5579	explain	_	
30-29	5580-5583	the	_	
30-30	5584-5591	reduced	_	
30-31	5592-5604	responsivity	_	
30-32	5605-5607	of	_	
30-33	5608-5611	the	_	
30-34	5612-5623	hippocampus	_	
30-35	5624-5626	to	_	
30-36	5627-5633	memory	_	
30-37	5634-5641	demands	_	
30-38	5641-5642	.	_	

#Text=With one exception, fMRI studies of episodic memory in schizophrenia have not systematically examined anterior versus posterior hippocampus.
31-1	5643-5647	With	_	
31-2	5648-5651	one	_	
31-3	5652-5661	exception	_	
31-4	5661-5662	,	_	
31-5	5663-5667	fMRI	_	
31-6	5668-5675	studies	_	
31-7	5676-5678	of	_	
31-8	5679-5687	episodic	_	
31-9	5688-5694	memory	_	
31-10	5695-5697	in	_	
31-11	5698-5711	schizophrenia	_	
31-12	5712-5716	have	_	
31-13	5717-5720	not	_	
31-14	5721-5735	systematically	_	
31-15	5736-5744	examined	_	
31-16	5745-5753	anterior	_	
31-17	5754-5760	versus	_	
31-18	5761-5770	posterior	_	
31-19	5771-5782	hippocampus	_	
31-20	5782-5783	.	_	

#Text=In an attempt to detect a consistent anterior/posterior pattern of group differences we performed a qualitative review and found roughly an equal number of studies that; 1) employed tasks that failed to engage the hippocampus or detect group differences in either anterior or posterior hippocampus, 2) utilized designs that were successful in detecting reduced activation in patients, relative to healthy controls, in the anterior hippocampus, or 3) utilized tasks that revealed evidence of reduced patient activation in the posterior hippocampus during episodic retrieval.
32-1	5784-5786	In	_	
32-2	5787-5789	an	_	
32-3	5790-5797	attempt	_	
32-4	5798-5800	to	_	
32-5	5801-5807	detect	_	
32-6	5808-5809	a	_	
32-7	5810-5820	consistent	_	
32-8	5821-5829	anterior	_	
32-9	5829-5830	/	_	
32-10	5830-5839	posterior	_	
32-11	5840-5847	pattern	_	
32-12	5848-5850	of	_	
32-13	5851-5856	group	_	
32-14	5857-5868	differences	_	
32-15	5869-5871	we	_	
32-16	5872-5881	performed	_	
32-17	5882-5883	a	_	
32-18	5884-5895	qualitative	_	
32-19	5896-5902	review	_	
32-20	5903-5906	and	_	
32-21	5907-5912	found	_	
32-22	5913-5920	roughly	_	
32-23	5921-5923	an	_	
32-24	5924-5929	equal	_	
32-25	5930-5936	number	_	
32-26	5937-5939	of	_	
32-27	5940-5947	studies	_	
32-28	5948-5952	that	_	
32-29	5952-5953	;	_	
32-30	5954-5955	1	_	
32-31	5955-5956	)	_	
32-32	5957-5965	employed	_	
32-33	5966-5971	tasks	_	
32-34	5972-5976	that	_	
32-35	5977-5983	failed	_	
32-36	5984-5986	to	_	
32-37	5987-5993	engage	_	
32-38	5994-5997	the	_	
32-39	5998-6009	hippocampus	_	
32-40	6010-6012	or	_	
32-41	6013-6019	detect	_	
32-42	6020-6025	group	_	
32-43	6026-6037	differences	_	
32-44	6038-6040	in	_	
32-45	6041-6047	either	_	
32-46	6048-6056	anterior	_	
32-47	6057-6059	or	_	
32-48	6060-6069	posterior	_	
32-49	6070-6081	hippocampus	_	
32-50	6081-6082	,	_	
32-51	6083-6084	2	_	
32-52	6084-6085	)	_	
32-53	6086-6094	utilized	_	
32-54	6095-6102	designs	_	
32-55	6103-6107	that	_	
32-56	6108-6112	were	_	
32-57	6113-6123	successful	_	
32-58	6124-6126	in	_	
32-59	6127-6136	detecting	_	
32-60	6137-6144	reduced	_	
32-61	6145-6155	activation	_	
32-62	6156-6158	in	_	
32-63	6159-6167	patients	_	
32-64	6167-6168	,	_	
32-65	6169-6177	relative	_	
32-66	6178-6180	to	_	
32-67	6181-6188	healthy	_	
32-68	6189-6197	controls	_	
32-69	6197-6198	,	_	
32-70	6199-6201	in	_	
32-71	6202-6205	the	_	
32-72	6206-6214	anterior	_	
32-73	6215-6226	hippocampus	_	
32-74	6226-6227	,	_	
32-75	6228-6230	or	_	
32-76	6231-6232	3	_	
32-77	6232-6233	)	_	
32-78	6234-6242	utilized	_	
32-79	6243-6248	tasks	_	
32-80	6249-6253	that	_	
32-81	6254-6262	revealed	_	
32-82	6263-6271	evidence	_	
32-83	6272-6274	of	_	
32-84	6275-6282	reduced	_	
32-85	6283-6290	patient	_	
32-86	6291-6301	activation	_	
32-87	6302-6304	in	_	
32-88	6305-6308	the	_	
32-89	6309-6318	posterior	_	
32-90	6319-6330	hippocampus	_	
32-91	6331-6337	during	_	
32-92	6338-6346	episodic	_	
32-93	6347-6356	retrieval	_	
32-94	6356-6357	.	_	

#Text=The one study that directly contrasted anterior and posterior hippocampus found that anterior hippocampal activity increased during novelty detection in healthy controls, and was reduced in unmedicated but not in medicated people with schizophrenia.
33-1	6358-6361	The	_	
33-2	6362-6365	one	_	
33-3	6366-6371	study	_	
33-4	6372-6376	that	_	
33-5	6377-6385	directly	_	
33-6	6386-6396	contrasted	_	
33-7	6397-6405	anterior	_	
33-8	6406-6409	and	_	
33-9	6410-6419	posterior	_	
33-10	6420-6431	hippocampus	_	
33-11	6432-6437	found	_	
33-12	6438-6442	that	_	
33-13	6443-6451	anterior	_	
33-14	6452-6463	hippocampal	_	
33-15	6464-6472	activity	_	
33-16	6473-6482	increased	_	
33-17	6483-6489	during	_	
33-18	6490-6497	novelty	_	
33-19	6498-6507	detection	_	
33-20	6508-6510	in	_	
33-21	6511-6518	healthy	_	
33-22	6519-6527	controls	_	
33-23	6527-6528	,	_	
33-24	6529-6532	and	_	
33-25	6533-6536	was	_	
33-26	6537-6544	reduced	_	
33-27	6545-6547	in	_	
33-28	6548-6559	unmedicated	_	
33-29	6560-6563	but	_	
33-30	6564-6567	not	_	
33-31	6568-6570	in	_	
33-32	6571-6580	medicated	_	
33-33	6581-6587	people	_	
33-34	6588-6592	with	_	
33-35	6593-6606	schizophrenia	_	
33-36	6606-6607	.	_	

#Text=Based on findings indicating potentially different effects on anterior and posterior hippocampus, the goal of the current study was to test the hypothesis that patients with schizophrenia are specifically impaired at activating the posterior hippocampus during episodic retrieval.
34-1	6608-6613	Based	_	
34-2	6614-6616	on	_	
34-3	6617-6625	findings	_	
34-4	6626-6636	indicating	_	
34-5	6637-6648	potentially	_	
34-6	6649-6658	different	_	
34-7	6659-6666	effects	_	
34-8	6667-6669	on	_	
34-9	6670-6678	anterior	_	
34-10	6679-6682	and	_	
34-11	6683-6692	posterior	_	
34-12	6693-6704	hippocampus	_	
34-13	6704-6705	,	_	
34-14	6706-6709	the	_	
34-15	6710-6714	goal	_	
34-16	6715-6717	of	_	
34-17	6718-6721	the	_	
34-18	6722-6729	current	_	
34-19	6730-6735	study	_	
34-20	6736-6739	was	_	
34-21	6740-6742	to	_	
34-22	6743-6747	test	_	
34-23	6748-6751	the	_	
34-24	6752-6762	hypothesis	_	
34-25	6763-6767	that	_	
34-26	6768-6776	patients	_	
34-27	6777-6781	with	_	
34-28	6782-6795	schizophrenia	_	
34-29	6796-6799	are	_	
34-30	6800-6812	specifically	_	
34-31	6813-6821	impaired	_	
34-32	6822-6824	at	_	
34-33	6825-6835	activating	_	
34-34	6836-6839	the	_	
34-35	6840-6849	posterior	_	
34-36	6850-6861	hippocampus	_	
34-37	6862-6868	during	_	
34-38	6869-6877	episodic	_	
34-39	6878-6887	retrieval	_	
34-40	6887-6888	.	_	

#Text=Participants were scanned while performing a memory paradigm that required detection of subtle changes to items or spatial configurations in complex visual scenes.
35-1	6889-6901	Participants	_	
35-2	6902-6906	were	_	
35-3	6907-6914	scanned	_	
35-4	6915-6920	while	_	
35-5	6921-6931	performing	_	
35-6	6932-6933	a	_	
35-7	6934-6940	memory	_	
35-8	6941-6949	paradigm	_	
35-9	6950-6954	that	_	
35-10	6955-6963	required	_	
35-11	6964-6973	detection	_	
35-12	6974-6976	of	_	
35-13	6977-6983	subtle	_	
35-14	6984-6991	changes	_	
35-15	6992-6994	to	_	
35-16	6995-7000	items	_	
35-17	7001-7003	or	_	
35-18	7004-7011	spatial	_	
35-19	7012-7026	configurations	_	
35-20	7027-7029	in	_	
35-21	7030-7037	complex	_	
35-22	7038-7044	visual	_	
35-23	7045-7051	scenes	_	
35-24	7051-7052	.	_	

#Text=In a previous eye-tracking study using a variant of the current task, we found that patients with schizophrenia spent less time viewing the portion of a scene that involved a spatial change in item location, but showed a normal increase in viewing when there was change in item identity, suggesting a disproportionate eye-movement memory deficit for spatial information.
36-1	7053-7055	In	_	
36-2	7056-7057	a	_	
36-3	7058-7066	previous	_	
36-4	7067-7079	eye-tracking	_	
36-5	7080-7085	study	_	
36-6	7086-7091	using	_	
36-7	7092-7093	a	_	
36-8	7094-7101	variant	_	
36-9	7102-7104	of	_	
36-10	7105-7108	the	_	
36-11	7109-7116	current	_	
36-12	7117-7121	task	_	
36-13	7121-7122	,	_	
36-14	7123-7125	we	_	
36-15	7126-7131	found	_	
36-16	7132-7136	that	_	
36-17	7137-7145	patients	_	
36-18	7146-7150	with	_	
36-19	7151-7164	schizophrenia	_	
36-20	7165-7170	spent	_	
36-21	7171-7175	less	_	
36-22	7176-7180	time	_	
36-23	7181-7188	viewing	_	
36-24	7189-7192	the	_	
36-25	7193-7200	portion	_	
36-26	7201-7203	of	_	
36-27	7204-7205	a	_	
36-28	7206-7211	scene	_	
36-29	7212-7216	that	_	
36-30	7217-7225	involved	_	
36-31	7226-7227	a	_	
36-32	7228-7235	spatial	_	
36-33	7236-7242	change	_	
36-34	7243-7245	in	_	
36-35	7246-7250	item	_	
36-36	7251-7259	location	_	
36-37	7259-7260	,	_	
36-38	7261-7264	but	_	
36-39	7265-7271	showed	_	
36-40	7272-7273	a	_	
36-41	7274-7280	normal	_	
36-42	7281-7289	increase	_	
36-43	7290-7292	in	_	
36-44	7293-7300	viewing	_	
36-45	7301-7305	when	_	
36-46	7306-7311	there	_	
36-47	7312-7315	was	_	
36-48	7316-7322	change	_	
36-49	7323-7325	in	_	
36-50	7326-7330	item	_	
36-51	7331-7339	identity	_	
36-52	7339-7340	,	_	
36-53	7341-7351	suggesting	_	
36-54	7352-7353	a	_	
36-55	7354-7370	disproportionate	_	
36-56	7371-7383	eye-movement	_	
36-57	7384-7390	memory	_	
36-58	7391-7398	deficit	_	
36-59	7399-7402	for	_	
36-60	7403-7410	spatial	_	
36-61	7411-7422	information	_	
36-62	7422-7423	.	_	

#Text=Based on findings indicating posterior hippocampal specialization for fine-grained spatial relationships and spatial context, we hypothesized that patients with schizophrenia would show relative reductions in posterior, but not anterior hippocampal activation during processing of spatial changes.
37-1	7424-7429	Based	_	
37-2	7430-7432	on	_	
37-3	7433-7441	findings	_	
37-4	7442-7452	indicating	_	
37-5	7453-7462	posterior	_	
37-6	7463-7474	hippocampal	_	
37-7	7475-7489	specialization	_	
37-8	7490-7493	for	_	
37-9	7494-7506	fine-grained	_	
37-10	7507-7514	spatial	_	
37-11	7515-7528	relationships	_	
37-12	7529-7532	and	_	
37-13	7533-7540	spatial	_	
37-14	7541-7548	context	_	
37-15	7548-7549	,	_	
37-16	7550-7552	we	_	
37-17	7553-7565	hypothesized	_	
37-18	7566-7570	that	_	
37-19	7571-7579	patients	_	
37-20	7580-7584	with	_	
37-21	7585-7598	schizophrenia	_	
37-22	7599-7604	would	_	
37-23	7605-7609	show	_	
37-24	7610-7618	relative	_	
37-25	7619-7629	reductions	_	
37-26	7630-7632	in	_	
37-27	7633-7642	posterior	_	
37-28	7642-7643	,	_	
37-29	7644-7647	but	_	
37-30	7648-7651	not	_	
37-31	7652-7660	anterior	_	
37-32	7661-7672	hippocampal	_	
37-33	7673-7683	activation	_	
37-34	7684-7690	during	_	
37-35	7691-7701	processing	_	
37-36	7702-7704	of	_	
37-37	7705-7712	spatial	_	
37-38	7713-7720	changes	_	
37-39	7720-7721	.	_	

#Text=Methods and materials
#Text=Participants
#Text=Data were acquired on 30 patients with schizophrenia and 30 healthy controls.
38-1	7722-7729	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
38-2	7730-7733	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
38-3	7734-7743	materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
38-4	7744-7756	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-5	7757-7761	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-6	7762-7766	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-7	7767-7775	acquired	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-8	7776-7778	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-9	7779-7781	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-10	7782-7790	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
38-11	7791-7795	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
38-12	7796-7809	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[7]	
38-13	7810-7813	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-14	7814-7816	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
38-15	7817-7824	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
38-16	7825-7833	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[8]	
38-17	7833-7834	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=Data were excluded for excessive relative frame-to-frame movement (i.e., > 0.4 mm, exceeding 3 standard deviations from the mean) in 1 control and 1 patient; for below chance performance in 1 control and 2 patients; for 1 control and 2 patients who stopped participation; for 1 control with an incidental abnormal anatomical finding; and for 1 patient with a technical malfunction (faulty button box), leaving a final sample of 24 patients with schizophrenia and 26 controls.
39-1	7835-7839	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-2	7840-7844	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-3	7845-7853	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-4	7854-7857	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-5	7858-7867	excessive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-6	7868-7876	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-7	7877-7891	frame-to-frame	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-8	7892-7900	movement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-9	7901-7902	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-10	7902-7905	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-11	7905-7906	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-12	7906-7907	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-13	7908-7909	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-14	7909-7910	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-15	7910-7913	0.4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-16	7913-7914	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-17	7914-7916	mm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-18	7916-7917	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-19	7918-7927	exceeding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-20	7928-7929	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-21	7930-7938	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-22	7939-7949	deviations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-23	7950-7954	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-24	7955-7958	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-25	7959-7963	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-26	7963-7964	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-27	7965-7967	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-28	7968-7969	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-29	7970-7977	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-30	7978-7981	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-31	7982-7983	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-32	7984-7991	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-33	7991-7992	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-34	7993-7996	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-35	7997-8002	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-36	8003-8009	chance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-37	8010-8021	performance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-38	8022-8024	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-39	8025-8026	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-40	8027-8034	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-41	8035-8038	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-42	8039-8040	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-43	8041-8049	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-44	8049-8050	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-45	8051-8054	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-46	8055-8056	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-47	8057-8064	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-48	8065-8068	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-49	8069-8070	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-50	8071-8079	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-51	8080-8083	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-52	8084-8091	stopped	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-53	8092-8105	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-54	8105-8106	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-55	8107-8110	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-56	8111-8112	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-57	8113-8120	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-58	8121-8125	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
39-59	8126-8128	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-60	8129-8139	incidental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-61	8140-8148	abnormal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-62	8149-8159	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-63	8160-8167	finding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-64	8167-8168	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-65	8169-8172	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-66	8173-8176	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-67	8177-8178	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-68	8179-8186	patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-69	8187-8191	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-70	8192-8193	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-71	8194-8203	technical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-72	8204-8215	malfunction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-73	8216-8217	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-74	8217-8223	faulty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-75	8224-8230	button	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-76	8231-8234	box	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-77	8234-8235	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-78	8235-8236	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-79	8237-8244	leaving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-80	8245-8246	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-81	8247-8252	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-82	8253-8259	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-83	8260-8262	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-84	8263-8265	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-85	8266-8274	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
39-86	8275-8279	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
39-87	8280-8293	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[11]	
39-88	8294-8297	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-89	8298-8300	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
39-90	8301-8309	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
39-91	8309-8310	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=Groups were matched for age, gender, handedness and parental education (Table 1).
40-1	8311-8317	Groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-2	8318-8322	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-3	8323-8330	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-4	8331-8334	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-5	8335-8338	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-6	8338-8339	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-7	8340-8346	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-8	8346-8347	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-9	8348-8358	handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-10	8359-8362	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-11	8363-8371	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-12	8372-8381	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-13	8382-8383	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-14	8383-8388	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-15	8389-8390	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-16	8390-8391	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
40-17	8391-8392	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Participant education was lower in patients.
41-1	8393-8404	Participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-2	8405-8414	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-3	8415-8418	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-4	8419-8424	lower	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-5	8425-8427	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-6	8428-8436	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
41-7	8436-8437	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=All patients were receiving medication (2 typical, 22 atypical), and clinically stable.
42-1	8438-8441	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-2	8442-8450	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-3	8451-8455	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-4	8456-8465	receiving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-5	8466-8476	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-6	8477-8478	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-7	8478-8479	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-8	8480-8487	typical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-9	8487-8488	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-10	8489-8491	22	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-11	8492-8500	atypical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-12	8500-8501	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-13	8501-8502	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-14	8503-8506	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-15	8507-8517	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-16	8518-8524	stable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
42-17	8524-8525	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Patients were early in their illness [Duration (mean ± standard deviation) = 3.02 ± 2.51 years], and overall symptom severity (BPRS total) was in the mild range (42.7 ± 13.3).
43-1	8526-8534	Patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-2	8535-8539	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-3	8540-8545	early	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-4	8546-8548	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-5	8549-8554	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-6	8555-8562	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-7	8563-8564	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-8	8564-8572	Duration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-9	8573-8574	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-10	8574-8578	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-11	8578-8579	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-12	8579-8580	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-13	8580-8581	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-14	8581-8589	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-15	8590-8599	deviation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-16	8599-8600	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-17	8600-8601	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-18	8601-8602	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-19	8602-8603	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-20	8603-8607	3.02	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-21	8607-8608	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-22	8608-8609	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-23	8609-8610	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-24	8610-8614	2.51	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-25	8614-8615	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-26	8615-8620	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-27	8620-8621	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-28	8621-8622	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-29	8623-8626	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-30	8627-8634	overall	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-31	8635-8642	symptom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|*[14]	
43-32	8643-8651	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-33	8652-8653	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-34	8653-8657	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale[15]	
43-35	8658-8663	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-36	8663-8664	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-37	8665-8668	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-38	8669-8671	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-39	8672-8675	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-40	8676-8680	mild	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-41	8681-8686	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-42	8687-8688	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-43	8688-8692	42.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-44	8692-8693	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-45	8693-8694	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-46	8694-8695	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-47	8695-8699	13.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-48	8699-8700	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
43-49	8700-8701	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Data collection began after participants provided written informed consent following Institutional Review Board approval.
44-1	8702-8706	Data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-2	8707-8717	collection	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-3	8718-8723	began	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-4	8724-8729	after	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-5	8730-8742	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-6	8743-8751	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-7	8752-8759	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-8	8760-8768	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-9	8769-8776	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-10	8777-8786	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-11	8787-8800	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-12	8801-8807	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-13	8808-8813	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-14	8814-8822	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
44-15	8822-8823	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Materials
#Text=Stimuli included 128 rendered scenes created using Punch!
45-1	8824-8833	Materials	_	
45-2	8834-8841	Stimuli	_	
45-3	8842-8850	included	_	
45-4	8851-8854	128	_	
45-5	8855-8863	rendered	_	
45-6	8864-8870	scenes	_	
45-7	8871-8878	created	_	
45-8	8879-8884	using	_	
45-9	8885-8890	Punch	_	
45-10	8890-8891	!	_	

#Text=Home Design software (Encore, Inc., El Segundo, CA).
46-1	8892-8896	Home	_	
46-2	8897-8903	Design	_	
46-3	8904-8912	software	_	
46-4	8913-8914	(	_	
46-5	8914-8920	Encore	_	
46-6	8920-8921	,	_	
46-7	8922-8925	Inc	_	
46-8	8925-8926	.	_	
46-9	8926-8927	,	_	
46-10	8928-8930	El	_	
46-11	8931-8938	Segundo	_	
46-12	8938-8939	,	_	
46-13	8940-8942	CA	_	
46-14	8942-8943	)	_	
46-15	8943-8944	.	_	

#Text=Three scene variants were created – the original, a version containing an item manipulation, and a version containing a spatial manipulation – producing a total of 384 scenes.
47-1	8945-8950	Three	_	
47-2	8951-8956	scene	_	
47-3	8957-8965	variants	_	
47-4	8966-8970	were	_	
47-5	8971-8978	created	_	
47-6	8979-8980	–	_	
47-7	8981-8984	the	_	
47-8	8985-8993	original	_	
47-9	8993-8994	,	_	
47-10	8995-8996	a	_	
47-11	8997-9004	version	_	
47-12	9005-9015	containing	_	
47-13	9016-9018	an	_	
47-14	9019-9023	item	_	
47-15	9024-9036	manipulation	_	
47-16	9036-9037	,	_	
47-17	9038-9041	and	_	
47-18	9042-9043	a	_	
47-19	9044-9051	version	_	
47-20	9052-9062	containing	_	
47-21	9063-9064	a	_	
47-22	9065-9072	spatial	_	
47-23	9073-9085	manipulation	_	
47-24	9086-9087	–	_	
47-25	9088-9097	producing	_	
47-26	9098-9099	a	_	
47-27	9100-9105	total	_	
47-28	9106-9108	of	_	
47-29	9109-9112	384	_	
47-30	9113-9119	scenes	_	
47-31	9119-9120	.	_	

#Text=One item embedded in each original scene was designated the critical item and, in manipulated versions, this item was either replaced with a different exemplar (item change) or displaced and moved to a new location (spatial change).
48-1	9121-9124	One	_	
48-2	9125-9129	item	_	
48-3	9130-9138	embedded	_	
48-4	9139-9141	in	_	
48-5	9142-9146	each	_	
48-6	9147-9155	original	_	
48-7	9156-9161	scene	_	
48-8	9162-9165	was	_	
48-9	9166-9176	designated	_	
48-10	9177-9180	the	_	
48-11	9181-9189	critical	_	
48-12	9190-9194	item	_	
48-13	9195-9198	and	_	
48-14	9198-9199	,	_	
48-15	9200-9202	in	_	
48-16	9203-9214	manipulated	_	
48-17	9215-9223	versions	_	
48-18	9223-9224	,	_	
48-19	9225-9229	this	_	
48-20	9230-9234	item	_	
48-21	9235-9238	was	_	
48-22	9239-9245	either	_	
48-23	9246-9254	replaced	_	
48-24	9255-9259	with	_	
48-25	9260-9261	a	_	
48-26	9262-9271	different	_	
48-27	9272-9280	exemplar	_	
48-28	9281-9282	(	_	
48-29	9282-9286	item	_	
48-30	9287-9293	change	_	
48-31	9293-9294	)	_	
48-32	9295-9297	or	_	
48-33	9298-9307	displaced	_	
48-34	9308-9311	and	_	
48-35	9312-9317	moved	_	
48-36	9318-9320	to	_	
48-37	9321-9322	a	_	
48-38	9323-9326	new	_	
48-39	9327-9335	location	_	
48-40	9336-9337	(	_	
48-41	9337-9344	spatial	_	
48-42	9345-9351	change	_	
48-43	9351-9352	)	_	
48-44	9352-9353	.	_	

#Text=Critical items were presented in the context of just one scene, and moved equally often from left (in the original scene) to right (in the changed scene) as right to left when the change was spatial.
49-1	9354-9362	Critical	_	
49-2	9363-9368	items	_	
49-3	9369-9373	were	_	
49-4	9374-9383	presented	_	
49-5	9384-9386	in	_	
49-6	9387-9390	the	_	
49-7	9391-9398	context	_	
49-8	9399-9401	of	_	
49-9	9402-9406	just	_	
49-10	9407-9410	one	_	
49-11	9411-9416	scene	_	
49-12	9416-9417	,	_	
49-13	9418-9421	and	_	
49-14	9422-9427	moved	_	
49-15	9428-9435	equally	_	
49-16	9436-9441	often	_	
49-17	9442-9446	from	_	
49-18	9447-9451	left	_	
49-19	9452-9453	(	_	
49-20	9453-9455	in	_	
49-21	9456-9459	the	_	
49-22	9460-9468	original	_	
49-23	9469-9474	scene	_	
49-24	9474-9475	)	_	
49-25	9476-9478	to	_	
49-26	9479-9484	right	_	
49-27	9485-9486	(	_	
49-28	9486-9488	in	_	
49-29	9489-9492	the	_	
49-30	9493-9500	changed	_	
49-31	9501-9506	scene	_	
49-32	9506-9507	)	_	
49-33	9508-9510	as	_	
49-34	9511-9516	right	_	
49-35	9517-9519	to	_	
49-36	9520-9524	left	_	
49-37	9525-9529	when	_	
49-38	9530-9533	the	_	
49-39	9534-9540	change	_	
49-40	9541-9544	was	_	
49-41	9545-9552	spatial	_	
49-42	9552-9553	.	_	

#Text=During encoding (Fig. 1a), participants were presented with orienting questions, directing their attention to the critical item, and were asked either about item features (e.g., “Does the lamp have a square shade?”)
50-1	9554-9560	During	_	
50-2	9561-9569	encoding	_	
50-3	9570-9571	(	_	
50-4	9571-9574	Fig	_	
50-5	9574-9575	.	_	
50-6	9576-9578	1a	_	
50-7	9578-9579	)	_	
50-8	9579-9580	,	_	
50-9	9581-9593	participants	_	
50-10	9594-9598	were	_	
50-11	9599-9608	presented	_	
50-12	9609-9613	with	_	
50-13	9614-9623	orienting	_	
50-14	9624-9633	questions	_	
50-15	9633-9634	,	_	
50-16	9635-9644	directing	_	
50-17	9645-9650	their	_	
50-18	9651-9660	attention	_	
50-19	9661-9663	to	_	
50-20	9664-9667	the	_	
50-21	9668-9676	critical	_	
50-22	9677-9681	item	_	
50-23	9681-9682	,	_	
50-24	9683-9686	and	_	
50-25	9687-9691	were	_	
50-26	9692-9697	asked	_	
50-27	9698-9704	either	_	
50-28	9705-9710	about	_	
50-29	9711-9715	item	_	
50-30	9716-9724	features	_	
50-31	9725-9726	(	_	
50-32	9726-9729	e.g	_	
50-33	9729-9730	.	_	
50-34	9730-9731	,	_	
50-35	9732-9733	“	_	
50-36	9733-9737	Does	_	
50-37	9738-9741	the	_	
50-38	9742-9746	lamp	_	
50-39	9747-9751	have	_	
50-40	9752-9753	a	_	
50-41	9754-9760	square	_	
50-42	9761-9766	shade	_	
50-43	9766-9767	?	_	
50-44	9767-9768	”	_	
50-45	9768-9769	)	_	

#Text=or spatial location (e.g., “Is the lamp on the table next to the couch?”).
51-1	9770-9772	or	_	
51-2	9773-9780	spatial	_	
51-3	9781-9789	location	_	
51-4	9790-9791	(	_	
51-5	9791-9794	e.g	_	
51-6	9794-9795	.	_	
51-7	9795-9796	,	_	
51-8	9797-9798	“	_	
51-9	9798-9800	Is	_	
51-10	9801-9804	the	_	
51-11	9805-9809	lamp	_	
51-12	9810-9812	on	_	
51-13	9813-9816	the	_	
51-14	9817-9822	table	_	
51-15	9823-9827	next	_	
51-16	9828-9830	to	_	
51-17	9831-9834	the	_	
51-18	9835-9840	couch	_	
51-19	9840-9841	?	_	
51-20	9841-9842	”	_	
51-21	9842-9843	)	_	
51-22	9843-9844	.	_	

#Text=These questions ensured that participants attended to and encoded critical items that might subsequently change during the test phase.
52-1	9845-9850	These	_	
52-2	9851-9860	questions	_	
52-3	9861-9868	ensured	_	
52-4	9869-9873	that	_	
52-5	9874-9886	participants	_	
52-6	9887-9895	attended	_	
52-7	9896-9898	to	_	
52-8	9899-9902	and	_	
52-9	9903-9910	encoded	_	
52-10	9911-9919	critical	_	
52-11	9920-9925	items	_	
52-12	9926-9930	that	_	
52-13	9931-9936	might	_	
52-14	9937-9949	subsequently	_	
52-15	9950-9956	change	_	
52-16	9957-9963	during	_	
52-17	9964-9967	the	_	
52-18	9968-9972	test	_	
52-19	9973-9978	phase	_	
52-20	9978-9979	.	_	

#Text=The experiment was designed so that the type of change at test (item or spatial) was always consistent with processing required by the initial orienting question.
53-1	9980-9983	The	_	
53-2	9984-9994	experiment	_	
53-3	9995-9998	was	_	
53-4	9999-10007	designed	_	
53-5	10008-10010	so	_	
53-6	10011-10015	that	_	
53-7	10016-10019	the	_	
53-8	10020-10024	type	_	
53-9	10025-10027	of	_	
53-10	10028-10034	change	_	
53-11	10035-10037	at	_	
53-12	10038-10042	test	_	
53-13	10043-10044	(	_	
53-14	10044-10048	item	_	
53-15	10049-10051	or	_	
53-16	10052-10059	spatial	_	
53-17	10059-10060	)	_	
53-18	10061-10064	was	_	
53-19	10065-10071	always	_	
53-20	10072-10082	consistent	_	
53-21	10083-10087	with	_	
53-22	10088-10098	processing	_	
53-23	10099-10107	required	_	
53-24	10108-10110	by	_	
53-25	10111-10114	the	_	
53-26	10115-10122	initial	_	
53-27	10123-10132	orienting	_	
53-28	10133-10141	question	_	
53-29	10141-10142	.	_	

#Text=Methods
#Text=After informed consent, each participant successfully completed a practice session before being situated in the fMRI scanner with head pads to minimize motion.
54-1	10143-10150	Methods	_	
54-2	10151-10156	After	_	
54-3	10157-10165	informed	_	
54-4	10166-10173	consent	_	
54-5	10173-10174	,	_	
54-6	10175-10179	each	_	
54-7	10180-10191	participant	_	
54-8	10192-10204	successfully	_	
54-9	10205-10214	completed	_	
54-10	10215-10216	a	_	
54-11	10217-10225	practice	_	
54-12	10226-10233	session	_	
54-13	10234-10240	before	_	
54-14	10241-10246	being	_	
54-15	10247-10255	situated	_	
54-16	10256-10258	in	_	
54-17	10259-10262	the	_	
54-18	10263-10267	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
54-19	10268-10275	scanner	_	
54-20	10276-10280	with	_	
54-21	10281-10285	head	_	
54-22	10286-10290	pads	_	
54-23	10291-10293	to	_	
54-24	10294-10302	minimize	_	
54-25	10303-10309	motion	_	
54-26	10309-10310	.	_	

#Text=Scanning consisted of four interleaved encoding and test runs.
55-1	10311-10319	Scanning	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-2	10320-10329	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-3	10330-10332	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-4	10333-10337	four	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-5	10338-10349	interleaved	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-6	10350-10358	encoding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-7	10359-10362	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-8	10363-10367	test	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-9	10368-10372	runs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	
55-10	10372-10373	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[17]	

#Text=Each encoding run consisted of 24 trials.
56-1	10374-10378	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-2	10379-10387	encoding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-3	10388-10391	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-4	10392-10401	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-5	10402-10404	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-6	10405-10407	24	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-7	10408-10414	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[18]	
56-8	10414-10415	.	_	

#Text=Trials initiated with scene presentation, which remained in view for 6 s.
57-1	10416-10422	Trials	_	
57-2	10423-10432	initiated	_	
57-3	10433-10437	with	_	
57-4	10438-10443	scene	_	
57-5	10444-10456	presentation	_	
57-6	10456-10457	,	_	
57-7	10458-10463	which	_	
57-8	10464-10472	remained	_	
57-9	10473-10475	in	_	
57-10	10476-10480	view	_	
57-11	10481-10484	for	_	
57-12	10485-10486	6	_	
57-13	10486-10487	 	_	
57-14	10487-10488	s	_	
57-15	10488-10489	.	_	

#Text=Orienting questions were played via noise cancelling headphones, and participants were instructed to make “yes” or “no” button presses, and attempt to commit each picture to memory.
58-1	10490-10499	Orienting	_	
58-2	10500-10509	questions	_	
58-3	10510-10514	were	_	
58-4	10515-10521	played	_	
58-5	10522-10525	via	_	
58-6	10526-10531	noise	_	
58-7	10532-10542	cancelling	_	
58-8	10543-10553	headphones	_	
58-9	10553-10554	,	_	
58-10	10555-10558	and	_	
58-11	10559-10571	participants	_	
58-12	10572-10576	were	_	
58-13	10577-10587	instructed	_	
58-14	10588-10590	to	_	
58-15	10591-10595	make	_	
58-16	10596-10597	“	_	
58-17	10597-10600	yes	_	
58-18	10600-10601	”	_	
58-19	10602-10604	or	_	
58-20	10605-10606	“	_	
58-21	10606-10608	no	_	
58-22	10608-10609	”	_	
58-23	10610-10616	button	_	
58-24	10617-10624	presses	_	
58-25	10624-10625	,	_	
58-26	10626-10629	and	_	
58-27	10630-10637	attempt	_	
58-28	10638-10640	to	_	
58-29	10641-10647	commit	_	
58-30	10648-10652	each	_	
58-31	10653-10660	picture	_	
58-32	10661-10663	to	_	
58-33	10664-10670	memory	_	
58-34	10670-10671	.	_	

#Text=Trials were separated by a variable duration inter-trial interval (ITI: 2–18 s), with a 1 s central fixation cross occurring during this ITI prior to onset of the next scene.
59-1	10672-10678	Trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-2	10679-10683	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-3	10684-10693	separated	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-4	10694-10696	by	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-5	10697-10698	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-6	10699-10707	variable	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-7	10708-10716	duration	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-8	10717-10728	inter-trial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-9	10729-10737	interval	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-10	10738-10739	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-11	10739-10742	ITI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-12	10742-10743	:	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-13	10744-10745	2	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-14	10745-10746	–	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-15	10746-10748	18	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-16	10748-10749	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-17	10749-10750	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-18	10750-10751	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-19	10751-10752	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-20	10753-10757	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-21	10758-10759	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-22	10760-10761	1	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-23	10761-10762	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-24	10762-10763	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-25	10764-10771	central	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-26	10772-10780	fixation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-27	10781-10786	cross	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-28	10787-10796	occurring	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-29	10797-10803	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-30	10804-10808	this	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-31	10809-10812	ITI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-32	10813-10818	prior	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-33	10819-10821	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-34	10822-10827	onset	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-35	10828-10830	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-36	10831-10834	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-37	10835-10839	next	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-38	10840-10845	scene	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
59-39	10845-10846	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	

#Text=Timing was optimized using Optseq (http://surfer.nmr.mgh.harvard.edu/optseq/).
60-1	10847-10853	Timing	_	
60-2	10854-10857	was	_	
60-3	10858-10867	optimized	_	
60-4	10868-10873	using	_	
60-5	10874-10880	Optseq	_	
60-6	10881-10882	(	_	
60-7	10882-10886	http	_	
60-8	10886-10887	:	_	
60-9	10887-10888	/	_	
60-10	10888-10889	/	_	
60-11	10889-10915	surfer.nmr.mgh.harvard.edu	_	
60-12	10915-10916	/	_	
60-13	10916-10922	optseq	_	
60-14	10922-10923	/	_	
60-15	10923-10924	)	_	
60-16	10924-10925	.	_	

#Text=Each encoding run lasted 278 s and, across four runs, participants encoded 96 trial-unique pictures.
61-1	10926-10930	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-2	10931-10939	encoding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-3	10940-10943	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-4	10944-10950	lasted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-5	10951-10954	278	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-6	10954-10955	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-7	10955-10956	s	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-8	10957-10960	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-9	10960-10961	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-10	10962-10968	across	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-11	10969-10973	four	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-12	10974-10978	runs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-13	10978-10979	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-14	10980-10992	participants	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-15	10993-11000	encoded	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-16	11001-11003	96	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-17	11004-11016	trial-unique	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-18	11017-11025	pictures	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	
61-19	11025-11026	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]	

#Text=Each test run consisted of 32 trials.
62-1	11027-11031	Each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-2	11032-11036	test	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-3	11037-11040	run	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-4	11041-11050	consisted	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-5	11051-11053	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-6	11054-11056	32	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-7	11057-11063	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	
62-8	11063-11064	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]	

#Text=Presented scenes were either new and had not been seen during encoding (novel condition: 8 trials), or had been studied previously (24 trials), and were counterbalanced across conditions.
63-1	11065-11074	Presented	_	
63-2	11075-11081	scenes	_	
63-3	11082-11086	were	_	
63-4	11087-11093	either	_	
63-5	11094-11097	new	_	
63-6	11098-11101	and	_	
63-7	11102-11105	had	_	
63-8	11106-11109	not	_	
63-9	11110-11114	been	_	
63-10	11115-11119	seen	_	
63-11	11120-11126	during	_	
63-12	11127-11135	encoding	_	
63-13	11136-11137	(	_	
63-14	11137-11142	novel	_	
63-15	11143-11152	condition	_	
63-16	11152-11153	:	_	
63-17	11154-11155	8	_	
63-18	11156-11162	trials	_	
63-19	11162-11163	)	_	
63-20	11163-11164	,	_	
63-21	11165-11167	or	_	
63-22	11168-11171	had	_	
63-23	11172-11176	been	_	
63-24	11177-11184	studied	_	
63-25	11185-11195	previously	_	
63-26	11196-11197	(	_	
63-27	11197-11199	24	_	
63-28	11200-11206	trials	_	
63-29	11206-11207	)	_	
63-30	11207-11208	,	_	
63-31	11209-11212	and	_	
63-32	11213-11217	were	_	
63-33	11218-11233	counterbalanced	_	
63-34	11234-11240	across	_	
63-35	11241-11251	conditions	_	
63-36	11251-11252	.	_	

#Text=Studied scenes were either unchanged (8 trials), contained a new item (item change: 8 trials), or contained a change in item location (spatial change: 8 trials).
64-1	11253-11260	Studied	_	
64-2	11261-11267	scenes	_	
64-3	11268-11272	were	_	
64-4	11273-11279	either	_	
64-5	11280-11289	unchanged	_	
64-6	11290-11291	(	_	
64-7	11291-11292	8	_	
64-8	11293-11299	trials	_	
64-9	11299-11300	)	_	
64-10	11300-11301	,	_	
64-11	11302-11311	contained	_	
64-12	11312-11313	a	_	
64-13	11314-11317	new	_	
64-14	11318-11322	item	_	
64-15	11323-11324	(	_	
64-16	11324-11328	item	_	
64-17	11329-11335	change	_	
64-18	11335-11336	:	_	
64-19	11337-11338	8	_	
64-20	11339-11345	trials	_	
64-21	11345-11346	)	_	
64-22	11346-11347	,	_	
64-23	11348-11350	or	_	
64-24	11351-11360	contained	_	
64-25	11361-11362	a	_	
64-26	11363-11369	change	_	
64-27	11370-11372	in	_	
64-28	11373-11377	item	_	
64-29	11378-11386	location	_	
64-30	11387-11388	(	_	
64-31	11388-11395	spatial	_	
64-32	11396-11402	change	_	
64-33	11402-11403	:	_	
64-34	11404-11405	8	_	
64-35	11406-11412	trials	_	
64-36	11412-11413	)	_	
64-37	11413-11414	.	_	

#Text=Each trial began with presentation of a scene for 6 s, and event timing was identical to encoding.
65-1	11415-11419	Each	_	
65-2	11420-11425	trial	_	
65-3	11426-11431	began	_	
65-4	11432-11436	with	_	
65-5	11437-11449	presentation	_	
65-6	11450-11452	of	_	
65-7	11453-11454	a	_	
65-8	11455-11460	scene	_	
65-9	11461-11464	for	_	
65-10	11465-11466	6	_	
65-11	11466-11467	 	_	
65-12	11467-11468	s	_	
65-13	11468-11469	,	_	
65-14	11470-11473	and	_	
65-15	11474-11479	event	_	
65-16	11480-11486	timing	_	
65-17	11487-11490	was	_	
65-18	11491-11500	identical	_	
65-19	11501-11503	to	_	
65-20	11504-11512	encoding	_	
65-21	11512-11513	.	_	

#Text=Participants were instructed to indicate as quickly and accurately as possible whether each scene was new (i.e. had not been seen in the corresponding encoding run), unchanged (i.e. seen before and completely unchanged), or changed (i.e. seen before, but now contained an item or a spatial change).
66-1	11514-11526	Participants	_	
66-2	11527-11531	were	_	
66-3	11532-11542	instructed	_	
66-4	11543-11545	to	_	
66-5	11546-11554	indicate	_	
66-6	11555-11557	as	_	
66-7	11558-11565	quickly	_	
66-8	11566-11569	and	_	
66-9	11570-11580	accurately	_	
66-10	11581-11583	as	_	
66-11	11584-11592	possible	_	
66-12	11593-11600	whether	_	
66-13	11601-11605	each	_	
66-14	11606-11611	scene	_	
66-15	11612-11615	was	_	
66-16	11616-11619	new	_	
66-17	11620-11621	(	_	
66-18	11621-11624	i.e	_	
66-19	11624-11625	.	_	
66-20	11626-11629	had	_	
66-21	11630-11633	not	_	
66-22	11634-11638	been	_	
66-23	11639-11643	seen	_	
66-24	11644-11646	in	_	
66-25	11647-11650	the	_	
66-26	11651-11664	corresponding	_	
66-27	11665-11673	encoding	_	
66-28	11674-11677	run	_	
66-29	11677-11678	)	_	
66-30	11678-11679	,	_	
66-31	11680-11689	unchanged	_	
66-32	11690-11691	(	_	
66-33	11691-11694	i.e	_	
66-34	11694-11695	.	_	
66-35	11696-11700	seen	_	
66-36	11701-11707	before	_	
66-37	11708-11711	and	_	
66-38	11712-11722	completely	_	
66-39	11723-11732	unchanged	_	
66-40	11732-11733	)	_	
66-41	11733-11734	,	_	
66-42	11735-11737	or	_	
66-43	11738-11745	changed	_	
66-44	11746-11747	(	_	
66-45	11747-11750	i.e	_	
66-46	11750-11751	.	_	
66-47	11752-11756	seen	_	
66-48	11757-11763	before	_	
66-49	11763-11764	,	_	
66-50	11765-11768	but	_	
66-51	11769-11772	now	_	
66-52	11773-11782	contained	_	
66-53	11783-11785	an	_	
66-54	11786-11790	item	_	
66-55	11791-11793	or	_	
66-56	11794-11795	a	_	
66-57	11796-11803	spatial	_	
66-58	11804-11810	change	_	
66-59	11810-11811	)	_	
66-60	11811-11812	.	_	

#Text=A variable duration ITI (2–18 s) culminated with a cross hair to encourage central fixation and alert participants to the next scene (see Fig. 1).
67-1	11813-11814	A	_	
67-2	11815-11823	variable	_	
67-3	11824-11832	duration	_	
67-4	11833-11836	ITI	_	
67-5	11837-11838	(	_	
67-6	11838-11839	2	_	
67-7	11839-11840	–	_	
67-8	11840-11842	18	_	
67-9	11842-11843	 	_	
67-10	11843-11844	s	_	
67-11	11844-11845	)	_	
67-12	11846-11856	culminated	_	
67-13	11857-11861	with	_	
67-14	11862-11863	a	_	
67-15	11864-11869	cross	_	
67-16	11870-11874	hair	_	
67-17	11875-11877	to	_	
67-18	11878-11887	encourage	_	
67-19	11888-11895	central	_	
67-20	11896-11904	fixation	_	
67-21	11905-11908	and	_	
67-22	11909-11914	alert	_	
67-23	11915-11927	participants	_	
67-24	11928-11930	to	_	
67-25	11931-11934	the	_	
67-26	11935-11939	next	_	
67-27	11940-11945	scene	_	
67-28	11946-11947	(	_	
67-29	11947-11950	see	_	
67-30	11951-11954	Fig	_	
67-31	11954-11955	.	_	
67-32	11956-11957	1	_	
67-33	11957-11958	)	_	
67-34	11958-11959	.	_	

#Text=Test runs lasted 366 s and, across four runs, participants completed 128 test trials.
68-1	11960-11964	Test	_	
68-2	11965-11969	runs	_	
68-3	11970-11976	lasted	_	
68-4	11977-11980	366	_	
68-5	11980-11981	 	_	
68-6	11981-11982	s	_	
68-7	11983-11986	and	_	
68-8	11986-11987	,	_	
68-9	11988-11994	across	_	
68-10	11995-11999	four	_	
68-11	12000-12004	runs	_	
68-12	12004-12005	,	_	
68-13	12006-12018	participants	_	
68-14	12019-12028	completed	_	
68-15	12029-12032	128	_	
68-16	12033-12037	test	_	
68-17	12038-12044	trials	_	
68-18	12044-12045	.	_	

#Text=Eye movements were also recorded during the test phase to examine eye movement memory effects.
69-1	12046-12049	Eye	_	
69-2	12050-12059	movements	_	
69-3	12060-12064	were	_	
69-4	12065-12069	also	_	
69-5	12070-12078	recorded	_	
69-6	12079-12085	during	_	
69-7	12086-12089	the	_	
69-8	12090-12094	test	_	
69-9	12095-12100	phase	_	
69-10	12101-12103	to	_	
69-11	12104-12111	examine	_	
69-12	12112-12115	eye	_	
69-13	12116-12124	movement	_	
69-14	12125-12131	memory	_	
69-15	12132-12139	effects	_	
69-16	12139-12140	.	_	

#Text=However, because of technical difficulties, eye movement data were available for only a subset of participants.
70-1	12141-12148	However	_	
70-2	12148-12149	,	_	
70-3	12150-12157	because	_	
70-4	12158-12160	of	_	
70-5	12161-12170	technical	_	
70-6	12171-12183	difficulties	_	
70-7	12183-12184	,	_	
70-8	12185-12188	eye	_	
70-9	12189-12197	movement	_	
70-10	12198-12202	data	_	
70-11	12203-12207	were	_	
70-12	12208-12217	available	_	
70-13	12218-12221	for	_	
70-14	12222-12226	only	_	
70-15	12227-12228	a	_	
70-16	12229-12235	subset	_	
70-17	12236-12238	of	_	
70-18	12239-12251	participants	_	
70-19	12251-12252	.	_	

#Text=Although the pattern of results paralleled earlier findings, because of the limited sample size, and because they are not a focus of the current investigation, eye tracking methods and results are summarized in Supplementary Materials.
#Text=fMRI acquisition
#Text=Data were obtained at the UC Davis Imaging Research Center on a 3-T Siemens Tim Trio scanner (Erlangen, Germany) with a Siemens 8 channel phased array coil.
71-1	12253-12261	Although	_	
71-2	12262-12265	the	_	
71-3	12266-12273	pattern	_	
71-4	12274-12276	of	_	
71-5	12277-12284	results	_	
71-6	12285-12295	paralleled	_	
71-7	12296-12303	earlier	_	
71-8	12304-12312	findings	_	
71-9	12312-12313	,	_	
71-10	12314-12321	because	_	
71-11	12322-12324	of	_	
71-12	12325-12328	the	_	
71-13	12329-12336	limited	_	
71-14	12337-12343	sample	_	
71-15	12344-12348	size	_	
71-16	12348-12349	,	_	
71-17	12350-12353	and	_	
71-18	12354-12361	because	_	
71-19	12362-12366	they	_	
71-20	12367-12370	are	_	
71-21	12371-12374	not	_	
71-22	12375-12376	a	_	
71-23	12377-12382	focus	_	
71-24	12383-12385	of	_	
71-25	12386-12389	the	_	
71-26	12390-12397	current	_	
71-27	12398-12411	investigation	_	
71-28	12411-12412	,	_	
71-29	12413-12416	eye	_	
71-30	12417-12425	tracking	_	
71-31	12426-12433	methods	_	
71-32	12434-12437	and	_	
71-33	12438-12445	results	_	
71-34	12446-12449	are	_	
71-35	12450-12460	summarized	_	
71-36	12461-12463	in	_	
71-37	12464-12477	Supplementary	_	
71-38	12478-12487	Materials	_	
71-39	12487-12488	.	_	
71-40	12489-12493	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
71-41	12494-12505	acquisition	_	
71-42	12506-12510	Data	_	
71-43	12511-12515	were	_	
71-44	12516-12524	obtained	_	
71-45	12525-12527	at	_	
71-46	12528-12531	the	_	
71-47	12532-12534	UC	_	
71-48	12535-12540	Davis	_	
71-49	12541-12548	Imaging	_	
71-50	12549-12557	Research	_	
71-51	12558-12564	Center	_	
71-52	12565-12567	on	_	
71-53	12568-12569	a	_	
71-54	12570-12571	3	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-55	12571-12572	-	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-56	12572-12573	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-57	12574-12581	Siemens	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-58	12582-12585	Tim	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-59	12586-12590	Trio	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-60	12591-12598	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]	
71-61	12599-12600	(	_	
71-62	12600-12608	Erlangen	_	
71-63	12608-12609	,	_	
71-64	12610-12617	Germany	_	
71-65	12617-12618	)	_	
71-66	12619-12623	with	_	
71-67	12624-12625	a	_	
71-68	12626-12633	Siemens	_	
71-69	12634-12635	8	_	
71-70	12636-12643	channel	_	
71-71	12644-12650	phased	_	
71-72	12651-12656	array	_	
71-73	12657-12661	coil	_	
71-74	12661-12662	.	_	

#Text=After acquiring a rapid 3-plane localizer, trans-axial T2 weighted images were acquired with spatial resolution of 0.4 × 0.4 × 4.0 mm.
72-1	12663-12668	After	_	
72-2	12669-12678	acquiring	_	
72-3	12679-12680	a	_	
72-4	12681-12686	rapid	_	
72-5	12687-12688	3	_	
72-6	12688-12689	-	_	
72-7	12689-12694	plane	_	
72-8	12695-12704	localizer	_	
72-9	12704-12705	,	_	
72-10	12706-12717	trans-axial	_	
72-11	12718-12720	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[23]	
72-12	12721-12729	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[23]	
72-13	12730-12736	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[23]	
72-14	12737-12741	were	_	
72-15	12742-12750	acquired	_	
72-16	12751-12755	with	_	
72-17	12756-12763	spatial	_	
72-18	12764-12774	resolution	_	
72-19	12775-12777	of	_	
72-20	12778-12781	0.4	_	
72-21	12781-12782	 	_	
72-22	12782-12783	×	_	
72-23	12783-12784	 	_	
72-24	12784-12787	0.4	_	
72-25	12787-12788	 	_	
72-26	12788-12789	×	_	
72-27	12789-12790	 	_	
72-28	12790-12793	4.0	_	
72-29	12793-12794	 	_	
72-30	12794-12796	mm	_	
72-31	12796-12797	.	_	

#Text=A reference field-map image with spatial resolution of 3.4 × 3.4 × 4.0 mm was used for motion and distortion correction.
73-1	12798-12799	A	_	
73-2	12800-12809	reference	_	
73-3	12810-12819	field-map	_	
73-4	12820-12825	image	_	
73-5	12826-12830	with	_	
73-6	12831-12838	spatial	_	
73-7	12839-12849	resolution	_	
73-8	12850-12852	of	_	
73-9	12853-12856	3.4	_	
73-10	12856-12857	 	_	
73-11	12857-12858	×	_	
73-12	12858-12859	 	_	
73-13	12859-12862	3.4	_	
73-14	12862-12863	 	_	
73-15	12863-12864	×	_	
73-16	12864-12865	 	_	
73-17	12865-12868	4.0	_	
73-18	12868-12869	 	_	
73-19	12869-12871	mm	_	
73-20	12872-12875	was	_	
73-21	12876-12880	used	_	
73-22	12881-12884	for	_	
73-23	12885-12891	motion	_	
73-24	12892-12895	and	_	
73-25	12896-12906	distortion	_	
73-26	12907-12917	correction	_	
73-27	12917-12918	.	_	

#Text=Functional images were acquired with blood oxygenation level dependent imaging (BOLD) using a 34-slice whole-brain, single-shot gradient-echo echo-planar sequence (TR 2000 ms, TE 27 ms, flip angle 90°, FOV 220 × 220 mm, slice thickness 4.0 mm, no gap).
74-1	12919-12929	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
74-2	12930-12936	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[25]	
74-3	12937-12941	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-4	12942-12950	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-5	12951-12955	with	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-6	12956-12961	blood	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-7	12962-12973	oxygenation	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-8	12974-12979	level	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-9	12980-12989	dependent	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-10	12990-12997	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-11	12998-12999	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-12	12999-13003	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-13	13003-13004	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[24]	
74-14	13005-13010	using	_	
74-15	13011-13012	a	_	
74-16	13013-13015	34	_	
74-17	13015-13016	-	_	
74-18	13016-13021	slice	_	
74-19	13022-13033	whole-brain	_	
74-20	13033-13034	,	_	
74-21	13035-13046	single-shot	_	
74-22	13047-13060	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
74-23	13061-13072	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
74-24	13073-13081	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]	
74-25	13082-13083	(	_	
74-26	13083-13085	TR	_	
74-27	13086-13090	2000	_	
74-28	13090-13091	 	_	
74-29	13091-13093	ms	_	
74-30	13093-13094	,	_	
74-31	13095-13097	TE	_	
74-32	13098-13100	27	_	
74-33	13100-13101	 	_	
74-34	13101-13103	ms	_	
74-35	13103-13104	,	_	
74-36	13105-13109	flip	_	
74-37	13110-13115	angle	_	
74-38	13116-13118	90	_	
74-39	13118-13119	°	_	
74-40	13119-13120	,	_	
74-41	13121-13124	FOV	_	
74-42	13125-13128	220	_	
74-43	13128-13129	 	_	
74-44	13129-13130	×	_	
74-45	13130-13131	 	_	
74-46	13131-13134	220	_	
74-47	13134-13135	 	_	
74-48	13135-13137	mm	_	
74-49	13137-13138	,	_	
74-50	13139-13144	slice	_	
74-51	13145-13154	thickness	_	
74-52	13155-13158	4.0	_	
74-53	13158-13159	 	_	
74-54	13159-13161	mm	_	
74-55	13161-13162	,	_	
74-56	13163-13165	no	_	
74-57	13166-13169	gap	_	
74-58	13169-13170	)	_	
74-59	13170-13171	.	_	

#Text=Structural T1-weighted images were acquired using an MPRAGE sequence (TR = 2000 ms, TE ~ 3.0 ms, FA = 8°, FOV = 256 × 240 mm, matrix: 256 × 256, voxel size: 1 mm isotropic, 208 sagittal slices).
#Text=fMRI processing
#Text=Pre-processing was accomplished with FMRI Expert Analysis Tool (FEAT) in the FMRIB Software Library (FSL version 4.1; www.fmrib.ox.ac.uk/fsl) using standard procedures, including fieldmap correction.
75-1	13172-13182	Structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
75-2	13183-13185	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
75-3	13185-13186	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
75-4	13186-13194	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
75-5	13195-13201	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]	
75-6	13202-13206	were	_	
75-7	13207-13215	acquired	_	
75-8	13216-13221	using	_	
75-9	13222-13224	an	_	
75-10	13225-13231	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	
75-11	13232-13240	sequence	_	
75-12	13241-13242	(	_	
75-13	13242-13244	TR	_	
75-14	13244-13245	 	_	
75-15	13245-13246	=	_	
75-16	13246-13247	 	_	
75-17	13247-13251	2000	_	
75-18	13251-13252	 	_	
75-19	13252-13254	ms	_	
75-20	13254-13255	,	_	
75-21	13256-13258	TE	_	
75-22	13259-13260	~	_	
75-23	13260-13261	 	_	
75-24	13261-13264	3.0	_	
75-25	13264-13265	 	_	
75-26	13265-13267	ms	_	
75-27	13267-13268	,	_	
75-28	13269-13271	FA	_	
75-29	13271-13272	 	_	
75-30	13272-13273	=	_	
75-31	13273-13274	 	_	
75-32	13274-13275	8	_	
75-33	13275-13276	°	_	
75-34	13276-13277	,	_	
75-35	13278-13281	FOV	_	
75-36	13281-13282	 	_	
75-37	13282-13283	=	_	
75-38	13283-13284	 	_	
75-39	13284-13287	256	_	
75-40	13287-13288	 	_	
75-41	13288-13289	×	_	
75-42	13289-13290	 	_	
75-43	13290-13293	240	_	
75-44	13293-13294	 	_	
75-45	13294-13296	mm	_	
75-46	13296-13297	,	_	
75-47	13298-13304	matrix	_	
75-48	13304-13305	:	_	
75-49	13306-13309	256	_	
75-50	13309-13310	 	_	
75-51	13310-13311	×	_	
75-52	13311-13312	 	_	
75-53	13312-13315	256	_	
75-54	13315-13316	,	_	
75-55	13317-13322	voxel	_	
75-56	13323-13327	size	_	
75-57	13327-13328	:	_	
75-58	13329-13330	1	_	
75-59	13330-13331	 	_	
75-60	13331-13333	mm	_	
75-61	13334-13343	isotropic	_	
75-62	13343-13344	,	_	
75-63	13345-13348	208	_	
75-64	13349-13357	sagittal	_	
75-65	13358-13364	slices	_	
75-66	13364-13365	)	_	
75-67	13365-13366	.	_	
75-68	13367-13371	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
75-69	13372-13382	processing	_	
75-70	13383-13397	Pre-processing	_	
75-71	13398-13401	was	_	
75-72	13402-13414	accomplished	_	
75-73	13415-13419	with	_	
75-74	13420-13424	FMRI	_	
75-75	13425-13431	Expert	_	
75-76	13432-13440	Analysis	_	
75-77	13441-13445	Tool	_	
75-78	13446-13447	(	_	
75-79	13447-13451	FEAT	_	
75-80	13451-13452	)	_	
75-81	13453-13455	in	_	
75-82	13456-13459	the	_	
75-83	13460-13465	FMRIB	_	
75-84	13466-13474	Software	_	
75-85	13475-13482	Library	_	
75-86	13483-13484	(	_	
75-87	13484-13487	FSL	_	
75-88	13488-13495	version	_	
75-89	13496-13499	4.1	_	
75-90	13499-13500	;	_	
75-91	13501-13519	www.fmrib.ox.ac.uk	_	
75-92	13519-13520	/	_	
75-93	13520-13523	fsl	_	
75-94	13523-13524	)	_	
75-95	13525-13530	using	_	
75-96	13531-13539	standard	_	
75-97	13540-13550	procedures	_	
75-98	13550-13551	,	_	
75-99	13552-13561	including	_	
75-100	13562-13570	fieldmap	_	
75-101	13571-13581	correction	_	
75-102	13581-13582	.	_	

#Text=Statistical analysis was performed using a general linear model (GLM) implemented in FEAT (FSL version 4.1).
76-1	13583-13594	Statistical	_	
76-2	13595-13603	analysis	_	
76-3	13604-13607	was	_	
76-4	13608-13617	performed	_	
76-5	13618-13623	using	_	
76-6	13624-13625	a	_	
76-7	13626-13633	general	_	
76-8	13634-13640	linear	_	
76-9	13641-13646	model	_	
76-10	13647-13648	(	_	
76-11	13648-13651	GLM	_	
76-12	13651-13652	)	_	
76-13	13653-13664	implemented	_	
76-14	13665-13667	in	_	
76-15	13668-13672	FEAT	_	
76-16	13673-13674	(	_	
76-17	13674-13677	FSL	_	
76-18	13678-13685	version	_	
76-19	13686-13689	4.1	_	
76-20	13689-13690	)	_	
76-21	13690-13691	.	_	

#Text=Test phase activity associated with responses for each scene type (unchanged, novel, item change, spatial change) was modeled for each 6 s presentation epoch by convolving a vector of expected neural activity with the 3 basis-function set of FMRIB's Linear Optimal Basis Sets (FLOBS), which adjusts the canonical hemodynamic response function to account for delay and dispersion in order to improve GLM fit.
77-1	13692-13696	Test	_	
77-2	13697-13702	phase	_	
77-3	13703-13711	activity	_	
77-4	13712-13722	associated	_	
77-5	13723-13727	with	_	
77-6	13728-13737	responses	_	
77-7	13738-13741	for	_	
77-8	13742-13746	each	_	
77-9	13747-13752	scene	_	
77-10	13753-13757	type	_	
77-11	13758-13759	(	_	
77-12	13759-13768	unchanged	_	
77-13	13768-13769	,	_	
77-14	13770-13775	novel	_	
77-15	13775-13776	,	_	
77-16	13777-13781	item	_	
77-17	13782-13788	change	_	
77-18	13788-13789	,	_	
77-19	13790-13797	spatial	_	
77-20	13798-13804	change	_	
77-21	13804-13805	)	_	
77-22	13806-13809	was	_	
77-23	13810-13817	modeled	_	
77-24	13818-13821	for	_	
77-25	13822-13826	each	_	
77-26	13827-13828	6	_	
77-27	13828-13829	 	_	
77-28	13829-13830	s	_	
77-29	13831-13843	presentation	_	
77-30	13844-13849	epoch	_	
77-31	13850-13852	by	_	
77-32	13853-13863	convolving	_	
77-33	13864-13865	a	_	
77-34	13866-13872	vector	_	
77-35	13873-13875	of	_	
77-36	13876-13884	expected	_	
77-37	13885-13891	neural	_	
77-38	13892-13900	activity	_	
77-39	13901-13905	with	_	
77-40	13906-13909	the	_	
77-41	13910-13911	3	_	
77-42	13912-13926	basis-function	_	
77-43	13927-13930	set	_	
77-44	13931-13933	of	_	
77-45	13934-13941	FMRIB's	_	
77-46	13942-13948	Linear	_	
77-47	13949-13956	Optimal	_	
77-48	13957-13962	Basis	_	
77-49	13963-13967	Sets	_	
77-50	13968-13969	(	_	
77-51	13969-13974	FLOBS	_	
77-52	13974-13975	)	_	
77-53	13975-13976	,	_	
77-54	13977-13982	which	_	
77-55	13983-13990	adjusts	_	
77-56	13991-13994	the	_	
77-57	13995-14004	canonical	_	
77-58	14005-14016	hemodynamic	_	
77-59	14017-14025	response	_	
77-60	14026-14034	function	_	
77-61	14035-14037	to	_	
77-62	14038-14045	account	_	
77-63	14046-14049	for	_	
77-64	14050-14055	delay	_	
77-65	14056-14059	and	_	
77-66	14060-14070	dispersion	_	
77-67	14071-14073	in	_	
77-68	14074-14079	order	_	
77-69	14080-14082	to	_	
77-70	14083-14090	improve	_	
77-71	14091-14094	GLM	_	
77-72	14095-14098	fit	_	
77-73	14098-14099	.	_	

#Text=Although both correct and incorrect responses were modeled, only correct responses were examined at the group level.
78-1	14100-14108	Although	_	
78-2	14109-14113	both	_	
78-3	14114-14121	correct	_	
78-4	14122-14125	and	_	
78-5	14126-14135	incorrect	_	
78-6	14136-14145	responses	_	
78-7	14146-14150	were	_	
78-8	14151-14158	modeled	_	
78-9	14158-14159	,	_	
78-10	14160-14164	only	_	
78-11	14165-14172	correct	_	
78-12	14173-14182	responses	_	
78-13	14183-14187	were	_	
78-14	14188-14196	examined	_	
78-15	14197-14199	at	_	
78-16	14200-14203	the	_	
78-17	14204-14209	group	_	
78-18	14210-14215	level	_	
78-19	14215-14216	.	_	

#Text=Temporal autocorrelation due to low frequency (“1/f”) noise was accounted for by pre-whitening (FSL's FILM).
79-1	14217-14225	Temporal	_	
79-2	14226-14241	autocorrelation	_	
79-3	14242-14245	due	_	
79-4	14246-14248	to	_	
79-5	14249-14252	low	_	
79-6	14253-14262	frequency	_	
79-7	14263-14264	(	_	
79-8	14264-14265	“	_	
79-9	14265-14266	1	_	
79-10	14266-14267	/	_	
79-11	14267-14268	f	_	
79-12	14268-14269	”	_	
79-13	14269-14270	)	_	
79-14	14271-14276	noise	_	
79-15	14277-14280	was	_	
79-16	14281-14290	accounted	_	
79-17	14291-14294	for	_	
79-18	14295-14297	by	_	
79-19	14298-14311	pre-whitening	_	
79-20	14312-14313	(	_	
79-21	14313-14318	FSL's	_	
79-22	14319-14323	FILM	_	
79-23	14323-14324	)	_	
79-24	14324-14325	.	_	

#Text=The 4 test runs were combined in a 2nd level fixed-effect analysis for each subject.
80-1	14326-14329	The	_	
80-2	14330-14331	4	_	
80-3	14332-14336	test	_	
80-4	14337-14341	runs	_	
80-5	14342-14346	were	_	
80-6	14347-14355	combined	_	
80-7	14356-14358	in	_	
80-8	14359-14360	a	_	
80-9	14361-14364	2nd	_	
80-10	14365-14370	level	_	
80-11	14371-14383	fixed-effect	_	
80-12	14384-14392	analysis	_	
80-13	14393-14396	for	_	
80-14	14397-14401	each	_	
80-15	14402-14409	subject	_	
80-16	14409-14410	.	_	

#Text=These parameter estimates were used in a 3rd level mixed-effects analysis to derive group-level maps that separately contrasted item and spatial change trials with unchanged trials for all subjects (FSL's FLAME).
81-1	14411-14416	These	_	
81-2	14417-14426	parameter	_	
81-3	14427-14436	estimates	_	
81-4	14437-14441	were	_	
81-5	14442-14446	used	_	
81-6	14447-14449	in	_	
81-7	14450-14451	a	_	
81-8	14452-14455	3rd	_	
81-9	14456-14461	level	_	
81-10	14462-14475	mixed-effects	_	
81-11	14476-14484	analysis	_	
81-12	14485-14487	to	_	
81-13	14488-14494	derive	_	
81-14	14495-14506	group-level	_	
81-15	14507-14511	maps	_	
81-16	14512-14516	that	_	
81-17	14517-14527	separately	_	
81-18	14528-14538	contrasted	_	
81-19	14539-14543	item	_	
81-20	14544-14547	and	_	
81-21	14548-14555	spatial	_	
81-22	14556-14562	change	_	
81-23	14563-14569	trials	_	
81-24	14570-14574	with	_	
81-25	14575-14584	unchanged	_	
81-26	14585-14591	trials	_	
81-27	14592-14595	for	_	
81-28	14596-14599	all	_	
81-29	14600-14608	subjects	_	
81-30	14609-14610	(	_	
81-31	14610-14615	FSL's	_	
81-32	14616-14621	FLAME	_	
81-33	14621-14622	)	_	
81-34	14622-14623	.	_	

#Text=Because relative motion (mean ± standard deviation, in mm) was greater in patients with schizophrenia (0.11 ± 0.06 mm) than in healthy controls (0.07 ± 0.03 mm; t(48) = − 2.92, p < 0.01), relative motion was included as a covariate of no-interest.
82-1	14624-14631	Because	_	
82-2	14632-14640	relative	_	
82-3	14641-14647	motion	_	
82-4	14648-14649	(	_	
82-5	14649-14653	mean	_	
82-6	14653-14654	 	_	
82-7	14654-14655	±	_	
82-8	14655-14656	 	_	
82-9	14656-14664	standard	_	
82-10	14665-14674	deviation	_	
82-11	14674-14675	,	_	
82-12	14676-14678	in	_	
82-13	14679-14681	mm	_	
82-14	14681-14682	)	_	
82-15	14683-14686	was	_	
82-16	14687-14694	greater	_	
82-17	14695-14697	in	_	
82-18	14698-14706	patients	_	
82-19	14707-14711	with	_	
82-20	14712-14725	schizophrenia	_	
82-21	14726-14727	(	_	
82-22	14727-14731	0.11	_	
82-23	14731-14732	 	_	
82-24	14732-14733	±	_	
82-25	14733-14734	 	_	
82-26	14734-14738	0.06	_	
82-27	14738-14739	 	_	
82-28	14739-14741	mm	_	
82-29	14741-14742	)	_	
82-30	14743-14747	than	_	
82-31	14748-14750	in	_	
82-32	14751-14758	healthy	_	
82-33	14759-14767	controls	_	
82-34	14768-14769	(	_	
82-35	14769-14773	0.07	_	
82-36	14773-14774	 	_	
82-37	14774-14775	±	_	
82-38	14775-14776	 	_	
82-39	14776-14780	0.03	_	
82-40	14780-14781	 	_	
82-41	14781-14783	mm	_	
82-42	14783-14784	;	_	
82-43	14785-14786	t	_	
82-44	14786-14787	(	_	
82-45	14787-14789	48	_	
82-46	14789-14790	)	_	
82-47	14790-14791	 	_	
82-48	14791-14792	=	_	
82-49	14792-14793	 	_	
82-50	14793-14794	−	_	
82-51	14794-14795	 	_	
82-52	14795-14799	2.92	_	
82-53	14799-14800	,	_	
82-54	14801-14802	p	_	
82-55	14802-14803	 	_	
82-56	14803-14804	<	_	
82-57	14804-14805	 	_	
82-58	14805-14809	0.01	_	
82-59	14809-14810	)	_	
82-60	14810-14811	,	_	
82-61	14812-14820	relative	_	
82-62	14821-14827	motion	_	
82-63	14828-14831	was	_	
82-64	14832-14840	included	_	
82-65	14841-14843	as	_	
82-66	14844-14845	a	_	
82-67	14846-14855	covariate	_	
82-68	14856-14858	of	_	
82-69	14859-14870	no-interest	_	
82-70	14870-14871	.	_	

#Text=To test hypotheses about the effects of memory for item versus spatial information on hippocampal activation, we used previously established methods, utilizing anatomical landmarks to define a single set of structural regions of interest (ROIs) in the head, body, and tail of the hippocampus that were examined for task effects and group differences for each contrast (i.e., item change minus unchanged, spatial change minus unchanged).
83-1	14872-14874	To	_	
83-2	14875-14879	test	_	
83-3	14880-14890	hypotheses	_	
83-4	14891-14896	about	_	
83-5	14897-14900	the	_	
83-6	14901-14908	effects	_	
83-7	14909-14911	of	_	
83-8	14912-14918	memory	_	
83-9	14919-14922	for	_	
83-10	14923-14927	item	_	
83-11	14928-14934	versus	_	
83-12	14935-14942	spatial	_	
83-13	14943-14954	information	_	
83-14	14955-14957	on	_	
83-15	14958-14969	hippocampal	_	
83-16	14970-14980	activation	_	
83-17	14980-14981	,	_	
83-18	14982-14984	we	_	
83-19	14985-14989	used	_	
83-20	14990-15000	previously	_	
83-21	15001-15012	established	_	
83-22	15013-15020	methods	_	
83-23	15020-15021	,	_	
83-24	15022-15031	utilizing	_	
83-25	15032-15042	anatomical	_	
83-26	15043-15052	landmarks	_	
83-27	15053-15055	to	_	
83-28	15056-15062	define	_	
83-29	15063-15064	a	_	
83-30	15065-15071	single	_	
83-31	15072-15075	set	_	
83-32	15076-15078	of	_	
83-33	15079-15089	structural	_	
83-34	15090-15097	regions	_	
83-35	15098-15100	of	_	
83-36	15101-15109	interest	_	
83-37	15110-15111	(	_	
83-38	15111-15115	ROIs	_	
83-39	15115-15116	)	_	
83-40	15117-15119	in	_	
83-41	15120-15123	the	_	
83-42	15124-15128	head	_	
83-43	15128-15129	,	_	
83-44	15130-15134	body	_	
83-45	15134-15135	,	_	
83-46	15136-15139	and	_	
83-47	15140-15144	tail	_	
83-48	15145-15147	of	_	
83-49	15148-15151	the	_	
83-50	15152-15163	hippocampus	_	
83-51	15164-15168	that	_	
83-52	15169-15173	were	_	
83-53	15174-15182	examined	_	
83-54	15183-15186	for	_	
83-55	15187-15191	task	_	
83-56	15192-15199	effects	_	
83-57	15200-15203	and	_	
83-58	15204-15209	group	_	
83-59	15210-15221	differences	_	
83-60	15222-15225	for	_	
83-61	15226-15230	each	_	
83-62	15231-15239	contrast	_	
83-63	15240-15241	(	_	
83-64	15241-15244	i.e	_	
83-65	15244-15245	.	_	
83-66	15245-15246	,	_	
83-67	15247-15251	item	_	
83-68	15252-15258	change	_	
83-69	15259-15264	minus	_	
83-70	15265-15274	unchanged	_	
83-71	15274-15275	,	_	
83-72	15276-15283	spatial	_	
83-73	15284-15290	change	_	
83-74	15291-15296	minus	_	
83-75	15297-15306	unchanged	_	
83-76	15306-15307	)	_	
83-77	15307-15308	.	_	

#Text=Given our hypotheses, results are summarized here only for the anterior (head) and posterior (tail) hippocampus, and body results are summarized in Supplementary Materials.
84-1	15309-15314	Given	_	
84-2	15315-15318	our	_	
84-3	15319-15329	hypotheses	_	
84-4	15329-15330	,	_	
84-5	15331-15338	results	_	
84-6	15339-15342	are	_	
84-7	15343-15353	summarized	_	
84-8	15354-15358	here	_	
84-9	15359-15363	only	_	
84-10	15364-15367	for	_	
84-11	15368-15371	the	_	
84-12	15372-15380	anterior	_	
84-13	15381-15382	(	_	
84-14	15382-15386	head	_	
84-15	15386-15387	)	_	
84-16	15388-15391	and	_	
84-17	15392-15401	posterior	_	
84-18	15402-15403	(	_	
84-19	15403-15407	tail	_	
84-20	15407-15408	)	_	
84-21	15409-15420	hippocampus	_	
84-22	15420-15421	,	_	
84-23	15422-15425	and	_	
84-24	15426-15430	body	_	
84-25	15431-15438	results	_	
84-26	15439-15442	are	_	
84-27	15443-15453	summarized	_	
84-28	15454-15456	in	_	
84-29	15457-15470	Supplementary	_	
84-30	15471-15480	Materials	_	
84-31	15480-15481	.	_	

#Text=The MNI coordinates marking the anterior/posterior, medial/lateral and superior/inferior bounds of the hippocampus were y = − 12/− 39, x = ± 18/±36, and z = 6/− 24.
85-1	15482-15485	The	_	
85-2	15486-15489	MNI	_	
85-3	15490-15501	coordinates	_	
85-4	15502-15509	marking	_	
85-5	15510-15513	the	_	
85-6	15514-15522	anterior	_	
85-7	15522-15523	/	_	
85-8	15523-15532	posterior	_	
85-9	15532-15533	,	_	
85-10	15534-15540	medial	_	
85-11	15540-15541	/	_	
85-12	15541-15548	lateral	_	
85-13	15549-15552	and	_	
85-14	15553-15561	superior	_	
85-15	15561-15562	/	_	
85-16	15562-15570	inferior	_	
85-17	15571-15577	bounds	_	
85-18	15578-15580	of	_	
85-19	15581-15584	the	_	
85-20	15585-15596	hippocampus	_	
85-21	15597-15601	were	_	
85-22	15602-15603	y	_	
85-23	15603-15604	 	_	
85-24	15604-15605	=	_	
85-25	15605-15606	 	_	
85-26	15606-15607	−	_	
85-27	15607-15608	 	_	
85-28	15608-15610	12	_	
85-29	15610-15611	/	_	
85-30	15611-15612	−	_	
85-31	15612-15613	 	_	
85-32	15613-15615	39	_	
85-33	15615-15616	,	_	
85-34	15617-15618	x	_	
85-35	15618-15619	 	_	
85-36	15619-15620	=	_	
85-37	15620-15621	 	_	
85-38	15621-15622	±	_	
85-39	15622-15623	 	_	
85-40	15623-15625	18	_	
85-41	15625-15626	/	_	
85-42	15626-15627	±	_	
85-43	15627-15629	36	_	
85-44	15629-15630	,	_	
85-45	15631-15634	and	_	
85-46	15635-15636	z	_	
85-47	15636-15637	 	_	
85-48	15637-15638	=	_	
85-49	15638-15639	 	_	
85-50	15639-15640	6	_	
85-51	15640-15641	/	_	
85-52	15641-15642	−	_	
85-53	15642-15643	 	_	
85-54	15643-15645	24	_	
85-55	15645-15646	.	_	

#Text=The hippocampus was subdivided into three sections of equal length – an anterior segment corresponding to the head, a middle segment corresponding to body, and a posterior segment corresponding to the tail (for a similar approach see).
86-1	15647-15650	The	_	
86-2	15651-15662	hippocampus	_	
86-3	15663-15666	was	_	
86-4	15667-15677	subdivided	_	
86-5	15678-15682	into	_	
86-6	15683-15688	three	_	
86-7	15689-15697	sections	_	
86-8	15698-15700	of	_	
86-9	15701-15706	equal	_	
86-10	15707-15713	length	_	
86-11	15714-15715	–	_	
86-12	15716-15718	an	_	
86-13	15719-15727	anterior	_	
86-14	15728-15735	segment	_	
86-15	15736-15749	corresponding	_	
86-16	15750-15752	to	_	
86-17	15753-15756	the	_	
86-18	15757-15761	head	_	
86-19	15761-15762	,	_	
86-20	15763-15764	a	_	
86-21	15765-15771	middle	_	
86-22	15772-15779	segment	_	
86-23	15780-15793	corresponding	_	
86-24	15794-15796	to	_	
86-25	15797-15801	body	_	
86-26	15801-15802	,	_	
86-27	15803-15806	and	_	
86-28	15807-15808	a	_	
86-29	15809-15818	posterior	_	
86-30	15819-15826	segment	_	
86-31	15827-15840	corresponding	_	
86-32	15841-15843	to	_	
86-33	15844-15847	the	_	
86-34	15848-15852	tail	_	
86-35	15853-15854	(	_	
86-36	15854-15857	for	_	
86-37	15858-15859	a	_	
86-38	15860-15867	similar	_	
86-39	15868-15876	approach	_	
86-40	15877-15880	see	_	
86-41	15880-15881	)	_	
86-42	15881-15882	.	_	

#Text=ROI analysis was followed by exploratory whole-brain analyses to identify additional task effects and group differences.
87-1	15883-15886	ROI	_	
87-2	15887-15895	analysis	_	
87-3	15896-15899	was	_	
87-4	15900-15908	followed	_	
87-5	15909-15911	by	_	
87-6	15912-15923	exploratory	_	
87-7	15924-15935	whole-brain	_	
87-8	15936-15944	analyses	_	
87-9	15945-15947	to	_	
87-10	15948-15956	identify	_	
87-11	15957-15967	additional	_	
87-12	15968-15972	task	_	
87-13	15973-15980	effects	_	
87-14	15981-15984	and	_	
87-15	15985-15990	group	_	
87-16	15991-16002	differences	_	
87-17	16002-16003	.	_	

#Text=For each ROI, voxelwise one-sample t-tests identified activated voxel clusters for two contrasts (item change minus unchanged, spatial change minus unchanged), across all participants, with a voxelwise threshold of z > 2.3, and a corrected cluster mass significance threshold of p < 0.05 based on Gaussian Random Field theory as implemented in FEAT.
88-1	16004-16007	For	_	
88-2	16008-16012	each	_	
88-3	16013-16016	ROI	_	
88-4	16016-16017	,	_	
88-5	16018-16027	voxelwise	_	
88-6	16028-16038	one-sample	_	
88-7	16039-16046	t-tests	_	
88-8	16047-16057	identified	_	
88-9	16058-16067	activated	_	
88-10	16068-16073	voxel	_	
88-11	16074-16082	clusters	_	
88-12	16083-16086	for	_	
88-13	16087-16090	two	_	
88-14	16091-16100	contrasts	_	
88-15	16101-16102	(	_	
88-16	16102-16106	item	_	
88-17	16107-16113	change	_	
88-18	16114-16119	minus	_	
88-19	16120-16129	unchanged	_	
88-20	16129-16130	,	_	
88-21	16131-16138	spatial	_	
88-22	16139-16145	change	_	
88-23	16146-16151	minus	_	
88-24	16152-16161	unchanged	_	
88-25	16161-16162	)	_	
88-26	16162-16163	,	_	
88-27	16164-16170	across	_	
88-28	16171-16174	all	_	
88-29	16175-16187	participants	_	
88-30	16187-16188	,	_	
88-31	16189-16193	with	_	
88-32	16194-16195	a	_	
88-33	16196-16205	voxelwise	_	
88-34	16206-16215	threshold	_	
88-35	16216-16218	of	_	
88-36	16219-16220	z	_	
88-37	16220-16221	 	_	
88-38	16221-16222	>	_	
88-39	16222-16223	 	_	
88-40	16223-16226	2.3	_	
88-41	16226-16227	,	_	
88-42	16228-16231	and	_	
88-43	16232-16233	a	_	
88-44	16234-16243	corrected	_	
88-45	16244-16251	cluster	_	
88-46	16252-16256	mass	_	
88-47	16257-16269	significance	_	
88-48	16270-16279	threshold	_	
88-49	16280-16282	of	_	
88-50	16283-16284	p	_	
88-51	16284-16285	 	_	
88-52	16285-16286	<	_	
88-53	16286-16287	 	_	
88-54	16287-16291	0.05	_	
88-55	16292-16297	based	_	
88-56	16298-16300	on	_	
88-57	16301-16309	Gaussian	_	
88-58	16310-16316	Random	_	
88-59	16317-16322	Field	_	
88-60	16323-16329	theory	_	
88-61	16330-16332	as	_	
88-62	16333-16344	implemented	_	
88-63	16345-16347	in	_	
88-64	16348-16352	FEAT	_	
88-65	16352-16353	.	_	

#Text=Resulting parameter estimates (beta weights) were extracted from anterior and posterior ROIs and averaged across hemispheres for each participant.
89-1	16354-16363	Resulting	_	
89-2	16364-16373	parameter	_	
89-3	16374-16383	estimates	_	
89-4	16384-16385	(	_	
89-5	16385-16389	beta	_	
89-6	16390-16397	weights	_	
89-7	16397-16398	)	_	
89-8	16399-16403	were	_	
89-9	16404-16413	extracted	_	
89-10	16414-16418	from	_	
89-11	16419-16427	anterior	_	
89-12	16428-16431	and	_	
89-13	16432-16441	posterior	_	
89-14	16442-16446	ROIs	_	
89-15	16447-16450	and	_	
89-16	16451-16459	averaged	_	
89-17	16460-16466	across	_	
89-18	16467-16478	hemispheres	_	
89-19	16479-16482	for	_	
89-20	16483-16487	each	_	
89-21	16488-16499	participant	_	
89-22	16499-16500	.	_	

#Text=Differences in parameter estimates as a function of group (patients, controls) and change condition (item, spatial) was evaluated using repeated measures analysis of variance (ANOVA) in SAS (version 9.3) separately for anterior and posterior hippocampus.
90-1	16501-16512	Differences	_	
90-2	16513-16515	in	_	
90-3	16516-16525	parameter	_	
90-4	16526-16535	estimates	_	
90-5	16536-16538	as	_	
90-6	16539-16540	a	_	
90-7	16541-16549	function	_	
90-8	16550-16552	of	_	
90-9	16553-16558	group	_	
90-10	16559-16560	(	_	
90-11	16560-16568	patients	_	
90-12	16568-16569	,	_	
90-13	16570-16578	controls	_	
90-14	16578-16579	)	_	
90-15	16580-16583	and	_	
90-16	16584-16590	change	_	
90-17	16591-16600	condition	_	
90-18	16601-16602	(	_	
90-19	16602-16606	item	_	
90-20	16606-16607	,	_	
90-21	16608-16615	spatial	_	
90-22	16615-16616	)	_	
90-23	16617-16620	was	_	
90-24	16621-16630	evaluated	_	
90-25	16631-16636	using	_	
90-26	16637-16645	repeated	_	
90-27	16646-16654	measures	_	
90-28	16655-16663	analysis	_	
90-29	16664-16666	of	_	
90-30	16667-16675	variance	_	
90-31	16676-16677	(	_	
90-32	16677-16682	ANOVA	_	
90-33	16682-16683	)	_	
90-34	16684-16686	in	_	
90-35	16687-16690	SAS	_	
90-36	16691-16692	(	_	
90-37	16692-16699	version	_	
90-38	16700-16703	9.3	_	
90-39	16703-16704	)	_	
90-40	16705-16715	separately	_	
90-41	16716-16719	for	_	
90-42	16720-16728	anterior	_	
90-43	16729-16732	and	_	
90-44	16733-16742	posterior	_	
90-45	16743-16754	hippocampus	_	
90-46	16754-16755	.	_	

#Text=Effect sizes for any significant group differences were estimated using Cohen's d.
91-1	16756-16762	Effect	_	
91-2	16763-16768	sizes	_	
91-3	16769-16772	for	_	
91-4	16773-16776	any	_	
91-5	16777-16788	significant	_	
91-6	16789-16794	group	_	
91-7	16795-16806	differences	_	
91-8	16807-16811	were	_	
91-9	16812-16821	estimated	_	
91-10	16822-16827	using	_	
91-11	16828-16835	Cohen's	_	
91-12	16836-16837	d	_	
91-13	16837-16838	.	_	

#Text=For the exploratory whole-brain analyses, two-sample t-tests were used to identify any group differences for each contrast, using the FSL whole brain gray matter mask, with the same thresholding and cluster-correction procedures as the ROI analysis.
92-1	16839-16842	For	_	
92-2	16843-16846	the	_	
92-3	16847-16858	exploratory	_	
92-4	16859-16870	whole-brain	_	
92-5	16871-16879	analyses	_	
92-6	16879-16880	,	_	
92-7	16881-16891	two-sample	_	
92-8	16892-16899	t-tests	_	
92-9	16900-16904	were	_	
92-10	16905-16909	used	_	
92-11	16910-16912	to	_	
92-12	16913-16921	identify	_	
92-13	16922-16925	any	_	
92-14	16926-16931	group	_	
92-15	16932-16943	differences	_	
92-16	16944-16947	for	_	
92-17	16948-16952	each	_	
92-18	16953-16961	contrast	_	
92-19	16961-16962	,	_	
92-20	16963-16968	using	_	
92-21	16969-16972	the	_	
92-22	16973-16976	FSL	_	
92-23	16977-16982	whole	_	
92-24	16983-16988	brain	_	
92-25	16989-16993	gray	_	
92-26	16994-17000	matter	_	
92-27	17001-17005	mask	_	
92-28	17005-17006	,	_	
92-29	17007-17011	with	_	
92-30	17012-17015	the	_	
92-31	17016-17020	same	_	
92-32	17021-17033	thresholding	_	
92-33	17034-17037	and	_	
92-34	17038-17056	cluster-correction	_	
92-35	17057-17067	procedures	_	
92-36	17068-17070	as	_	
92-37	17071-17074	the	_	
92-38	17075-17078	ROI	_	
92-39	17079-17087	analysis	_	
92-40	17087-17088	.	_	

#Text=Results
#Text=Performance
#Text=Examination of recognition accuracy revealed a main effect of group on percent correct performance [F(1,48) = 8.59, p < 0.01].
93-1	17089-17096	Results	_	
93-2	17097-17108	Performance	_	
93-3	17109-17120	Examination	_	
93-4	17121-17123	of	_	
93-5	17124-17135	recognition	_	
93-6	17136-17144	accuracy	_	
93-7	17145-17153	revealed	_	
93-8	17154-17155	a	_	
93-9	17156-17160	main	_	
93-10	17161-17167	effect	_	
93-11	17168-17170	of	_	
93-12	17171-17176	group	_	
93-13	17177-17179	on	_	
93-14	17180-17187	percent	_	
93-15	17188-17195	correct	_	
93-16	17196-17207	performance	_	
93-17	17208-17209	[	_	
93-18	17209-17210	F	_	
93-19	17210-17211	(	_	
93-20	17211-17215	1,48	_	
93-21	17215-17216	)	_	
93-22	17216-17217	 	_	
93-23	17217-17218	=	_	
93-24	17218-17219	 	_	
93-25	17219-17223	8.59	_	
93-26	17223-17224	,	_	
93-27	17225-17226	p	_	
93-28	17226-17227	 	_	
93-29	17227-17228	<	_	
93-30	17228-17229	 	_	
93-31	17229-17233	0.01	_	
93-32	17233-17234	]	_	
93-33	17234-17235	.	_	

#Text=Performance (mean ± standard deviation) was less accurate in patients with schizophrenia for unchanged (72.5 ± 13.5 patients, 82.4 ± 9.1 controls), item change (63.5 ± 17.7 patients, 73.7 ± 12.2 controls), and spatial change scenes (72.3 ± 14.7 patients, 80.0 ± 12.0 controls).
94-1	17236-17247	Performance	_	
94-2	17248-17249	(	_	
94-3	17249-17253	mean	_	
94-4	17253-17254	 	_	
94-5	17254-17255	±	_	
94-6	17255-17256	 	_	
94-7	17256-17264	standard	_	
94-8	17265-17274	deviation	_	
94-9	17274-17275	)	_	
94-10	17276-17279	was	_	
94-11	17280-17284	less	_	
94-12	17285-17293	accurate	_	
94-13	17294-17296	in	_	
94-14	17297-17305	patients	_	
94-15	17306-17310	with	_	
94-16	17311-17324	schizophrenia	_	
94-17	17325-17328	for	_	
94-18	17329-17338	unchanged	_	
94-19	17339-17340	(	_	
94-20	17340-17344	72.5	_	
94-21	17344-17345	 	_	
94-22	17345-17346	±	_	
94-23	17346-17347	 	_	
94-24	17347-17351	13.5	_	
94-25	17352-17360	patients	_	
94-26	17360-17361	,	_	
94-27	17362-17366	82.4	_	
94-28	17366-17367	 	_	
94-29	17367-17368	±	_	
94-30	17368-17369	 	_	
94-31	17369-17372	9.1	_	
94-32	17373-17381	controls	_	
94-33	17381-17382	)	_	
94-34	17382-17383	,	_	
94-35	17384-17388	item	_	
94-36	17389-17395	change	_	
94-37	17396-17397	(	_	
94-38	17397-17401	63.5	_	
94-39	17401-17402	 	_	
94-40	17402-17403	±	_	
94-41	17403-17404	 	_	
94-42	17404-17408	17.7	_	
94-43	17409-17417	patients	_	
94-44	17417-17418	,	_	
94-45	17419-17423	73.7	_	
94-46	17423-17424	 	_	
94-47	17424-17425	±	_	
94-48	17425-17426	 	_	
94-49	17426-17430	12.2	_	
94-50	17431-17439	controls	_	
94-51	17439-17440	)	_	
94-52	17440-17441	,	_	
94-53	17442-17445	and	_	
94-54	17446-17453	spatial	_	
94-55	17454-17460	change	_	
94-56	17461-17467	scenes	_	
94-57	17468-17469	(	_	
94-58	17469-17473	72.3	_	
94-59	17473-17474	 	_	
94-60	17474-17475	±	_	
94-61	17475-17476	 	_	
94-62	17476-17480	14.7	_	
94-63	17481-17489	patients	_	
94-64	17489-17490	,	_	
94-65	17491-17495	80.0	_	
94-66	17495-17496	 	_	
94-67	17496-17497	±	_	
94-68	17497-17498	 	_	
94-69	17498-17502	12.0	_	
94-70	17503-17511	controls	_	
94-71	17511-17512	)	_	
94-72	17512-17513	.	_	

#Text=There was also a main effect of scene type [F(2,47) = 9.10, p < 0.0005], with all participants performing better on unchanged versus item change (77.6 ± 12.4 and 68.8 ± 15.8 respectively; F(1,49) = 14.8, p < 0.001), and spatial change versus item change scenes (75.7 ± 13.6 and 68.8 ± 15.8 respectively; F(1,49) = 15.9, p < 0.0005).
95-1	17514-17519	There	_	
95-2	17520-17523	was	_	
95-3	17524-17528	also	_	
95-4	17529-17530	a	_	
95-5	17531-17535	main	_	
95-6	17536-17542	effect	_	
95-7	17543-17545	of	_	
95-8	17546-17551	scene	_	
95-9	17552-17556	type	_	
95-10	17557-17558	[	_	
95-11	17558-17559	F	_	
95-12	17559-17560	(	_	
95-13	17560-17564	2,47	_	
95-14	17564-17565	)	_	
95-15	17565-17566	 	_	
95-16	17566-17567	=	_	
95-17	17567-17568	 	_	
95-18	17568-17572	9.10	_	
95-19	17572-17573	,	_	
95-20	17574-17575	p	_	
95-21	17575-17576	 	_	
95-22	17576-17577	<	_	
95-23	17577-17578	 	_	
95-24	17578-17584	0.0005	_	
95-25	17584-17585	]	_	
95-26	17585-17586	,	_	
95-27	17587-17591	with	_	
95-28	17592-17595	all	_	
95-29	17596-17608	participants	_	
95-30	17609-17619	performing	_	
95-31	17620-17626	better	_	
95-32	17627-17629	on	_	
95-33	17630-17639	unchanged	_	
95-34	17640-17646	versus	_	
95-35	17647-17651	item	_	
95-36	17652-17658	change	_	
95-37	17659-17660	(	_	
95-38	17660-17664	77.6	_	
95-39	17664-17665	 	_	
95-40	17665-17666	±	_	
95-41	17666-17667	 	_	
95-42	17667-17671	12.4	_	
95-43	17672-17675	and	_	
95-44	17676-17680	68.8	_	
95-45	17680-17681	 	_	
95-46	17681-17682	±	_	
95-47	17682-17683	 	_	
95-48	17683-17687	15.8	_	
95-49	17688-17700	respectively	_	
95-50	17700-17701	;	_	
95-51	17702-17703	F	_	
95-52	17703-17704	(	_	
95-53	17704-17708	1,49	_	
95-54	17708-17709	)	_	
95-55	17709-17710	 	_	
95-56	17710-17711	=	_	
95-57	17711-17712	 	_	
95-58	17712-17716	14.8	_	
95-59	17716-17717	,	_	
95-60	17718-17719	p	_	
95-61	17719-17720	 	_	
95-62	17720-17721	<	_	
95-63	17721-17722	 	_	
95-64	17722-17727	0.001	_	
95-65	17727-17728	)	_	
95-66	17728-17729	,	_	
95-67	17730-17733	and	_	
95-68	17734-17741	spatial	_	
95-69	17742-17748	change	_	
95-70	17749-17755	versus	_	
95-71	17756-17760	item	_	
95-72	17761-17767	change	_	
95-73	17768-17774	scenes	_	
95-74	17775-17776	(	_	
95-75	17776-17780	75.7	_	
95-76	17780-17781	 	_	
95-77	17781-17782	±	_	
95-78	17782-17783	 	_	
95-79	17783-17787	13.6	_	
95-80	17788-17791	and	_	
95-81	17792-17796	68.8	_	
95-82	17796-17797	 	_	
95-83	17797-17798	±	_	
95-84	17798-17799	 	_	
95-85	17799-17803	15.8	_	
95-86	17804-17816	respectively	_	
95-87	17816-17817	;	_	
95-88	17818-17819	F	_	
95-89	17819-17820	(	_	
95-90	17820-17824	1,49	_	
95-91	17824-17825	)	_	
95-92	17825-17826	 	_	
95-93	17826-17827	=	_	
95-94	17827-17828	 	_	
95-95	17828-17832	15.9	_	
95-96	17832-17833	,	_	
95-97	17834-17835	p	_	
95-98	17835-17836	 	_	
95-99	17836-17837	<	_	
95-100	17837-17838	 	_	
95-101	17838-17844	0.0005	_	
95-102	17844-17845	)	_	
95-103	17845-17846	.	_	

#Text=However, there was no group by scene type interaction [F(2,47) = 0.77, p = 0.47].
96-1	17847-17854	However	_	
96-2	17854-17855	,	_	
96-3	17856-17861	there	_	
96-4	17862-17865	was	_	
96-5	17866-17868	no	_	
96-6	17869-17874	group	_	
96-7	17875-17877	by	_	
96-8	17878-17883	scene	_	
96-9	17884-17888	type	_	
96-10	17889-17900	interaction	_	
96-11	17901-17902	[	_	
96-12	17902-17903	F	_	
96-13	17903-17904	(	_	
96-14	17904-17908	2,47	_	
96-15	17908-17909	)	_	
96-16	17909-17910	 	_	
96-17	17910-17911	=	_	
96-18	17911-17912	 	_	
96-19	17912-17916	0.77	_	
96-20	17916-17917	,	_	
96-21	17918-17919	p	_	
96-22	17919-17920	 	_	
96-23	17920-17921	=	_	
96-24	17921-17922	 	_	
96-25	17922-17926	0.47	_	
96-26	17926-17927	]	_	
96-27	17927-17928	.	_	

#Text=Because of these performance differences, fMRI contrasts were restricted to correct trials only.
#Text=fMRI results
#Text=When hippocampal ROIs were examined for item and relational change trials, there were no hemisphere by group [F(1,48) = 0.05, p = 0.83], hemisphere by change trial [F(1,48) = 0.04, p = 0.84], or hemisphere by group by change trial interactions [F(1,48) = 2.0, p = 0.16].
97-1	17929-17936	Because	_	
97-2	17937-17939	of	_	
97-3	17940-17945	these	_	
97-4	17946-17957	performance	_	
97-5	17958-17969	differences	_	
97-6	17969-17970	,	_	
97-7	17971-17975	fMRI	_	
97-8	17976-17985	contrasts	_	
97-9	17986-17990	were	_	
97-10	17991-18001	restricted	_	
97-11	18002-18004	to	_	
97-12	18005-18012	correct	_	
97-13	18013-18019	trials	_	
97-14	18020-18024	only	_	
97-15	18024-18025	.	_	
97-16	18026-18030	fMRI	_	
97-17	18031-18038	results	_	
97-18	18039-18043	When	_	
97-19	18044-18055	hippocampal	_	
97-20	18056-18060	ROIs	_	
97-21	18061-18065	were	_	
97-22	18066-18074	examined	_	
97-23	18075-18078	for	_	
97-24	18079-18083	item	_	
97-25	18084-18087	and	_	
97-26	18088-18098	relational	_	
97-27	18099-18105	change	_	
97-28	18106-18112	trials	_	
97-29	18112-18113	,	_	
97-30	18114-18119	there	_	
97-31	18120-18124	were	_	
97-32	18125-18127	no	_	
97-33	18128-18138	hemisphere	_	
97-34	18139-18141	by	_	
97-35	18142-18147	group	_	
97-36	18148-18149	[	_	
97-37	18149-18150	F	_	
97-38	18150-18151	(	_	
97-39	18151-18155	1,48	_	
97-40	18155-18156	)	_	
97-41	18156-18157	 	_	
97-42	18157-18158	=	_	
97-43	18158-18159	 	_	
97-44	18159-18163	0.05	_	
97-45	18163-18164	,	_	
97-46	18165-18166	p	_	
97-47	18166-18167	 	_	
97-48	18167-18168	=	_	
97-49	18168-18169	 	_	
97-50	18169-18173	0.83	_	
97-51	18173-18174	]	_	
97-52	18174-18175	,	_	
97-53	18176-18186	hemisphere	_	
97-54	18187-18189	by	_	
97-55	18190-18196	change	_	
97-56	18197-18202	trial	_	
97-57	18203-18204	[	_	
97-58	18204-18205	F	_	
97-59	18205-18206	(	_	
97-60	18206-18210	1,48	_	
97-61	18210-18211	)	_	
97-62	18211-18212	 	_	
97-63	18212-18213	=	_	
97-64	18213-18214	 	_	
97-65	18214-18218	0.04	_	
97-66	18218-18219	,	_	
97-67	18220-18221	p	_	
97-68	18221-18222	 	_	
97-69	18222-18223	=	_	
97-70	18223-18224	 	_	
97-71	18224-18228	0.84	_	
97-72	18228-18229	]	_	
97-73	18229-18230	,	_	
97-74	18231-18233	or	_	
97-75	18234-18244	hemisphere	_	
97-76	18245-18247	by	_	
97-77	18248-18253	group	_	
97-78	18254-18256	by	_	
97-79	18257-18263	change	_	
97-80	18264-18269	trial	_	
97-81	18270-18282	interactions	_	
97-82	18283-18284	[	_	
97-83	18284-18285	F	_	
97-84	18285-18286	(	_	
97-85	18286-18290	1,48	_	
97-86	18290-18291	)	_	
97-87	18291-18292	 	_	
97-88	18292-18293	=	_	
97-89	18293-18294	 	_	
97-90	18294-18297	2.0	_	
97-91	18297-18298	,	_	
97-92	18299-18300	p	_	
97-93	18300-18301	 	_	
97-94	18301-18302	=	_	
97-95	18302-18303	 	_	
97-96	18303-18307	0.16	_	
97-97	18307-18308	]	_	
97-98	18308-18309	.	_	

#Text=We, therefore, examined bilateral parameter estimates in subsequent analyses.
98-1	18310-18312	We	_	
98-2	18312-18313	,	_	
98-3	18314-18323	therefore	_	
98-4	18323-18324	,	_	
98-5	18325-18333	examined	_	
98-6	18334-18343	bilateral	_	
98-7	18344-18353	parameter	_	
98-8	18354-18363	estimates	_	
98-9	18364-18366	in	_	
98-10	18367-18377	subsequent	_	
98-11	18378-18386	analyses	_	
98-12	18386-18387	.	_	

#Text=In the anterior hippocampus, there was a main effect of change trial [F(1,48) = 9.87, p < 0.005], and a change trial by group interaction [F(1,48) = 5.41, p < 0.05].
99-1	18388-18390	In	_	
99-2	18391-18394	the	_	
99-3	18395-18403	anterior	_	
99-4	18404-18415	hippocampus	_	
99-5	18415-18416	,	_	
99-6	18417-18422	there	_	
99-7	18423-18426	was	_	
99-8	18427-18428	a	_	
99-9	18429-18433	main	_	
99-10	18434-18440	effect	_	
99-11	18441-18443	of	_	
99-12	18444-18450	change	_	
99-13	18451-18456	trial	_	
99-14	18457-18458	[	_	
99-15	18458-18459	F	_	
99-16	18459-18460	(	_	
99-17	18460-18464	1,48	_	
99-18	18464-18465	)	_	
99-19	18465-18466	 	_	
99-20	18466-18467	=	_	
99-21	18467-18468	 	_	
99-22	18468-18472	9.87	_	
99-23	18472-18473	,	_	
99-24	18474-18475	p	_	
99-25	18475-18476	 	_	
99-26	18476-18477	<	_	
99-27	18477-18478	 	_	
99-28	18478-18483	0.005	_	
99-29	18483-18484	]	_	
99-30	18484-18485	,	_	
99-31	18486-18489	and	_	
99-32	18490-18491	a	_	
99-33	18492-18498	change	_	
99-34	18499-18504	trial	_	
99-35	18505-18507	by	_	
99-36	18508-18513	group	_	
99-37	18514-18525	interaction	_	
99-38	18526-18527	[	_	
99-39	18527-18528	F	_	
99-40	18528-18529	(	_	
99-41	18529-18533	1,48	_	
99-42	18533-18534	)	_	
99-43	18534-18535	 	_	
99-44	18535-18536	=	_	
99-45	18536-18537	 	_	
99-46	18537-18541	5.41	_	
99-47	18541-18542	,	_	
99-48	18543-18544	p	_	
99-49	18544-18545	 	_	
99-50	18545-18546	<	_	
99-51	18546-18547	 	_	
99-52	18547-18551	0.05	_	
99-53	18551-18552	]	_	
99-54	18552-18553	.	_	

#Text=As seen in Fig. 2, this interaction was due to greater anterior hippocampal activation in patients with schizophrenia versus healthy participants for the item change condition [F(1,48) = 4.23, p < 0.05; Cohen's d = 0.51], with no group differences when there was a spatial change [F(1,48) = 0.12, p = 0.73; Cohen's d = 0.10].
100-1	18554-18556	As	_	
100-2	18557-18561	seen	_	
100-3	18562-18564	in	_	
100-4	18565-18568	Fig	_	
100-5	18568-18569	.	_	
100-6	18570-18571	2	_	
100-7	18571-18572	,	_	
100-8	18573-18577	this	_	
100-9	18578-18589	interaction	_	
100-10	18590-18593	was	_	
100-11	18594-18597	due	_	
100-12	18598-18600	to	_	
100-13	18601-18608	greater	_	
100-14	18609-18617	anterior	_	
100-15	18618-18629	hippocampal	_	
100-16	18630-18640	activation	_	
100-17	18641-18643	in	_	
100-18	18644-18652	patients	_	
100-19	18653-18657	with	_	
100-20	18658-18671	schizophrenia	_	
100-21	18672-18678	versus	_	
100-22	18679-18686	healthy	_	
100-23	18687-18699	participants	_	
100-24	18700-18703	for	_	
100-25	18704-18707	the	_	
100-26	18708-18712	item	_	
100-27	18713-18719	change	_	
100-28	18720-18729	condition	_	
100-29	18730-18731	[	_	
100-30	18731-18732	F	_	
100-31	18732-18733	(	_	
100-32	18733-18737	1,48	_	
100-33	18737-18738	)	_	
100-34	18738-18739	 	_	
100-35	18739-18740	=	_	
100-36	18740-18741	 	_	
100-37	18741-18745	4.23	_	
100-38	18745-18746	,	_	
100-39	18747-18748	p	_	
100-40	18748-18749	 	_	
100-41	18749-18750	<	_	
100-42	18750-18751	 	_	
100-43	18751-18755	0.05	_	
100-44	18755-18756	;	_	
100-45	18757-18764	Cohen's	_	
100-46	18765-18766	d	_	
100-47	18766-18767	 	_	
100-48	18767-18768	=	_	
100-49	18768-18769	 	_	
100-50	18769-18773	0.51	_	
100-51	18773-18774	]	_	
100-52	18774-18775	,	_	
100-53	18776-18780	with	_	
100-54	18781-18783	no	_	
100-55	18784-18789	group	_	
100-56	18790-18801	differences	_	
100-57	18802-18806	when	_	
100-58	18807-18812	there	_	
100-59	18813-18816	was	_	
100-60	18817-18818	a	_	
100-61	18819-18826	spatial	_	
100-62	18827-18833	change	_	
100-63	18834-18835	[	_	
100-64	18835-18836	F	_	
100-65	18836-18837	(	_	
100-66	18837-18841	1,48	_	
100-67	18841-18842	)	_	
100-68	18842-18843	 	_	
100-69	18843-18844	=	_	
100-70	18844-18845	 	_	
100-71	18845-18849	0.12	_	
100-72	18849-18850	,	_	
100-73	18851-18852	p	_	
100-74	18852-18853	 	_	
100-75	18853-18854	=	_	
100-76	18854-18855	 	_	
100-77	18855-18859	0.73	_	
100-78	18859-18860	;	_	
100-79	18861-18868	Cohen's	_	
100-80	18869-18870	d	_	
100-81	18870-18871	 	_	
100-82	18871-18872	=	_	
100-83	18872-18873	 	_	
100-84	18873-18877	0.10	_	
100-85	18877-18878	]	_	
100-86	18878-18879	.	_	

#Text=Examination of the posterior hippocampus revealed the hypothesized reduction in task-related activation in patients.
101-1	18880-18891	Examination	_	
101-2	18892-18894	of	_	
101-3	18895-18898	the	_	
101-4	18899-18908	posterior	_	
101-5	18909-18920	hippocampus	_	
101-6	18921-18929	revealed	_	
101-7	18930-18933	the	_	
101-8	18934-18946	hypothesized	_	
101-9	18947-18956	reduction	_	
101-10	18957-18959	in	_	
101-11	18960-18972	task-related	_	
101-12	18973-18983	activation	_	
101-13	18984-18986	in	_	
101-14	18987-18995	patients	_	
101-15	18995-18996	.	_	

#Text=There was a main effect of group [F(1,48) = 4.86, p < 0.05], and a change trial by group interaction [F(1,48) = 4.79, p < 0.05].
102-1	18997-19002	There	_	
102-2	19003-19006	was	_	
102-3	19007-19008	a	_	
102-4	19009-19013	main	_	
102-5	19014-19020	effect	_	
102-6	19021-19023	of	_	
102-7	19024-19029	group	_	
102-8	19030-19031	[	_	
102-9	19031-19032	F	_	
102-10	19032-19033	(	_	
102-11	19033-19037	1,48	_	
102-12	19037-19038	)	_	
102-13	19038-19039	 	_	
102-14	19039-19040	=	_	
102-15	19040-19041	 	_	
102-16	19041-19045	4.86	_	
102-17	19045-19046	,	_	
102-18	19047-19048	p	_	
102-19	19048-19049	 	_	
102-20	19049-19050	<	_	
102-21	19050-19051	 	_	
102-22	19051-19055	0.05	_	
102-23	19055-19056	]	_	
102-24	19056-19057	,	_	
102-25	19058-19061	and	_	
102-26	19062-19063	a	_	
102-27	19064-19070	change	_	
102-28	19071-19076	trial	_	
102-29	19077-19079	by	_	
102-30	19080-19085	group	_	
102-31	19086-19097	interaction	_	
102-32	19098-19099	[	_	
102-33	19099-19100	F	_	
102-34	19100-19101	(	_	
102-35	19101-19105	1,48	_	
102-36	19105-19106	)	_	
102-37	19106-19107	 	_	
102-38	19107-19108	=	_	
102-39	19108-19109	 	_	
102-40	19109-19113	4.79	_	
102-41	19113-19114	,	_	
102-42	19115-19116	p	_	
102-43	19116-19117	 	_	
102-44	19117-19118	<	_	
102-45	19118-19119	 	_	
102-46	19119-19123	0.05	_	
102-47	19123-19124	]	_	
102-48	19124-19125	.	_	

#Text=This interaction was due to reduced activation in the posterior hippocampus in patients relative to healthy controls for correct spatial change trials [F(1,48) = 8.76, p < 0.005; Cohen's d = 0.83].
103-1	19126-19130	This	_	
103-2	19131-19142	interaction	_	
103-3	19143-19146	was	_	
103-4	19147-19150	due	_	
103-5	19151-19153	to	_	
103-6	19154-19161	reduced	_	
103-7	19162-19172	activation	_	
103-8	19173-19175	in	_	
103-9	19176-19179	the	_	
103-10	19180-19189	posterior	_	
103-11	19190-19201	hippocampus	_	
103-12	19202-19204	in	_	
103-13	19205-19213	patients	_	
103-14	19214-19222	relative	_	
103-15	19223-19225	to	_	
103-16	19226-19233	healthy	_	
103-17	19234-19242	controls	_	
103-18	19243-19246	for	_	
103-19	19247-19254	correct	_	
103-20	19255-19262	spatial	_	
103-21	19263-19269	change	_	
103-22	19270-19276	trials	_	
103-23	19277-19278	[	_	
103-24	19278-19279	F	_	
103-25	19279-19280	(	_	
103-26	19280-19284	1,48	_	
103-27	19284-19285	)	_	
103-28	19285-19286	 	_	
103-29	19286-19287	=	_	
103-30	19287-19288	 	_	
103-31	19288-19292	8.76	_	
103-32	19292-19293	,	_	
103-33	19294-19295	p	_	
103-34	19295-19296	 	_	
103-35	19296-19297	<	_	
103-36	19297-19298	 	_	
103-37	19298-19303	0.005	_	
103-38	19303-19304	;	_	
103-39	19305-19312	Cohen's	_	
103-40	19313-19314	d	_	
103-41	19314-19315	 	_	
103-42	19315-19316	=	_	
103-43	19316-19317	 	_	
103-44	19317-19321	0.83	_	
103-45	19321-19322	]	_	
103-46	19322-19323	.	_	

#Text=Conversely, there was no group difference in posterior hippocampal activation when participants correctly recognized item changes [F(1,48) = 0.96, p = 0.33; Cohen's d = 0.27].
104-1	19324-19334	Conversely	_	
104-2	19334-19335	,	_	
104-3	19336-19341	there	_	
104-4	19342-19345	was	_	
104-5	19346-19348	no	_	
104-6	19349-19354	group	_	
104-7	19355-19365	difference	_	
104-8	19366-19368	in	_	
104-9	19369-19378	posterior	_	
104-10	19379-19390	hippocampal	_	
104-11	19391-19401	activation	_	
104-12	19402-19406	when	_	
104-13	19407-19419	participants	_	
104-14	19420-19429	correctly	_	
104-15	19430-19440	recognized	_	
104-16	19441-19445	item	_	
104-17	19446-19453	changes	_	
104-18	19454-19455	[	_	
104-19	19455-19456	F	_	
104-20	19456-19457	(	_	
104-21	19457-19461	1,48	_	
104-22	19461-19462	)	_	
104-23	19462-19463	 	_	
104-24	19463-19464	=	_	
104-25	19464-19465	 	_	
104-26	19465-19469	0.96	_	
104-27	19469-19470	,	_	
104-28	19471-19472	p	_	
104-29	19472-19473	 	_	
104-30	19473-19474	=	_	
104-31	19474-19475	 	_	
104-32	19475-19479	0.33	_	
104-33	19479-19480	;	_	
104-34	19481-19488	Cohen's	_	
104-35	19489-19490	d	_	
104-36	19490-19491	 	_	
104-37	19491-19492	=	_	
104-38	19492-19493	 	_	
104-39	19493-19497	0.27	_	
104-40	19497-19498	]	_	
104-41	19498-19499	.	_	

#Text=Exploratory whole brain analyses revealed additional group differences for spatial change but not for item change conditions.
105-1	19500-19511	Exploratory	_	
105-2	19512-19517	whole	_	
105-3	19518-19523	brain	_	
105-4	19524-19532	analyses	_	
105-5	19533-19541	revealed	_	
105-6	19542-19552	additional	_	
105-7	19553-19558	group	_	
105-8	19559-19570	differences	_	
105-9	19571-19574	for	_	
105-10	19575-19582	spatial	_	
105-11	19583-19589	change	_	
105-12	19590-19593	but	_	
105-13	19594-19597	not	_	
105-14	19598-19601	for	_	
105-15	19602-19606	item	_	
105-16	19607-19613	change	_	
105-17	19614-19624	conditions	_	
105-18	19624-19625	.	_	

#Text=For the contrast of spatial change with unchanged trials, patients with schizophrenia, relative to healthy controls, had reduced bilateral activation in the precuneus and reduced left hemisphere activation in the lateral and medial prefrontal cortex, inferior and superior parietal cortex and cerebellum (Fig. 3; Supplementary Materials Table 1).
106-1	19626-19629	For	_	
106-2	19630-19633	the	_	
106-3	19634-19642	contrast	_	
106-4	19643-19645	of	_	
106-5	19646-19653	spatial	_	
106-6	19654-19660	change	_	
106-7	19661-19665	with	_	
106-8	19666-19675	unchanged	_	
106-9	19676-19682	trials	_	
106-10	19682-19683	,	_	
106-11	19684-19692	patients	_	
106-12	19693-19697	with	_	
106-13	19698-19711	schizophrenia	_	
106-14	19711-19712	,	_	
106-15	19713-19721	relative	_	
106-16	19722-19724	to	_	
106-17	19725-19732	healthy	_	
106-18	19733-19741	controls	_	
106-19	19741-19742	,	_	
106-20	19743-19746	had	_	
106-21	19747-19754	reduced	_	
106-22	19755-19764	bilateral	_	
106-23	19765-19775	activation	_	
106-24	19776-19778	in	_	
106-25	19779-19782	the	_	
106-26	19783-19792	precuneus	_	
106-27	19793-19796	and	_	
106-28	19797-19804	reduced	_	
106-29	19805-19809	left	_	
106-30	19810-19820	hemisphere	_	
106-31	19821-19831	activation	_	
106-32	19832-19834	in	_	
106-33	19835-19838	the	_	
106-34	19839-19846	lateral	_	
106-35	19847-19850	and	_	
106-36	19851-19857	medial	_	
106-37	19858-19868	prefrontal	_	
106-38	19869-19875	cortex	_	
106-39	19875-19876	,	_	
106-40	19877-19885	inferior	_	
106-41	19886-19889	and	_	
106-42	19890-19898	superior	_	
106-43	19899-19907	parietal	_	
106-44	19908-19914	cortex	_	
106-45	19915-19918	and	_	
106-46	19919-19929	cerebellum	_	
106-47	19930-19931	(	_	
106-48	19931-19934	Fig	_	
106-49	19934-19935	.	_	
106-50	19936-19937	3	_	
106-51	19937-19938	;	_	
106-52	19939-19952	Supplementary	_	
106-53	19953-19962	Materials	_	
106-54	19963-19968	Table	_	
106-55	19969-19970	1	_	
106-56	19970-19971	)	_	
106-57	19971-19972	.	_	

#Text=There was no evidence of greater activation in patients with schizophrenia relative to healthy controls for either contrast.
107-1	19973-19978	There	_	
107-2	19979-19982	was	_	
107-3	19983-19985	no	_	
107-4	19986-19994	evidence	_	
107-5	19995-19997	of	_	
107-6	19998-20005	greater	_	
107-7	20006-20016	activation	_	
107-8	20017-20019	in	_	
107-9	20020-20028	patients	_	
107-10	20029-20033	with	_	
107-11	20034-20047	schizophrenia	_	
107-12	20048-20056	relative	_	
107-13	20057-20059	to	_	
107-14	20060-20067	healthy	_	
107-15	20068-20076	controls	_	
107-16	20077-20080	for	_	
107-17	20081-20087	either	_	
107-18	20088-20096	contrast	_	
107-19	20096-20097	.	_	

#Text=Discussion
#Text=The goal of the present study was to utilize a previously validated scene memory paradigm to contrast memory for spatial versus item changes in complex scenes, and test the effects of schizophrenia on anterior and posterior hippocampal activation during successful change detection.
108-1	20098-20108	Discussion	_	
108-2	20109-20112	The	_	
108-3	20113-20117	goal	_	
108-4	20118-20120	of	_	
108-5	20121-20124	the	_	
108-6	20125-20132	present	_	
108-7	20133-20138	study	_	
108-8	20139-20142	was	_	
108-9	20143-20145	to	_	
108-10	20146-20153	utilize	_	
108-11	20154-20155	a	_	
108-12	20156-20166	previously	_	
108-13	20167-20176	validated	_	
108-14	20177-20182	scene	_	
108-15	20183-20189	memory	_	
108-16	20190-20198	paradigm	_	
108-17	20199-20201	to	_	
108-18	20202-20210	contrast	_	
108-19	20211-20217	memory	_	
108-20	20218-20221	for	_	
108-21	20222-20229	spatial	_	
108-22	20230-20236	versus	_	
108-23	20237-20241	item	_	
108-24	20242-20249	changes	_	
108-25	20250-20252	in	_	
108-26	20253-20260	complex	_	
108-27	20261-20267	scenes	_	
108-28	20267-20268	,	_	
108-29	20269-20272	and	_	
108-30	20273-20277	test	_	
108-31	20278-20281	the	_	
108-32	20282-20289	effects	_	
108-33	20290-20292	of	_	
108-34	20293-20306	schizophrenia	_	
108-35	20307-20309	on	_	
108-36	20310-20318	anterior	_	
108-37	20319-20322	and	_	
108-38	20323-20332	posterior	_	
108-39	20333-20344	hippocampal	_	
108-40	20345-20355	activation	_	
108-41	20356-20362	during	_	
108-42	20363-20373	successful	_	
108-43	20374-20380	change	_	
108-44	20381-20390	detection	_	
108-45	20390-20391	.	_	

#Text=Based on evidence that the posterior hippocampus mediates memory for fine-grained spatial information, and prior evidence that patients show unimpaired eye-movement memory effects for item but not for spatial changes, we predicted that patients would be specifically impaired in their ability to recruit the posterior hippocampus to detect spatial changes, but that there would be no group difference during detection of item changes. fMRI results supported the prediction of reduced posterior hippocampal activation in patients with schizophrenia during recognition of spatial changes, but, unexpectedly, also showed a group difference in the anterior hippocampus, in which patients demonstrated greater activation than healthy controls during correct recognition of item changes.
109-1	20392-20397	Based	_	
109-2	20398-20400	on	_	
109-3	20401-20409	evidence	_	
109-4	20410-20414	that	_	
109-5	20415-20418	the	_	
109-6	20419-20428	posterior	_	
109-7	20429-20440	hippocampus	_	
109-8	20441-20449	mediates	_	
109-9	20450-20456	memory	_	
109-10	20457-20460	for	_	
109-11	20461-20473	fine-grained	_	
109-12	20474-20481	spatial	_	
109-13	20482-20493	information	_	
109-14	20493-20494	,	_	
109-15	20495-20498	and	_	
109-16	20499-20504	prior	_	
109-17	20505-20513	evidence	_	
109-18	20514-20518	that	_	
109-19	20519-20527	patients	_	
109-20	20528-20532	show	_	
109-21	20533-20543	unimpaired	_	
109-22	20544-20556	eye-movement	_	
109-23	20557-20563	memory	_	
109-24	20564-20571	effects	_	
109-25	20572-20575	for	_	
109-26	20576-20580	item	_	
109-27	20581-20584	but	_	
109-28	20585-20588	not	_	
109-29	20589-20592	for	_	
109-30	20593-20600	spatial	_	
109-31	20601-20608	changes	_	
109-32	20608-20609	,	_	
109-33	20610-20612	we	_	
109-34	20613-20622	predicted	_	
109-35	20623-20627	that	_	
109-36	20628-20636	patients	_	
109-37	20637-20642	would	_	
109-38	20643-20645	be	_	
109-39	20646-20658	specifically	_	
109-40	20659-20667	impaired	_	
109-41	20668-20670	in	_	
109-42	20671-20676	their	_	
109-43	20677-20684	ability	_	
109-44	20685-20687	to	_	
109-45	20688-20695	recruit	_	
109-46	20696-20699	the	_	
109-47	20700-20709	posterior	_	
109-48	20710-20721	hippocampus	_	
109-49	20722-20724	to	_	
109-50	20725-20731	detect	_	
109-51	20732-20739	spatial	_	
109-52	20740-20747	changes	_	
109-53	20747-20748	,	_	
109-54	20749-20752	but	_	
109-55	20753-20757	that	_	
109-56	20758-20763	there	_	
109-57	20764-20769	would	_	
109-58	20770-20772	be	_	
109-59	20773-20775	no	_	
109-60	20776-20781	group	_	
109-61	20782-20792	difference	_	
109-62	20793-20799	during	_	
109-63	20800-20809	detection	_	
109-64	20810-20812	of	_	
109-65	20813-20817	item	_	
109-66	20818-20825	changes	_	
109-67	20825-20826	.	_	
109-68	20827-20831	fMRI	_	
109-69	20832-20839	results	_	
109-70	20840-20849	supported	_	
109-71	20850-20853	the	_	
109-72	20854-20864	prediction	_	
109-73	20865-20867	of	_	
109-74	20868-20875	reduced	_	
109-75	20876-20885	posterior	_	
109-76	20886-20897	hippocampal	_	
109-77	20898-20908	activation	_	
109-78	20909-20911	in	_	
109-79	20912-20920	patients	_	
109-80	20921-20925	with	_	
109-81	20926-20939	schizophrenia	_	
109-82	20940-20946	during	_	
109-83	20947-20958	recognition	_	
109-84	20959-20961	of	_	
109-85	20962-20969	spatial	_	
109-86	20970-20977	changes	_	
109-87	20977-20978	,	_	
109-88	20979-20982	but	_	
109-89	20982-20983	,	_	
109-90	20984-20996	unexpectedly	_	
109-91	20996-20997	,	_	
109-92	20998-21002	also	_	
109-93	21003-21009	showed	_	
109-94	21010-21011	a	_	
109-95	21012-21017	group	_	
109-96	21018-21028	difference	_	
109-97	21029-21031	in	_	
109-98	21032-21035	the	_	
109-99	21036-21044	anterior	_	
109-100	21045-21056	hippocampus	_	
109-101	21056-21057	,	_	
109-102	21058-21060	in	_	
109-103	21061-21066	which	_	
109-104	21067-21075	patients	_	
109-105	21076-21088	demonstrated	_	
109-106	21089-21096	greater	_	
109-107	21097-21107	activation	_	
109-108	21108-21112	than	_	
109-109	21113-21120	healthy	_	
109-110	21121-21129	controls	_	
109-111	21130-21136	during	_	
109-112	21137-21144	correct	_	
109-113	21145-21156	recognition	_	
109-114	21157-21159	of	_	
109-115	21160-21164	item	_	
109-116	21165-21172	changes	_	
109-117	21172-21173	.	_	

#Text=As noted in the introduction, the dorsal hippocampus in rats, which is homologous to the posterior hippocampus in humans, is known to support fine-grained representation of spatial configurations, and dorsal hippocampal lesions impair spatial memory.
110-1	21174-21176	As	_	
110-2	21177-21182	noted	_	
110-3	21183-21185	in	_	
110-4	21186-21189	the	_	
110-5	21190-21202	introduction	_	
110-6	21202-21203	,	_	
110-7	21204-21207	the	_	
110-8	21208-21214	dorsal	_	
110-9	21215-21226	hippocampus	_	
110-10	21227-21229	in	_	
110-11	21230-21234	rats	_	
110-12	21234-21235	,	_	
110-13	21236-21241	which	_	
110-14	21242-21244	is	_	
110-15	21245-21255	homologous	_	
110-16	21256-21258	to	_	
110-17	21259-21262	the	_	
110-18	21263-21272	posterior	_	
110-19	21273-21284	hippocampus	_	
110-20	21285-21287	in	_	
110-21	21288-21294	humans	_	
110-22	21294-21295	,	_	
110-23	21296-21298	is	_	
110-24	21299-21304	known	_	
110-25	21305-21307	to	_	
110-26	21308-21315	support	_	
110-27	21316-21328	fine-grained	_	
110-28	21329-21343	representation	_	
110-29	21344-21346	of	_	
110-30	21347-21354	spatial	_	
110-31	21355-21369	configurations	_	
110-32	21369-21370	,	_	
110-33	21371-21374	and	_	
110-34	21375-21381	dorsal	_	
110-35	21382-21393	hippocampal	_	
110-36	21394-21401	lesions	_	
110-37	21402-21408	impair	_	
110-38	21409-21416	spatial	_	
110-39	21417-21423	memory	_	
110-40	21423-21424	.	_	

#Text=The present paradigm was designed to place heavy demands on these processes by assessing memory for subtle changes in the positions of objects in a complex scene.
111-1	21425-21428	The	_	
111-2	21429-21436	present	_	
111-3	21437-21445	paradigm	_	
111-4	21446-21449	was	_	
111-5	21450-21458	designed	_	
111-6	21459-21461	to	_	
111-7	21462-21467	place	_	
111-8	21468-21473	heavy	_	
111-9	21474-21481	demands	_	
111-10	21482-21484	on	_	
111-11	21485-21490	these	_	
111-12	21491-21500	processes	_	
111-13	21501-21503	by	_	
111-14	21504-21513	assessing	_	
111-15	21514-21520	memory	_	
111-16	21521-21524	for	_	
111-17	21525-21531	subtle	_	
111-18	21532-21539	changes	_	
111-19	21540-21542	in	_	
111-20	21543-21546	the	_	
111-21	21547-21556	positions	_	
111-22	21557-21559	of	_	
111-23	21560-21567	objects	_	
111-24	21568-21570	in	_	
111-25	21571-21572	a	_	
111-26	21573-21580	complex	_	
111-27	21581-21586	scene	_	
111-28	21586-21587	.	_	

#Text=Consistent with this, fMRI results showed that healthy controls relied disproportionately on the posterior hippocampus to detect item and spatial changes.
112-1	21588-21598	Consistent	_	
112-2	21599-21603	with	_	
112-3	21604-21608	this	_	
112-4	21608-21609	,	_	
112-5	21610-21614	fMRI	_	
112-6	21615-21622	results	_	
112-7	21623-21629	showed	_	
112-8	21630-21634	that	_	
112-9	21635-21642	healthy	_	
112-10	21643-21651	controls	_	
112-11	21652-21658	relied	_	
112-12	21659-21677	disproportionately	_	
112-13	21678-21680	on	_	
112-14	21681-21684	the	_	
112-15	21685-21694	posterior	_	
112-16	21695-21706	hippocampus	_	
112-17	21707-21709	to	_	
112-18	21710-21716	detect	_	
112-19	21717-21721	item	_	
112-20	21722-21725	and	_	
112-21	21726-21733	spatial	_	
112-22	21734-21741	changes	_	
112-23	21741-21742	.	_	

#Text=The notion that the posterior hippocampus may be particularly vulnerable to the pathophysiology of schizophrenia was first suggested by post-mortem studies.
113-1	21743-21746	The	_	
113-2	21747-21753	notion	_	
113-3	21754-21758	that	_	
113-4	21759-21762	the	_	
113-5	21763-21772	posterior	_	
113-6	21773-21784	hippocampus	_	
113-7	21785-21788	may	_	
113-8	21789-21791	be	_	
113-9	21792-21804	particularly	_	
113-10	21805-21815	vulnerable	_	
113-11	21816-21818	to	_	
113-12	21819-21822	the	_	
113-13	21823-21838	pathophysiology	_	
113-14	21839-21841	of	_	
113-15	21842-21855	schizophrenia	_	
113-16	21856-21859	was	_	
113-17	21860-21865	first	_	
113-18	21866-21875	suggested	_	
113-19	21876-21878	by	_	
113-20	21879-21890	post-mortem	_	
113-21	21891-21898	studies	_	
113-22	21898-21899	.	_	

#Text=More recently, a resting state fMRI study used dynamic causal modeling (DCM) to demonstrate that connectivity from the hippocampus to inferior frontal gyrus was reduced in patients with schizophrenia and in individuals at high risk for psychosis in the posterior but not in the anterior hippocampus.
114-1	21900-21904	More	_	
114-2	21905-21913	recently	_	
114-3	21913-21914	,	_	
114-4	21915-21916	a	_	
114-5	21917-21924	resting	_	
114-6	21925-21930	state	_	
114-7	21931-21935	fMRI	_	
114-8	21936-21941	study	_	
114-9	21942-21946	used	_	
114-10	21947-21954	dynamic	_	
114-11	21955-21961	causal	_	
114-12	21962-21970	modeling	_	
114-13	21971-21972	(	_	
114-14	21972-21975	DCM	_	
114-15	21975-21976	)	_	
114-16	21977-21979	to	_	
114-17	21980-21991	demonstrate	_	
114-18	21992-21996	that	_	
114-19	21997-22009	connectivity	_	
114-20	22010-22014	from	_	
114-21	22015-22018	the	_	
114-22	22019-22030	hippocampus	_	
114-23	22031-22033	to	_	
114-24	22034-22042	inferior	_	
114-25	22043-22050	frontal	_	
114-26	22051-22056	gyrus	_	
114-27	22057-22060	was	_	
114-28	22061-22068	reduced	_	
114-29	22069-22071	in	_	
114-30	22072-22080	patients	_	
114-31	22081-22085	with	_	
114-32	22086-22099	schizophrenia	_	
114-33	22100-22103	and	_	
114-34	22104-22106	in	_	
114-35	22107-22118	individuals	_	
114-36	22119-22121	at	_	
114-37	22122-22126	high	_	
114-38	22127-22131	risk	_	
114-39	22132-22135	for	_	
114-40	22136-22145	psychosis	_	
114-41	22146-22148	in	_	
114-42	22149-22152	the	_	
114-43	22153-22162	posterior	_	
114-44	22163-22166	but	_	
114-45	22167-22170	not	_	
114-46	22171-22173	in	_	
114-47	22174-22177	the	_	
114-48	22178-22186	anterior	_	
114-49	22187-22198	hippocampus	_	
114-50	22198-22199	.	_	

#Text=Moreover, a structural MRI study demonstrated regionally specific volumetric reductions in the tail of the hippocampus that were more prominent in patients with schizophrenia than in patients with major depressive disorder.
115-1	22200-22208	Moreover	_	
115-2	22208-22209	,	_	
115-3	22210-22211	a	_	
115-4	22212-22222	structural	_	
115-5	22223-22226	MRI	_	
115-6	22227-22232	study	_	
115-7	22233-22245	demonstrated	_	
115-8	22246-22256	regionally	_	
115-9	22257-22265	specific	_	
115-10	22266-22276	volumetric	_	
115-11	22277-22287	reductions	_	
115-12	22288-22290	in	_	
115-13	22291-22294	the	_	
115-14	22295-22299	tail	_	
115-15	22300-22302	of	_	
115-16	22303-22306	the	_	
115-17	22307-22318	hippocampus	_	
115-18	22319-22323	that	_	
115-19	22324-22328	were	_	
115-20	22329-22333	more	_	
115-21	22334-22343	prominent	_	
115-22	22344-22346	in	_	
115-23	22347-22355	patients	_	
115-24	22356-22360	with	_	
115-25	22361-22374	schizophrenia	_	
115-26	22375-22379	than	_	
115-27	22380-22382	in	_	
115-28	22383-22391	patients	_	
115-29	22392-22396	with	_	
115-30	22397-22402	major	_	
115-31	22403-22413	depressive	_	
115-32	22414-22422	disorder	_	
115-33	22422-22423	.	_	

#Text=The present study provides further support to the notion of a dysfunctional posterior hippocampus in people with schizophrenia and suggests that future fMRI studies may wish to separately examine anterior and posterior portions of the hippocampus rather than treating it as a unitary structure.
116-1	22424-22427	The	_	
116-2	22428-22435	present	_	
116-3	22436-22441	study	_	
116-4	22442-22450	provides	_	
116-5	22451-22458	further	_	
116-6	22459-22466	support	_	
116-7	22467-22469	to	_	
116-8	22470-22473	the	_	
116-9	22474-22480	notion	_	
116-10	22481-22483	of	_	
116-11	22484-22485	a	_	
116-12	22486-22499	dysfunctional	_	
116-13	22500-22509	posterior	_	
116-14	22510-22521	hippocampus	_	
116-15	22522-22524	in	_	
116-16	22525-22531	people	_	
116-17	22532-22536	with	_	
116-18	22537-22550	schizophrenia	_	
116-19	22551-22554	and	_	
116-20	22555-22563	suggests	_	
116-21	22564-22568	that	_	
116-22	22569-22575	future	_	
116-23	22576-22580	fMRI	_	
116-24	22581-22588	studies	_	
116-25	22589-22592	may	_	
116-26	22593-22597	wish	_	
116-27	22598-22600	to	_	
116-28	22601-22611	separately	_	
116-29	22612-22619	examine	_	
116-30	22620-22628	anterior	_	
116-31	22629-22632	and	_	
116-32	22633-22642	posterior	_	
116-33	22643-22651	portions	_	
116-34	22652-22654	of	_	
116-35	22655-22658	the	_	
116-36	22659-22670	hippocampus	_	
116-37	22671-22677	rather	_	
116-38	22678-22682	than	_	
116-39	22683-22691	treating	_	
116-40	22692-22694	it	_	
116-41	22695-22697	as	_	
116-42	22698-22699	a	_	
116-43	22700-22707	unitary	_	
116-44	22708-22717	structure	_	
116-45	22717-22718	.	_	

#Text=An unexpected finding was that, during detection of item changes, activity in the anterior hippocampus was abnormally increased in patients with schizophrenia relative to healthy controls.
117-1	22719-22721	An	_	
117-2	22722-22732	unexpected	_	
117-3	22733-22740	finding	_	
117-4	22741-22744	was	_	
117-5	22745-22749	that	_	
117-6	22749-22750	,	_	
117-7	22751-22757	during	_	
117-8	22758-22767	detection	_	
117-9	22768-22770	of	_	
117-10	22771-22775	item	_	
117-11	22776-22783	changes	_	
117-12	22783-22784	,	_	
117-13	22785-22793	activity	_	
117-14	22794-22796	in	_	
117-15	22797-22800	the	_	
117-16	22801-22809	anterior	_	
117-17	22810-22821	hippocampus	_	
117-18	22822-22825	was	_	
117-19	22826-22836	abnormally	_	
117-20	22837-22846	increased	_	
117-21	22847-22849	in	_	
117-22	22850-22858	patients	_	
117-23	22859-22863	with	_	
117-24	22864-22877	schizophrenia	_	
117-25	22878-22886	relative	_	
117-26	22887-22889	to	_	
117-27	22890-22897	healthy	_	
117-28	22898-22906	controls	_	
117-29	22906-22907	.	_	

#Text=Although this finding was not predicted, it fits well with theories proposing that portions of the anterior hippocampus are “hyperactive” in schizophrenia.
118-1	22908-22916	Although	_	
118-2	22917-22921	this	_	
118-3	22922-22929	finding	_	
118-4	22930-22933	was	_	
118-5	22934-22937	not	_	
118-6	22938-22947	predicted	_	
118-7	22947-22948	,	_	
118-8	22949-22951	it	_	
118-9	22952-22956	fits	_	
118-10	22957-22961	well	_	
118-11	22962-22966	with	_	
118-12	22967-22975	theories	_	
118-13	22976-22985	proposing	_	
118-14	22986-22990	that	_	
118-15	22991-22999	portions	_	
118-16	23000-23002	of	_	
118-17	23003-23006	the	_	
118-18	23007-23015	anterior	_	
118-19	23016-23027	hippocampus	_	
118-20	23028-23031	are	_	
118-21	23032-23033	“	_	
118-22	23033-23044	hyperactive	_	
118-23	23044-23045	”	_	
118-24	23046-23048	in	_	
118-25	23049-23062	schizophrenia	_	
118-26	23062-23063	.	_	

#Text=According to this view, either abnormal modulation of phasic dopamine activity, or disrupted glutamatergic or GABAergic signaling may lead to hyperexcitability in the anterior hippocampus.
119-1	23064-23073	According	_	
119-2	23074-23076	to	_	
119-3	23077-23081	this	_	
119-4	23082-23086	view	_	
119-5	23086-23087	,	_	
119-6	23088-23094	either	_	
119-7	23095-23103	abnormal	_	
119-8	23104-23114	modulation	_	
119-9	23115-23117	of	_	
119-10	23118-23124	phasic	_	
119-11	23125-23133	dopamine	_	
119-12	23134-23142	activity	_	
119-13	23142-23143	,	_	
119-14	23144-23146	or	_	
119-15	23147-23156	disrupted	_	
119-16	23157-23170	glutamatergic	_	
119-17	23171-23173	or	_	
119-18	23174-23183	GABAergic	_	
119-19	23184-23193	signaling	_	
119-20	23194-23197	may	_	
119-21	23198-23202	lead	_	
119-22	23203-23205	to	_	
119-23	23206-23223	hyperexcitability	_	
119-24	23224-23226	in	_	
119-25	23227-23230	the	_	
119-26	23231-23239	anterior	_	
119-27	23240-23251	hippocampus	_	
119-28	23251-23252	.	_	

#Text=A possible explanation for patient hyperactivity in the current study is that patients may have disproportionately relied on the anterior hippocampus to successfully detect item changes.
120-1	23253-23254	A	_	
120-2	23255-23263	possible	_	
120-3	23264-23275	explanation	_	
120-4	23276-23279	for	_	
120-5	23280-23287	patient	_	
120-6	23288-23301	hyperactivity	_	
120-7	23302-23304	in	_	
120-8	23305-23308	the	_	
120-9	23309-23316	current	_	
120-10	23317-23322	study	_	
120-11	23323-23325	is	_	
120-12	23326-23330	that	_	
120-13	23331-23339	patients	_	
120-14	23340-23343	may	_	
120-15	23344-23348	have	_	
120-16	23349-23367	disproportionately	_	
120-17	23368-23374	relied	_	
120-18	23375-23377	on	_	
120-19	23378-23381	the	_	
120-20	23382-23390	anterior	_	
120-21	23391-23402	hippocampus	_	
120-22	23403-23405	to	_	
120-23	23406-23418	successfully	_	
120-24	23419-23425	detect	_	
120-25	23426-23430	item	_	
120-26	23431-23438	changes	_	
120-27	23438-23439	.	_	

#Text=If the model of is correct, patients may have been relying on a coarse-grained representation of the studied scene, whereas controls relied on a more fine-grained, detailed representation.
121-1	23440-23442	If	_	
121-2	23443-23446	the	_	
121-3	23447-23452	model	_	
121-4	23453-23455	of	_	
121-5	23456-23458	is	_	
121-6	23459-23466	correct	_	
121-7	23466-23467	,	_	
121-8	23468-23476	patients	_	
121-9	23477-23480	may	_	
121-10	23481-23485	have	_	
121-11	23486-23490	been	_	
121-12	23491-23498	relying	_	
121-13	23499-23501	on	_	
121-14	23502-23503	a	_	
121-15	23504-23518	coarse-grained	_	
121-16	23519-23533	representation	_	
121-17	23534-23536	of	_	
121-18	23537-23540	the	_	
121-19	23541-23548	studied	_	
121-20	23549-23554	scene	_	
121-21	23554-23555	,	_	
121-22	23556-23563	whereas	_	
121-23	23564-23572	controls	_	
121-24	23573-23579	relied	_	
121-25	23580-23582	on	_	
121-26	23583-23584	a	_	
121-27	23585-23589	more	_	
121-28	23590-23602	fine-grained	_	
121-29	23602-23603	,	_	
121-30	23604-23612	detailed	_	
121-31	23613-23627	representation	_	
121-32	23627-23628	.	_	

#Text=An alternative explanation is that patients may have relied upon relatively spared function in an anterior temporal memory network in order to compensate for dysfunctional posterior medial network activity.
122-1	23629-23631	An	_	
122-2	23632-23643	alternative	_	
122-3	23644-23655	explanation	_	
122-4	23656-23658	is	_	
122-5	23659-23663	that	_	
122-6	23664-23672	patients	_	
122-7	23673-23676	may	_	
122-8	23677-23681	have	_	
122-9	23682-23688	relied	_	
122-10	23689-23693	upon	_	
122-11	23694-23704	relatively	_	
122-12	23705-23711	spared	_	
122-13	23712-23720	function	_	
122-14	23721-23723	in	_	
122-15	23724-23726	an	_	
122-16	23727-23735	anterior	_	
122-17	23736-23744	temporal	_	
122-18	23745-23751	memory	_	
122-19	23752-23759	network	_	
122-20	23760-23762	in	_	
122-21	23763-23768	order	_	
122-22	23769-23771	to	_	
122-23	23772-23782	compensate	_	
122-24	23783-23786	for	_	
122-25	23787-23800	dysfunctional	_	
122-26	23801-23810	posterior	_	
122-27	23811-23817	medial	_	
122-28	23818-23825	network	_	
122-29	23826-23834	activity	_	
122-30	23834-23835	.	_	

#Text=The anterior temporal network has preferential connectivity with the anterior hippocampus, and includes the lateral entorhinal, perirhinal, and lateral orbitofrontal cortex.
123-1	23836-23839	The	_	
123-2	23840-23848	anterior	_	
123-3	23849-23857	temporal	_	
123-4	23858-23865	network	_	
123-5	23866-23869	has	_	
123-6	23870-23882	preferential	_	
123-7	23883-23895	connectivity	_	
123-8	23896-23900	with	_	
123-9	23901-23904	the	_	
123-10	23905-23913	anterior	_	
123-11	23914-23925	hippocampus	_	
123-12	23925-23926	,	_	
123-13	23927-23930	and	_	
123-14	23931-23939	includes	_	
123-15	23940-23943	the	_	
123-16	23944-23951	lateral	_	
123-17	23952-23962	entorhinal	_	
123-18	23962-23963	,	_	
123-19	23964-23974	perirhinal	_	
123-20	23974-23975	,	_	
123-21	23976-23979	and	_	
123-22	23980-23987	lateral	_	
123-23	23988-24001	orbitofrontal	_	
123-24	24002-24008	cortex	_	
123-25	24008-24009	.	_	

#Text=This anterior temporal network has been implicated in familiarity-based item recognition and semantic processes that are less severely impaired in patients with schizophrenia.
124-1	24010-24014	This	_	
124-2	24015-24023	anterior	_	
124-3	24024-24032	temporal	_	
124-4	24033-24040	network	_	
124-5	24041-24044	has	_	
124-6	24045-24049	been	_	
124-7	24050-24060	implicated	_	
124-8	24061-24063	in	_	
124-9	24064-24081	familiarity-based	_	
124-10	24082-24086	item	_	
124-11	24087-24098	recognition	_	
124-12	24099-24102	and	_	
124-13	24103-24111	semantic	_	
124-14	24112-24121	processes	_	
124-15	24122-24126	that	_	
124-16	24127-24130	are	_	
124-17	24131-24135	less	_	
124-18	24136-24144	severely	_	
124-19	24145-24153	impaired	_	
124-20	24154-24156	in	_	
124-21	24157-24165	patients	_	
124-22	24166-24170	with	_	
124-23	24171-24184	schizophrenia	_	
124-24	24184-24185	.	_	

#Text=In contrast, the posterior medial network includes the parahippocampal, retrosplenial, medial prefrontal, and posterior cingulate cortex, and shows preferential connectivity with the posterior hippocampus.
125-1	24186-24188	In	_	
125-2	24189-24197	contrast	_	
125-3	24197-24198	,	_	
125-4	24199-24202	the	_	
125-5	24203-24212	posterior	_	
125-6	24213-24219	medial	_	
125-7	24220-24227	network	_	
125-8	24228-24236	includes	_	
125-9	24237-24240	the	_	
125-10	24241-24256	parahippocampal	_	
125-11	24256-24257	,	_	
125-12	24258-24271	retrosplenial	_	
125-13	24271-24272	,	_	
125-14	24273-24279	medial	_	
125-15	24280-24290	prefrontal	_	
125-16	24290-24291	,	_	
125-17	24292-24295	and	_	
125-18	24296-24305	posterior	_	
125-19	24306-24315	cingulate	_	
125-20	24316-24322	cortex	_	
125-21	24322-24323	,	_	
125-22	24324-24327	and	_	
125-23	24328-24333	shows	_	
125-24	24334-24346	preferential	_	
125-25	24347-24359	connectivity	_	
125-26	24360-24364	with	_	
125-27	24365-24368	the	_	
125-28	24369-24378	posterior	_	
125-29	24379-24390	hippocampus	_	
125-30	24390-24391	.	_	

#Text=Activation in this posterior medial network is enhanced during recollection-based recognition and spatial memory retrieval - processes that are known to be impaired in patients with schizophrenia.
126-1	24392-24402	Activation	_	
126-2	24403-24405	in	_	
126-3	24406-24410	this	_	
126-4	24411-24420	posterior	_	
126-5	24421-24427	medial	_	
126-6	24428-24435	network	_	
126-7	24436-24438	is	_	
126-8	24439-24447	enhanced	_	
126-9	24448-24454	during	_	
126-10	24455-24473	recollection-based	_	
126-11	24474-24485	recognition	_	
126-12	24486-24489	and	_	
126-13	24490-24497	spatial	_	
126-14	24498-24504	memory	_	
126-15	24505-24514	retrieval	_	
126-16	24515-24516	-	_	
126-17	24517-24526	processes	_	
126-18	24527-24531	that	_	
126-19	24532-24535	are	_	
126-20	24536-24541	known	_	
126-21	24542-24544	to	_	
126-22	24545-24547	be	_	
126-23	24548-24556	impaired	_	
126-24	24557-24559	in	_	
126-25	24560-24568	patients	_	
126-26	24569-24573	with	_	
126-27	24574-24587	schizophrenia	_	
126-28	24587-24588	.	_	

#Text=This explanation is admittedly speculative, and whole-brain results did not reveal a pattern of regional impairments during spatial memory that could clearly be assigned to either network.
127-1	24589-24593	This	_	
127-2	24594-24605	explanation	_	
127-3	24606-24608	is	_	
127-4	24609-24619	admittedly	_	
127-5	24620-24631	speculative	_	
127-6	24631-24632	,	_	
127-7	24633-24636	and	_	
127-8	24637-24648	whole-brain	_	
127-9	24649-24656	results	_	
127-10	24657-24660	did	_	
127-11	24661-24664	not	_	
127-12	24665-24671	reveal	_	
127-13	24672-24673	a	_	
127-14	24674-24681	pattern	_	
127-15	24682-24684	of	_	
127-16	24685-24693	regional	_	
127-17	24694-24705	impairments	_	
127-18	24706-24712	during	_	
127-19	24713-24720	spatial	_	
127-20	24721-24727	memory	_	
127-21	24728-24732	that	_	
127-22	24733-24738	could	_	
127-23	24739-24746	clearly	_	
127-24	24747-24749	be	_	
127-25	24750-24758	assigned	_	
127-26	24759-24761	to	_	
127-27	24762-24768	either	_	
127-28	24769-24776	network	_	
127-29	24776-24777	.	_	

#Text=A possible way forward may be to examine resting-state functional connectivity in these anterior temporal and posterior medial networks in relation to validated measures of specific encoding and retrieval processes.
128-1	24778-24779	A	_	
128-2	24780-24788	possible	_	
128-3	24789-24792	way	_	
128-4	24793-24800	forward	_	
128-5	24801-24804	may	_	
128-6	24805-24807	be	_	
128-7	24808-24810	to	_	
128-8	24811-24818	examine	_	
128-9	24819-24832	resting-state	_	
128-10	24833-24843	functional	_	
128-11	24844-24856	connectivity	_	
128-12	24857-24859	in	_	
128-13	24860-24865	these	_	
128-14	24866-24874	anterior	_	
128-15	24875-24883	temporal	_	
128-16	24884-24887	and	_	
128-17	24888-24897	posterior	_	
128-18	24898-24904	medial	_	
128-19	24905-24913	networks	_	
128-20	24914-24916	in	_	
128-21	24917-24925	relation	_	
128-22	24926-24928	to	_	
128-23	24929-24938	validated	_	
128-24	24939-24947	measures	_	
128-25	24948-24950	of	_	
128-26	24951-24959	specific	_	
128-27	24960-24968	encoding	_	
128-28	24969-24972	and	_	
128-29	24973-24982	retrieval	_	
128-30	24983-24992	processes	_	
128-31	24992-24993	.	_	

#Text=People with schizophrenia also had memory impairments across item change and spatial change conditions.
129-1	24994-25000	People	_	
129-2	25001-25005	with	_	
129-3	25006-25019	schizophrenia	_	
129-4	25020-25024	also	_	
129-5	25025-25028	had	_	
129-6	25029-25035	memory	_	
129-7	25036-25047	impairments	_	
129-8	25048-25054	across	_	
129-9	25055-25059	item	_	
129-10	25060-25066	change	_	
129-11	25067-25070	and	_	
129-12	25071-25078	spatial	_	
129-13	25079-25085	change	_	
129-14	25086-25096	conditions	_	
129-15	25096-25097	.	_	

#Text=Although this might seem surprising, it parallels results from our previous study, which also found that patients showed a generalized deficit in detection of both item and spatial changes, but showed specific eye movement memory deficits only for spatial memory trials (see current Supplementary Materials).
130-1	25098-25106	Although	_	
130-2	25107-25111	this	_	
130-3	25112-25117	might	_	
130-4	25118-25122	seem	_	
130-5	25123-25133	surprising	_	
130-6	25133-25134	,	_	
130-7	25135-25137	it	_	
130-8	25138-25147	parallels	_	
130-9	25148-25155	results	_	
130-10	25156-25160	from	_	
130-11	25161-25164	our	_	
130-12	25165-25173	previous	_	
130-13	25174-25179	study	_	
130-14	25179-25180	,	_	
130-15	25181-25186	which	_	
130-16	25187-25191	also	_	
130-17	25192-25197	found	_	
130-18	25198-25202	that	_	
130-19	25203-25211	patients	_	
130-20	25212-25218	showed	_	
130-21	25219-25220	a	_	
130-22	25221-25232	generalized	_	
130-23	25233-25240	deficit	_	
130-24	25241-25243	in	_	
130-25	25244-25253	detection	_	
130-26	25254-25256	of	_	
130-27	25257-25261	both	_	
130-28	25262-25266	item	_	
130-29	25267-25270	and	_	
130-30	25271-25278	spatial	_	
130-31	25279-25286	changes	_	
130-32	25286-25287	,	_	
130-33	25288-25291	but	_	
130-34	25292-25298	showed	_	
130-35	25299-25307	specific	_	
130-36	25308-25311	eye	_	
130-37	25312-25320	movement	_	
130-38	25321-25327	memory	_	
130-39	25328-25336	deficits	_	
130-40	25337-25341	only	_	
130-41	25342-25345	for	_	
130-42	25346-25353	spatial	_	
130-43	25354-25360	memory	_	
130-44	25361-25367	trials	_	
130-45	25368-25369	(	_	
130-46	25369-25372	see	_	
130-47	25373-25380	current	_	
130-48	25381-25394	Supplementary	_	
130-49	25395-25404	Materials	_	
130-50	25404-25405	)	_	
130-51	25405-25406	.	_	

#Text=Participants learned each item in relation to the item's location in a complex visual scene, which provided a very strong learning context.
131-1	25407-25419	Participants	_	
131-2	25420-25427	learned	_	
131-3	25428-25432	each	_	
131-4	25433-25437	item	_	
131-5	25438-25440	in	_	
131-6	25441-25449	relation	_	
131-7	25450-25452	to	_	
131-8	25453-25456	the	_	
131-9	25457-25463	item's	_	
131-10	25464-25472	location	_	
131-11	25473-25475	in	_	
131-12	25476-25477	a	_	
131-13	25478-25485	complex	_	
131-14	25486-25492	visual	_	
131-15	25493-25498	scene	_	
131-16	25498-25499	,	_	
131-17	25500-25505	which	_	
131-18	25506-25514	provided	_	
131-19	25515-25516	a	_	
131-20	25517-25521	very	_	
131-21	25522-25528	strong	_	
131-22	25529-25537	learning	_	
131-23	25538-25545	context	_	
131-24	25545-25546	.	_	

#Text=It is well established that when items are initially associated with a strong context, recognition of the items is context dependent (see, for example,).
132-1	25547-25549	It	_	
132-2	25550-25552	is	_	
132-3	25553-25557	well	_	
132-4	25558-25569	established	_	
132-5	25570-25574	that	_	
132-6	25575-25579	when	_	
132-7	25580-25585	items	_	
132-8	25586-25589	are	_	
132-9	25590-25599	initially	_	
132-10	25600-25610	associated	_	
132-11	25611-25615	with	_	
132-12	25616-25617	a	_	
132-13	25618-25624	strong	_	
132-14	25625-25632	context	_	
132-15	25632-25633	,	_	
132-16	25634-25645	recognition	_	
132-17	25646-25648	of	_	
132-18	25649-25652	the	_	
132-19	25653-25658	items	_	
132-20	25659-25661	is	_	
132-21	25662-25669	context	_	
132-22	25670-25679	dependent	_	
132-23	25680-25681	(	_	
132-24	25681-25684	see	_	
132-25	25684-25685	,	_	
132-26	25686-25689	for	_	
132-27	25690-25697	example	_	
132-28	25697-25698	,	_	
132-29	25698-25699	)	_	
132-30	25699-25700	.	_	

#Text=Given well-known deficits in item-context binding in schizophrenia (see, ( ) for review), it is not surprising that patients showed item memory as well as spatial memory deficits.
133-1	25701-25706	Given	_	
133-2	25707-25717	well-known	_	
133-3	25718-25726	deficits	_	
133-4	25727-25729	in	_	
133-5	25730-25742	item-context	_	
133-6	25743-25750	binding	_	
133-7	25751-25753	in	_	
133-8	25754-25767	schizophrenia	_	
133-9	25768-25769	(	_	
133-10	25769-25772	see	_	
133-11	25772-25773	,	_	
133-12	25774-25775	(	_	
133-13	25776-25777	)	_	
133-14	25778-25781	for	_	
133-15	25782-25788	review	_	
133-16	25788-25789	)	_	
133-17	25789-25790	,	_	
133-18	25791-25793	it	_	
133-19	25794-25796	is	_	
133-20	25797-25800	not	_	
133-21	25801-25811	surprising	_	
133-22	25812-25816	that	_	
133-23	25817-25825	patients	_	
133-24	25826-25832	showed	_	
133-25	25833-25837	item	_	
133-26	25838-25844	memory	_	
133-27	25845-25847	as	_	
133-28	25848-25852	well	_	
133-29	25853-25855	as	_	
133-30	25856-25863	spatial	_	
133-31	25864-25870	memory	_	
133-32	25871-25879	deficits	_	
133-33	25879-25880	.	_	

#Text=To facilitate study compliance, we studied medicated and clinically stable patients with relatively mild symptoms, raising the issue of a potential medication confound.
134-1	25881-25883	To	_	
134-2	25884-25894	facilitate	_	
134-3	25895-25900	study	_	
134-4	25901-25911	compliance	_	
134-5	25911-25912	,	_	
134-6	25913-25915	we	_	
134-7	25916-25923	studied	_	
134-8	25924-25933	medicated	_	
134-9	25934-25937	and	_	
134-10	25938-25948	clinically	_	
134-11	25949-25955	stable	_	
134-12	25956-25964	patients	_	
134-13	25965-25969	with	_	
134-14	25970-25980	relatively	_	
134-15	25981-25985	mild	_	
134-16	25986-25994	symptoms	_	
134-17	25994-25995	,	_	
134-18	25996-26003	raising	_	
134-19	26004-26007	the	_	
134-20	26008-26013	issue	_	
134-21	26014-26016	of	_	
134-22	26017-26018	a	_	
134-23	26019-26028	potential	_	
134-24	26029-26039	medication	_	
134-25	26040-26048	confound	_	
134-26	26048-26049	.	_	

#Text=Our decision to study medicated patients was partially driven by the complexity of our task design, which would be difficult to successfully administer to more symptomatic individuals.
135-1	26050-26053	Our	_	
135-2	26054-26062	decision	_	
135-3	26063-26065	to	_	
135-4	26066-26071	study	_	
135-5	26072-26081	medicated	_	
135-6	26082-26090	patients	_	
135-7	26091-26094	was	_	
135-8	26095-26104	partially	_	
135-9	26105-26111	driven	_	
135-10	26112-26114	by	_	
135-11	26115-26118	the	_	
135-12	26119-26129	complexity	_	
135-13	26130-26132	of	_	
135-14	26133-26136	our	_	
135-15	26137-26141	task	_	
135-16	26142-26148	design	_	
135-17	26148-26149	,	_	
135-18	26150-26155	which	_	
135-19	26156-26161	would	_	
135-20	26162-26164	be	_	
135-21	26165-26174	difficult	_	
135-22	26175-26177	to	_	
135-23	26178-26190	successfully	_	
135-24	26191-26201	administer	_	
135-25	26202-26204	to	_	
135-26	26205-26209	more	_	
135-27	26210-26221	symptomatic	_	
135-28	26222-26233	individuals	_	
135-29	26233-26234	.	_	

#Text=Either resting-state studies, or studies with less complex designs, such as novelty detection, tend to be more successful at studying unmedicated patients.
136-1	26235-26241	Either	_	
136-2	26242-26255	resting-state	_	
136-3	26256-26263	studies	_	
136-4	26263-26264	,	_	
136-5	26265-26267	or	_	
136-6	26268-26275	studies	_	
136-7	26276-26280	with	_	
136-8	26281-26285	less	_	
136-9	26286-26293	complex	_	
136-10	26294-26301	designs	_	
136-11	26301-26302	,	_	
136-12	26303-26307	such	_	
136-13	26308-26310	as	_	
136-14	26311-26318	novelty	_	
136-15	26319-26328	detection	_	
136-16	26328-26329	,	_	
136-17	26330-26334	tend	_	
136-18	26335-26337	to	_	
136-19	26338-26340	be	_	
136-20	26341-26345	more	_	
136-21	26346-26356	successful	_	
136-22	26357-26359	at	_	
136-23	26360-26368	studying	_	
136-24	26369-26380	unmedicated	_	
136-25	26381-26389	patients	_	
136-26	26389-26390	.	_	

#Text=Examination of these memory processes with the current task paradigm in individuals who are at clinical or genetic high risk for psychosis, but are not medicated, is another approach that may help to identify any role that medication plays in this differential pattern of anterior and posterior hippocampal functioning in patients with schizophrenia.
137-1	26391-26402	Examination	_	
137-2	26403-26405	of	_	
137-3	26406-26411	these	_	
137-4	26412-26418	memory	_	
137-5	26419-26428	processes	_	
137-6	26429-26433	with	_	
137-7	26434-26437	the	_	
137-8	26438-26445	current	_	
137-9	26446-26450	task	_	
137-10	26451-26459	paradigm	_	
137-11	26460-26462	in	_	
137-12	26463-26474	individuals	_	
137-13	26475-26478	who	_	
137-14	26479-26482	are	_	
137-15	26483-26485	at	_	
137-16	26486-26494	clinical	_	
137-17	26495-26497	or	_	
137-18	26498-26505	genetic	_	
137-19	26506-26510	high	_	
137-20	26511-26515	risk	_	
137-21	26516-26519	for	_	
137-22	26520-26529	psychosis	_	
137-23	26529-26530	,	_	
137-24	26531-26534	but	_	
137-25	26535-26538	are	_	
137-26	26539-26542	not	_	
137-27	26543-26552	medicated	_	
137-28	26552-26553	,	_	
137-29	26554-26556	is	_	
137-30	26557-26564	another	_	
137-31	26565-26573	approach	_	
137-32	26574-26578	that	_	
137-33	26579-26582	may	_	
137-34	26583-26587	help	_	
137-35	26588-26590	to	_	
137-36	26591-26599	identify	_	
137-37	26600-26603	any	_	
137-38	26604-26608	role	_	
137-39	26609-26613	that	_	
137-40	26614-26624	medication	_	
137-41	26625-26630	plays	_	
137-42	26631-26633	in	_	
137-43	26634-26638	this	_	
137-44	26639-26651	differential	_	
137-45	26652-26659	pattern	_	
137-46	26660-26662	of	_	
137-47	26663-26671	anterior	_	
137-48	26672-26675	and	_	
137-49	26676-26685	posterior	_	
137-50	26686-26697	hippocampal	_	
137-51	26698-26709	functioning	_	
137-52	26710-26712	in	_	
137-53	26713-26721	patients	_	
137-54	26722-26726	with	_	
137-55	26727-26740	schizophrenia	_	
137-56	26740-26741	.	_	

#Text=Nevertheless, the observed group by condition interactions for both the anterior and posterior hippocampus are difficult to attribute to a medication confound, which might be expected to have a less regionally and functionally specific impact on hippocampal processing.
138-1	26742-26754	Nevertheless	_	
138-2	26754-26755	,	_	
138-3	26756-26759	the	_	
138-4	26760-26768	observed	_	
138-5	26769-26774	group	_	
138-6	26775-26777	by	_	
138-7	26778-26787	condition	_	
138-8	26788-26800	interactions	_	
138-9	26801-26804	for	_	
138-10	26805-26809	both	_	
138-11	26810-26813	the	_	
138-12	26814-26822	anterior	_	
138-13	26823-26826	and	_	
138-14	26827-26836	posterior	_	
138-15	26837-26848	hippocampus	_	
138-16	26849-26852	are	_	
138-17	26853-26862	difficult	_	
138-18	26863-26865	to	_	
138-19	26866-26875	attribute	_	
138-20	26876-26878	to	_	
138-21	26879-26880	a	_	
138-22	26881-26891	medication	_	
138-23	26892-26900	confound	_	
138-24	26900-26901	,	_	
138-25	26902-26907	which	_	
138-26	26908-26913	might	_	
138-27	26914-26916	be	_	
138-28	26917-26925	expected	_	
138-29	26926-26928	to	_	
138-30	26929-26933	have	_	
138-31	26934-26935	a	_	
138-32	26936-26940	less	_	
138-33	26941-26951	regionally	_	
138-34	26952-26955	and	_	
138-35	26956-26968	functionally	_	
138-36	26969-26977	specific	_	
138-37	26978-26984	impact	_	
138-38	26985-26987	on	_	
138-39	26988-26999	hippocampal	_	
138-40	27000-27010	processing	_	
138-41	27010-27011	.	_	

#Text=The current study was not designed to identify group differences in encoding-related activity (e.g., subsequent memory effects), which is a promising area for future research.
139-1	27012-27015	The	_	
139-2	27016-27023	current	_	
139-3	27024-27029	study	_	
139-4	27030-27033	was	_	
139-5	27034-27037	not	_	
139-6	27038-27046	designed	_	
139-7	27047-27049	to	_	
139-8	27050-27058	identify	_	
139-9	27059-27064	group	_	
139-10	27065-27076	differences	_	
139-11	27077-27079	in	_	
139-12	27080-27096	encoding-related	_	
139-13	27097-27105	activity	_	
139-14	27106-27107	(	_	
139-15	27107-27110	e.g	_	
139-16	27110-27111	.	_	
139-17	27111-27112	,	_	
139-18	27113-27123	subsequent	_	
139-19	27124-27130	memory	_	
139-20	27131-27138	effects	_	
139-21	27138-27139	)	_	
139-22	27139-27140	,	_	
139-23	27141-27146	which	_	
139-24	27147-27149	is	_	
139-25	27150-27151	a	_	
139-26	27152-27161	promising	_	
139-27	27162-27166	area	_	
139-28	27167-27170	for	_	
139-29	27171-27177	future	_	
139-30	27178-27186	research	_	
139-31	27186-27187	.	_	

#Text=Conclusions
#Text=In summary, there was strong evidence that patients with schizophrenia have a regionally specific impairment in posterior hippocampal activation during retrieval of fine-grained spatial information, which parallels previous findings of an absence of eye-movement memory effects for spatial but not for item information.
140-1	27188-27199	Conclusions	_	
140-2	27200-27202	In	_	
140-3	27203-27210	summary	_	
140-4	27210-27211	,	_	
140-5	27212-27217	there	_	
140-6	27218-27221	was	_	
140-7	27222-27228	strong	_	
140-8	27229-27237	evidence	_	
140-9	27238-27242	that	_	
140-10	27243-27251	patients	_	
140-11	27252-27256	with	_	
140-12	27257-27270	schizophrenia	_	
140-13	27271-27275	have	_	
140-14	27276-27277	a	_	
140-15	27278-27288	regionally	_	
140-16	27289-27297	specific	_	
140-17	27298-27308	impairment	_	
140-18	27309-27311	in	_	
140-19	27312-27321	posterior	_	
140-20	27322-27333	hippocampal	_	
140-21	27334-27344	activation	_	
140-22	27345-27351	during	_	
140-23	27352-27361	retrieval	_	
140-24	27362-27364	of	_	
140-25	27365-27377	fine-grained	_	
140-26	27378-27385	spatial	_	
140-27	27386-27397	information	_	
140-28	27397-27398	,	_	
140-29	27399-27404	which	_	
140-30	27405-27414	parallels	_	
140-31	27415-27423	previous	_	
140-32	27424-27432	findings	_	
140-33	27433-27435	of	_	
140-34	27436-27438	an	_	
140-35	27439-27446	absence	_	
140-36	27447-27449	of	_	
140-37	27450-27462	eye-movement	_	
140-38	27463-27469	memory	_	
140-39	27470-27477	effects	_	
140-40	27478-27481	for	_	
140-41	27482-27489	spatial	_	
140-42	27490-27493	but	_	
140-43	27494-27497	not	_	
140-44	27498-27501	for	_	
140-45	27502-27506	item	_	
140-46	27507-27518	information	_	
140-47	27518-27519	.	_	

#Text=Although the unexpected finding of abnormally increased anterior hippocampal activation during detection of item changes may relate to consistent evidence of anterior hippocampal hyperactivity during resting-state, this is not a fully satisfactory explanation, and more work needs to be done to integrate resting-state with task-based fMRI data to better understand the mneumonic and other functional consequences of what appears to be a differential impact of schizophrenia across the long axis of the hippocampus.
141-1	27520-27528	Although	_	
141-2	27529-27532	the	_	
141-3	27533-27543	unexpected	_	
141-4	27544-27551	finding	_	
141-5	27552-27554	of	_	
141-6	27555-27565	abnormally	_	
141-7	27566-27575	increased	_	
141-8	27576-27584	anterior	_	
141-9	27585-27596	hippocampal	_	
141-10	27597-27607	activation	_	
141-11	27608-27614	during	_	
141-12	27615-27624	detection	_	
141-13	27625-27627	of	_	
141-14	27628-27632	item	_	
141-15	27633-27640	changes	_	
141-16	27641-27644	may	_	
141-17	27645-27651	relate	_	
141-18	27652-27654	to	_	
141-19	27655-27665	consistent	_	
141-20	27666-27674	evidence	_	
141-21	27675-27677	of	_	
141-22	27678-27686	anterior	_	
141-23	27687-27698	hippocampal	_	
141-24	27699-27712	hyperactivity	_	
141-25	27713-27719	during	_	
141-26	27720-27733	resting-state	_	
141-27	27733-27734	,	_	
141-28	27735-27739	this	_	
141-29	27740-27742	is	_	
141-30	27743-27746	not	_	
141-31	27747-27748	a	_	
141-32	27749-27754	fully	_	
141-33	27755-27767	satisfactory	_	
141-34	27768-27779	explanation	_	
141-35	27779-27780	,	_	
141-36	27781-27784	and	_	
141-37	27785-27789	more	_	
141-38	27790-27794	work	_	
141-39	27795-27800	needs	_	
141-40	27801-27803	to	_	
141-41	27804-27806	be	_	
141-42	27807-27811	done	_	
141-43	27812-27814	to	_	
141-44	27815-27824	integrate	_	
141-45	27825-27838	resting-state	_	
141-46	27839-27843	with	_	
141-47	27844-27854	task-based	_	
141-48	27855-27859	fMRI	_	
141-49	27860-27864	data	_	
141-50	27865-27867	to	_	
141-51	27868-27874	better	_	
141-52	27875-27885	understand	_	
141-53	27886-27889	the	_	
141-54	27890-27899	mneumonic	_	
141-55	27900-27903	and	_	
141-56	27904-27909	other	_	
141-57	27910-27920	functional	_	
141-58	27921-27933	consequences	_	
141-59	27934-27936	of	_	
141-60	27937-27941	what	_	
141-61	27942-27949	appears	_	
141-62	27950-27952	to	_	
141-63	27953-27955	be	_	
141-64	27956-27957	a	_	
141-65	27958-27970	differential	_	
141-66	27971-27977	impact	_	
141-67	27978-27980	of	_	
141-68	27981-27994	schizophrenia	_	
141-69	27995-28001	across	_	
141-70	28002-28005	the	_	
141-71	28006-28010	long	_	
141-72	28011-28015	axis	_	
141-73	28016-28018	of	_	
141-74	28019-28022	the	_	
141-75	28023-28034	hippocampus	_	
141-76	28034-28035	.	_	

#Text=Funding sources
#Text=This research was supported by the  [grants: R01MH084895 and R01MH105411].
142-1	28036-28043	Funding	_	
142-2	28044-28051	sources	_	
142-3	28052-28056	This	_	
142-4	28057-28065	research	_	
142-5	28066-28069	was	_	
142-6	28070-28079	supported	_	
142-7	28080-28082	by	_	
142-8	28083-28086	the	_	
142-9	28088-28089	[	_	
142-10	28089-28095	grants	_	
142-11	28095-28096	:	_	
142-12	28097-28108	R01MH084895	_	
142-13	28109-28112	and	_	
142-14	28113-28124	R01MH105411	_	
142-15	28124-28125	]	_	
142-16	28125-28126	.	_	

#Text=Financial disclosures
#Text=Dr.
143-1	28127-28136	Financial	_	
143-2	28137-28148	disclosures	_	
143-3	28149-28151	Dr	_	
143-4	28151-28152	.	_	

#Text=Ragland has received research grants from the NIH and NARSAD.
144-1	28153-28160	Ragland	_	
144-2	28161-28164	has	_	
144-3	28165-28173	received	_	
144-4	28174-28182	research	_	
144-5	28183-28189	grants	_	
144-6	28190-28194	from	_	
144-7	28195-28198	the	_	
144-8	28199-28202	NIH	_	
144-9	28203-28206	and	_	
144-10	28207-28213	NARSAD	_	
144-11	28213-28214	.	_	

#Text=Mr.
145-1	28215-28217	Mr	_	
145-2	28217-28218	.	_	

#Text=Layher has no currently active grant or contract support from private or public sources.
146-1	28219-28225	Layher	_	
146-2	28226-28229	has	_	
146-3	28230-28232	no	_	
146-4	28233-28242	currently	_	
146-5	28243-28249	active	_	
146-6	28250-28255	grant	_	
146-7	28256-28258	or	_	
146-8	28259-28267	contract	_	
146-9	28268-28275	support	_	
146-10	28276-28280	from	_	
146-11	28281-28288	private	_	
146-12	28289-28291	or	_	
146-13	28292-28298	public	_	
146-14	28299-28306	sources	_	
146-15	28306-28307	.	_	

#Text=Dr.
147-1	28308-28310	Dr	_	
147-2	28310-28311	.	_	

#Text=Hannula has received research grants from the NIH and NSF.
148-1	28312-28319	Hannula	_	
148-2	28320-28323	has	_	
148-3	28324-28332	received	_	
148-4	28333-28341	research	_	
148-5	28342-28348	grants	_	
148-6	28349-28353	from	_	
148-7	28354-28357	the	_	
148-8	28358-28361	NIH	_	
148-9	28362-28365	and	_	
148-10	28366-28369	NSF	_	
148-11	28369-28370	.	_	

#Text=Dr.
149-1	28371-28373	Dr	_	
149-2	28373-28374	.	_	

#Text=Niendam has received research grants from the NIH, NARSAD, the Robert Wood Johnson Foundation, and the UC Davis Behavioral Health Center of Excellence.
150-1	28375-28382	Niendam	_	
150-2	28383-28386	has	_	
150-3	28387-28395	received	_	
150-4	28396-28404	research	_	
150-5	28405-28411	grants	_	
150-6	28412-28416	from	_	
150-7	28417-28420	the	_	
150-8	28421-28424	NIH	_	
150-9	28424-28425	,	_	
150-10	28426-28432	NARSAD	_	
150-11	28432-28433	,	_	
150-12	28434-28437	the	_	
150-13	28438-28444	Robert	_	
150-14	28445-28449	Wood	_	
150-15	28450-28457	Johnson	_	
150-16	28458-28468	Foundation	_	
150-17	28468-28469	,	_	
150-18	28470-28473	and	_	
150-19	28474-28477	the	_	
150-20	28478-28480	UC	_	
150-21	28481-28486	Davis	_	
150-22	28487-28497	Behavioral	_	
150-23	28498-28504	Health	_	
150-24	28505-28511	Center	_	
150-25	28512-28514	of	_	
150-26	28515-28525	Excellence	_	
150-27	28525-28526	.	_	

#Text=Dr.
151-1	28527-28529	Dr	_	
151-2	28529-28530	.	_	

#Text=Lesh has no currently active grant or contract support from private or public sources.
152-1	28531-28535	Lesh	_	
152-2	28536-28539	has	_	
152-3	28540-28542	no	_	
152-4	28543-28552	currently	_	
152-5	28553-28559	active	_	
152-6	28560-28565	grant	_	
152-7	28566-28568	or	_	
152-8	28569-28577	contract	_	
152-9	28578-28585	support	_	
152-10	28586-28590	from	_	
152-11	28591-28598	private	_	
152-12	28599-28601	or	_	
152-13	28602-28608	public	_	
152-14	28609-28616	sources	_	
152-15	28616-28617	.	_	

#Text=Dr.
153-1	28618-28620	Dr	_	
153-2	28620-28621	.	_	

#Text=Solomon has received research grants from the NIH and the UC Davis Behavioral Health Center of Excellence.
154-1	28622-28629	Solomon	_	
154-2	28630-28633	has	_	
154-3	28634-28642	received	_	
154-4	28643-28651	research	_	
154-5	28652-28658	grants	_	
154-6	28659-28663	from	_	
154-7	28664-28667	the	_	
154-8	28668-28671	NIH	_	
154-9	28672-28675	and	_	
154-10	28676-28679	the	_	
154-11	28680-28682	UC	_	
154-12	28683-28688	Davis	_	
154-13	28689-28699	Behavioral	_	
154-14	28700-28706	Health	_	
154-15	28707-28713	Center	_	
154-16	28714-28716	of	_	
154-17	28717-28727	Excellence	_	
154-18	28727-28728	.	_	

#Text=Dr.
155-1	28729-28731	Dr	_	
155-2	28731-28732	.	_	

#Text=Carter has received research grants from the NIMH, NIDA, and the Robert Wood Johnson Foundation.
156-1	28733-28739	Carter	_	
156-2	28740-28743	has	_	
156-3	28744-28752	received	_	
156-4	28753-28761	research	_	
156-5	28762-28768	grants	_	
156-6	28769-28773	from	_	
156-7	28774-28777	the	_	
156-8	28778-28782	NIMH	_	
156-9	28782-28783	,	_	
156-10	28784-28788	NIDA	_	
156-11	28788-28789	,	_	
156-12	28790-28793	and	_	
156-13	28794-28797	the	_	
156-14	28798-28804	Robert	_	
156-15	28805-28809	Wood	_	
156-16	28810-28817	Johnson	_	
156-17	28818-28828	Foundation	_	
156-18	28828-28829	.	_	

#Text=Dr.
157-1	28830-28832	Dr	_	
157-2	28832-28833	.	_	

#Text=Ranganath has received research grants from the NIH, the Department of Defense, and has been an external consultant for Helicon Pharmaceuticals.
158-1	28834-28843	Ranganath	_	
158-2	28844-28847	has	_	
158-3	28848-28856	received	_	
158-4	28857-28865	research	_	
158-5	28866-28872	grants	_	
158-6	28873-28877	from	_	
158-7	28878-28881	the	_	
158-8	28882-28885	NIH	_	
158-9	28885-28886	,	_	
158-10	28887-28890	the	_	
158-11	28891-28901	Department	_	
158-12	28902-28904	of	_	
158-13	28905-28912	Defense	_	
158-14	28912-28913	,	_	
158-15	28914-28917	and	_	
158-16	28918-28921	has	_	
158-17	28922-28926	been	_	
158-18	28927-28929	an	_	
158-19	28930-28938	external	_	
158-20	28939-28949	consultant	_	
158-21	28950-28953	for	_	
158-22	28954-28961	Helicon	_	
158-23	28962-28977	Pharmaceuticals	_	
158-24	28977-28978	.	_	

#Text=References
#Text=Is associative recognition more impaired than item recognition memory in schizophrenia?
159-1	28979-28989	References	_	
159-2	28990-28992	Is	_	
159-3	28993-29004	associative	_	
159-4	29005-29016	recognition	_	
159-5	29017-29021	more	_	
159-6	29022-29030	impaired	_	
159-7	29031-29035	than	_	
159-8	29036-29040	item	_	
159-9	29041-29052	recognition	_	
159-10	29053-29059	memory	_	
159-11	29060-29062	in	_	
159-12	29063-29076	schizophrenia	_	
159-13	29076-29077	?	_	

#Text=A meta-analysis
#Text=Neural correlates of memory for items and for associations: an event-related functional magnetic resonance imaging study
#Text=Regional dissociations within the hippocampus–memory and anxiety
#Text=A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
#Text=Functional integration between the posterior hippocampus and prefrontal cortex is impaired in both first episode schizophrenia and the at risk mental state
#Text=The influence of encoding strategy on episodic memory and cortical activity in schizophrenia
#Text=The anterior hippocampus supports a coarse, global environmental representation and the posterior hippocampus supports fine-grained, local environmental representations
#Text=From details to large scale: the representation of environmental positions follows a granularity gradient along the human hippocampal and entorhinal anterior-posterior axis
#Text=Are the dorsal and ventral hippocampus functionally distinct structures?
160-1	29078-29079	A	_	
160-2	29080-29093	meta-analysis	_	
160-3	29094-29100	Neural	_	
160-4	29101-29111	correlates	_	
160-5	29112-29114	of	_	
160-6	29115-29121	memory	_	
160-7	29122-29125	for	_	
160-8	29126-29131	items	_	
160-9	29132-29135	and	_	
160-10	29136-29139	for	_	
160-11	29140-29152	associations	_	
160-12	29152-29153	:	_	
160-13	29154-29156	an	_	
160-14	29157-29170	event-related	_	
160-15	29171-29181	functional	_	
160-16	29182-29190	magnetic	_	
160-17	29191-29200	resonance	_	
160-18	29201-29208	imaging	_	
160-19	29209-29214	study	_	
160-20	29215-29223	Regional	_	
160-21	29224-29237	dissociations	_	
160-22	29238-29244	within	_	
160-23	29245-29248	the	_	
160-24	29249-29267	hippocampus–memory	_	
160-25	29268-29271	and	_	
160-26	29272-29279	anxiety	_	
160-27	29280-29281	A	_	
160-28	29282-29291	reduction	_	
160-29	29292-29294	of	_	
160-30	29295-29307	nonpyramidal	_	
160-31	29308-29313	cells	_	
160-32	29314-29316	in	_	
160-33	29317-29323	sector	_	
160-34	29324-29327	CA2	_	
160-35	29328-29330	of	_	
160-36	29331-29345	schizophrenics	_	
160-37	29346-29349	and	_	
160-38	29350-29355	manic	_	
160-39	29356-29367	depressives	_	
160-40	29368-29378	Functional	_	
160-41	29379-29390	integration	_	
160-42	29391-29398	between	_	
160-43	29399-29402	the	_	
160-44	29403-29412	posterior	_	
160-45	29413-29424	hippocampus	_	
160-46	29425-29428	and	_	
160-47	29429-29439	prefrontal	_	
160-48	29440-29446	cortex	_	
160-49	29447-29449	is	_	
160-50	29450-29458	impaired	_	
160-51	29459-29461	in	_	
160-52	29462-29466	both	_	
160-53	29467-29472	first	_	
160-54	29473-29480	episode	_	
160-55	29481-29494	schizophrenia	_	
160-56	29495-29498	and	_	
160-57	29499-29502	the	_	
160-58	29503-29505	at	_	
160-59	29506-29510	risk	_	
160-60	29511-29517	mental	_	
160-61	29518-29523	state	_	
160-62	29524-29527	The	_	
160-63	29528-29537	influence	_	
160-64	29538-29540	of	_	
160-65	29541-29549	encoding	_	
160-66	29550-29558	strategy	_	
160-67	29559-29561	on	_	
160-68	29562-29570	episodic	_	
160-69	29571-29577	memory	_	
160-70	29578-29581	and	_	
160-71	29582-29590	cortical	_	
160-72	29591-29599	activity	_	
160-73	29600-29602	in	_	
160-74	29603-29616	schizophrenia	_	
160-75	29617-29620	The	_	
160-76	29621-29629	anterior	_	
160-77	29630-29641	hippocampus	_	
160-78	29642-29650	supports	_	
160-79	29651-29652	a	_	
160-80	29653-29659	coarse	_	
160-81	29659-29660	,	_	
160-82	29661-29667	global	_	
160-83	29668-29681	environmental	_	
160-84	29682-29696	representation	_	
160-85	29697-29700	and	_	
160-86	29701-29704	the	_	
160-87	29705-29714	posterior	_	
160-88	29715-29726	hippocampus	_	
160-89	29727-29735	supports	_	
160-90	29736-29748	fine-grained	_	
160-91	29748-29749	,	_	
160-92	29750-29755	local	_	
160-93	29756-29769	environmental	_	
160-94	29770-29785	representations	_	
160-95	29786-29790	From	_	
160-96	29791-29798	details	_	
160-97	29799-29801	to	_	
160-98	29802-29807	large	_	
160-99	29808-29813	scale	_	
160-100	29813-29814	:	_	
160-101	29815-29818	the	_	
160-102	29819-29833	representation	_	
160-103	29834-29836	of	_	
160-104	29837-29850	environmental	_	
160-105	29851-29860	positions	_	
160-106	29861-29868	follows	_	
160-107	29869-29870	a	_	
160-108	29871-29882	granularity	_	
160-109	29883-29891	gradient	_	
160-110	29892-29897	along	_	
160-111	29898-29901	the	_	
160-112	29902-29907	human	_	
160-113	29908-29919	hippocampal	_	
160-114	29920-29923	and	_	
160-115	29924-29934	entorhinal	_	
160-116	29935-29953	anterior-posterior	_	
160-117	29954-29958	axis	_	
160-118	29959-29962	Are	_	
160-119	29963-29966	the	_	
160-120	29967-29973	dorsal	_	
160-121	29974-29977	and	_	
160-122	29978-29985	ventral	_	
160-123	29986-29997	hippocampus	_	
160-124	29998-30010	functionally	_	
160-125	30011-30019	distinct	_	
160-126	30020-30030	structures	_	
160-127	30030-30031	?	_	

#Text=Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia
#Text=
#Text=The long and the short of it: relational memory impairments in amnesia, even at short lags.
161-1	30032-30040	Dopamine	_	
161-2	30041-30047	system	_	
161-3	30048-30061	dysregulation	_	
161-4	30062-30064	by	_	
161-5	30065-30068	the	_	
161-6	30069-30080	hippocampus	_	
161-7	30080-30081	:	_	
161-8	30082-30094	implications	_	
161-9	30095-30098	for	_	
161-10	30099-30102	the	_	
161-11	30103-30118	pathophysiology	_	
161-12	30119-30122	and	_	
161-13	30123-30132	treatment	_	
161-14	30133-30135	of	_	
161-15	30136-30149	schizophrenia	_	
161-16	30151-30154	The	_	
161-17	30155-30159	long	_	
161-18	30160-30163	and	_	
161-19	30164-30167	the	_	
161-20	30168-30173	short	_	
161-21	30174-30176	of	_	
161-22	30177-30179	it	_	
161-23	30179-30180	:	_	
161-24	30181-30191	relational	_	
161-25	30192-30198	memory	_	
161-26	30199-30210	impairments	_	
161-27	30211-30213	in	_	
161-28	30214-30221	amnesia	_	
161-29	30221-30222	,	_	
161-30	30223-30227	even	_	
161-31	30228-30230	at	_	
161-32	30231-30236	short	_	
161-33	30237-30241	lags	_	
161-34	30241-30242	.	_	

#Text=Medial temporal lobe activity predicts successful relational memory binding
#Text=Use of eye movement monitoring to examine item and relational memory in schizophrenia
#Text=Worth a glance: using eye movements to investigate the cognitive neuroscience of memory
#Text=Medial temporal lobe contributions to cued retrieval of items and contexts
#Text=GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
#Text=Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
#Text=Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity
#Text=Precise spatial coding is preserved along the longitudinal hippocampal axis
#Text=Finite scale of spatial representation in the hippocampus
#Text=Abberant hippocampal connectivity in unmedicated patients with schizophrenia and effects of antipsychotic medication: a longitudinal resting state functional MRI study
#Text=The dynamics of hippocampal activation during encoding of overlapping sequences
#Text=Associative memory encoding and recognition in schizophrenia: an event-related fMRI study
#Text=Relational memory as a possible neurocognitive marker of schizophrenia
#Text=Recollection and familiarity in schizophrenia: a quantitative review
#Text=Differential connectivity of perirhinal and parahippocampal cortices within human hippocampal subregions revealed by high-resolution functional imaging
#Text=Recollection and familiarity in schizophrenia: a quantitative review
#Text=Effects of changed semantic context on recognition memory
#Text=Category-specificity in the human medial temporal lobe cortex
#Text=Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
#Text=Hippocampal volumetrics in treatment-resistant depression and schizophrenia: the devil's in de-tail
#Text=Distributed encoding and retrieval of spatial memory in the hippocampus
#Text=fMRI studies of successful emotional memory encoding: a quantitative meta-analysis
#Text=The neural basis of relational memory deficits in schizophrenia
#Text=Long-axis specialization of the human hippocampus
#Text=Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia
#Text=Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition
#Text=Functional and neuroanatomic specificity of episodic memory dysfunction in schizophrenia: a functional magnetic resonance imaging study of the relational and item-specific encoding task
#Text=Neural mechanisms for detecting and remembering novel events
#Text=Two cortical systems for memory-guided behaviour
#Text=The cognitive neuroscience of memory function and dysfunction in schizophrenia
#Text=Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders
#Text=Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver
#Text=Event-related fMRI studies of episodic encoding and retrieval: meta-analyses using activation likelihood estimation
#Text=Event congruency enhances episodic memory encoding through semantic elaboration and relational binding
#Text=Dissociating intentional learning from relative novelty responses in the medial temporal lobe
#Text=Functional organization of the hippocampal longitudinal axis
#Text=Increased hippocampal CA1 cerebral blood volume in schizophrenia
#Text=The hippocampal formation in schizophrenia
#Text=Hippocampal novelty activations in schizophrenia: disease and medication effects
#Text=Transitive inference in schizophrenia: impairments in relational memory organization
#Text=Remember and know judgments during recognition in chronic schizophrenia
#Text=Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia
#Text=
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nicl.2016.11.017.
162-1	30243-30249	Medial	_	
162-2	30250-30258	temporal	_	
162-3	30259-30263	lobe	_	
162-4	30264-30272	activity	_	
162-5	30273-30281	predicts	_	
162-6	30282-30292	successful	_	
162-7	30293-30303	relational	_	
162-8	30304-30310	memory	_	
162-9	30311-30318	binding	_	
162-10	30319-30322	Use	_	
162-11	30323-30325	of	_	
162-12	30326-30329	eye	_	
162-13	30330-30338	movement	_	
162-14	30339-30349	monitoring	_	
162-15	30350-30352	to	_	
162-16	30353-30360	examine	_	
162-17	30361-30365	item	_	
162-18	30366-30369	and	_	
162-19	30370-30380	relational	_	
162-20	30381-30387	memory	_	
162-21	30388-30390	in	_	
162-22	30391-30404	schizophrenia	_	
162-23	30405-30410	Worth	_	
162-24	30411-30412	a	_	
162-25	30413-30419	glance	_	
162-26	30419-30420	:	_	
162-27	30421-30426	using	_	
162-28	30427-30430	eye	_	
162-29	30431-30440	movements	_	
162-30	30441-30443	to	_	
162-31	30444-30455	investigate	_	
162-32	30456-30459	the	_	
162-33	30460-30469	cognitive	_	
162-34	30470-30482	neuroscience	_	
162-35	30483-30485	of	_	
162-36	30486-30492	memory	_	
162-37	30493-30499	Medial	_	
162-38	30500-30508	temporal	_	
162-39	30509-30513	lobe	_	
162-40	30514-30527	contributions	_	
162-41	30528-30530	to	_	
162-42	30531-30535	cued	_	
162-43	30536-30545	retrieval	_	
162-44	30546-30548	of	_	
162-45	30549-30554	items	_	
162-46	30555-30558	and	_	
162-47	30559-30567	contexts	_	
162-48	30568-30577	GABAergic	_	
162-49	30578-30588	mechanisms	_	
162-50	30589-30591	of	_	
162-51	30592-30603	hippocampal	_	
162-52	30604-30617	hyperactivity	_	
162-53	30618-30620	in	_	
162-54	30621-30634	schizophrenia	_	
162-55	30635-30643	Impaired	_	
162-56	30644-30655	recruitment	_	
162-57	30656-30658	of	_	
162-58	30659-30662	the	_	
162-59	30663-30674	hippocampus	_	
162-60	30675-30681	during	_	
162-61	30682-30691	conscious	_	
162-62	30692-30704	recollection	_	
162-63	30705-30707	in	_	
162-64	30708-30721	schizophrenia	_	
162-65	30722-30730	Distinct	_	
162-66	30731-30739	cortical	_	
162-67	30740-30747	anatomy	_	
162-68	30748-30754	linked	_	
162-69	30755-30757	to	_	
162-70	30758-30768	subregions	_	
162-71	30769-30771	of	_	
162-72	30772-30775	the	_	
162-73	30776-30782	medial	_	
162-74	30783-30791	temporal	_	
162-75	30792-30796	lobe	_	
162-76	30797-30805	revealed	_	
162-77	30806-30808	by	_	
162-78	30809-30818	intrinsic	_	
162-79	30819-30829	functional	_	
162-80	30830-30842	connectivity	_	
162-81	30843-30850	Precise	_	
162-82	30851-30858	spatial	_	
162-83	30859-30865	coding	_	
162-84	30866-30868	is	_	
162-85	30869-30878	preserved	_	
162-86	30879-30884	along	_	
162-87	30885-30888	the	_	
162-88	30889-30901	longitudinal	_	
162-89	30902-30913	hippocampal	_	
162-90	30914-30918	axis	_	
162-91	30919-30925	Finite	_	
162-92	30926-30931	scale	_	
162-93	30932-30934	of	_	
162-94	30935-30942	spatial	_	
162-95	30943-30957	representation	_	
162-96	30958-30960	in	_	
162-97	30961-30964	the	_	
162-98	30965-30976	hippocampus	_	
162-99	30977-30985	Abberant	_	
162-100	30986-30997	hippocampal	_	
162-101	30998-31010	connectivity	_	
162-102	31011-31013	in	_	
162-103	31014-31025	unmedicated	_	
162-104	31026-31034	patients	_	
162-105	31035-31039	with	_	
162-106	31040-31053	schizophrenia	_	
162-107	31054-31057	and	_	
162-108	31058-31065	effects	_	
162-109	31066-31068	of	_	
162-110	31069-31082	antipsychotic	_	
162-111	31083-31093	medication	_	
162-112	31093-31094	:	_	
162-113	31095-31096	a	_	
162-114	31097-31109	longitudinal	_	
162-115	31110-31117	resting	_	
162-116	31118-31123	state	_	
162-117	31124-31134	functional	_	
162-118	31135-31138	MRI	_	
162-119	31139-31144	study	_	
162-120	31145-31148	The	_	
162-121	31149-31157	dynamics	_	
162-122	31158-31160	of	_	
162-123	31161-31172	hippocampal	_	
162-124	31173-31183	activation	_	
162-125	31184-31190	during	_	
162-126	31191-31199	encoding	_	
162-127	31200-31202	of	_	
162-128	31203-31214	overlapping	_	
162-129	31215-31224	sequences	_	
162-130	31225-31236	Associative	_	
162-131	31237-31243	memory	_	
162-132	31244-31252	encoding	_	
162-133	31253-31256	and	_	
162-134	31257-31268	recognition	_	
162-135	31269-31271	in	_	
162-136	31272-31285	schizophrenia	_	
162-137	31285-31286	:	_	
162-138	31287-31289	an	_	
162-139	31290-31303	event-related	_	
162-140	31304-31308	fMRI	_	
162-141	31309-31314	study	_	
162-142	31315-31325	Relational	_	
162-143	31326-31332	memory	_	
162-144	31333-31335	as	_	
162-145	31336-31337	a	_	
162-146	31338-31346	possible	_	
162-147	31347-31361	neurocognitive	_	
162-148	31362-31368	marker	_	
162-149	31369-31371	of	_	
162-150	31372-31385	schizophrenia	_	
162-151	31386-31398	Recollection	_	
162-152	31399-31402	and	_	
162-153	31403-31414	familiarity	_	
162-154	31415-31417	in	_	
162-155	31418-31431	schizophrenia	_	
162-156	31431-31432	:	_	
162-157	31433-31434	a	_	
162-158	31435-31447	quantitative	_	
162-159	31448-31454	review	_	
162-160	31455-31467	Differential	_	
162-161	31468-31480	connectivity	_	
162-162	31481-31483	of	_	
162-163	31484-31494	perirhinal	_	
162-164	31495-31498	and	_	
162-165	31499-31514	parahippocampal	_	
162-166	31515-31523	cortices	_	
162-167	31524-31530	within	_	
162-168	31531-31536	human	_	
162-169	31537-31548	hippocampal	_	
162-170	31549-31559	subregions	_	
162-171	31560-31568	revealed	_	
162-172	31569-31571	by	_	
162-173	31572-31587	high-resolution	_	
162-174	31588-31598	functional	_	
162-175	31599-31606	imaging	_	
162-176	31607-31619	Recollection	_	
162-177	31620-31623	and	_	
162-178	31624-31635	familiarity	_	
162-179	31636-31638	in	_	
162-180	31639-31652	schizophrenia	_	
162-181	31652-31653	:	_	
162-182	31654-31655	a	_	
162-183	31656-31668	quantitative	_	
162-184	31669-31675	review	_	
162-185	31676-31683	Effects	_	
162-186	31684-31686	of	_	
162-187	31687-31694	changed	_	
162-188	31695-31703	semantic	_	
162-189	31704-31711	context	_	
162-190	31712-31714	on	_	
162-191	31715-31726	recognition	_	
162-192	31727-31733	memory	_	
162-193	31734-31754	Category-specificity	_	
162-194	31755-31757	in	_	
162-195	31758-31761	the	_	
162-196	31762-31767	human	_	
162-197	31768-31774	medial	_	
162-198	31775-31783	temporal	_	
162-199	31784-31788	lobe	_	
162-200	31789-31795	cortex	_	
162-201	31796-31807	Hippocampal	_	
162-202	31808-31821	dysregulation	_	
162-203	31822-31824	of	_	
162-204	31825-31833	dopamine	_	
162-205	31834-31840	system	_	
162-206	31841-31849	function	_	
162-207	31850-31853	and	_	
162-208	31854-31857	the	_	
162-209	31858-31873	pathophysiology	_	
162-210	31874-31876	of	_	
162-211	31877-31890	schizophrenia	_	
162-212	31891-31902	Hippocampal	_	
162-213	31903-31914	volumetrics	_	
162-214	31915-31917	in	_	
162-215	31918-31937	treatment-resistant	_	
162-216	31938-31948	depression	_	
162-217	31949-31952	and	_	
162-218	31953-31966	schizophrenia	_	
162-219	31966-31967	:	_	
162-220	31968-31971	the	_	
162-221	31972-31979	devil's	_	
162-222	31980-31982	in	_	
162-223	31983-31990	de-tail	_	
162-224	31991-32002	Distributed	_	
162-225	32003-32011	encoding	_	
162-226	32012-32015	and	_	
162-227	32016-32025	retrieval	_	
162-228	32026-32028	of	_	
162-229	32029-32036	spatial	_	
162-230	32037-32043	memory	_	
162-231	32044-32046	in	_	
162-232	32047-32050	the	_	
162-233	32051-32062	hippocampus	_	
162-234	32063-32067	fMRI	_	
162-235	32068-32075	studies	_	
162-236	32076-32078	of	_	
162-237	32079-32089	successful	_	
162-238	32090-32099	emotional	_	
162-239	32100-32106	memory	_	
162-240	32107-32115	encoding	_	
162-241	32115-32116	:	_	
162-242	32117-32118	a	_	
162-243	32119-32131	quantitative	_	
162-244	32132-32145	meta-analysis	_	
162-245	32146-32149	The	_	
162-246	32150-32156	neural	_	
162-247	32157-32162	basis	_	
162-248	32163-32165	of	_	
162-249	32166-32176	relational	_	
162-250	32177-32183	memory	_	
162-251	32184-32192	deficits	_	
162-252	32193-32195	in	_	
162-253	32196-32209	schizophrenia	_	
162-254	32210-32219	Long-axis	_	
162-255	32220-32234	specialization	_	
162-256	32235-32237	of	_	
162-257	32238-32241	the	_	
162-258	32242-32247	human	_	
162-259	32248-32259	hippocampus	_	
162-260	32260-32273	Event-related	_	
162-261	32274-32278	fMRI	_	
162-262	32279-32281	of	_	
162-263	32282-32296	frontotemporal	_	
162-264	32297-32305	activity	_	
162-265	32306-32312	during	_	
162-266	32313-32317	word	_	
162-267	32318-32326	encoding	_	
162-268	32327-32330	and	_	
162-269	32331-32342	recognition	_	
162-270	32343-32345	in	_	
162-271	32346-32359	schizophrenia	_	
162-272	32360-32380	Levels-of-processing	_	
162-273	32381-32387	effect	_	
162-274	32388-32390	on	_	
162-275	32391-32405	frontotemporal	_	
162-276	32406-32414	function	_	
162-277	32415-32417	in	_	
162-278	32418-32431	schizophrenia	_	
162-279	32432-32438	during	_	
162-280	32439-32443	word	_	
162-281	32444-32452	encoding	_	
162-282	32453-32456	and	_	
162-283	32457-32468	recognition	_	
162-284	32469-32479	Functional	_	
162-285	32480-32483	and	_	
162-286	32484-32497	neuroanatomic	_	
162-287	32498-32509	specificity	_	
162-288	32510-32512	of	_	
162-289	32513-32521	episodic	_	
162-290	32522-32528	memory	_	
162-291	32529-32540	dysfunction	_	
162-292	32541-32543	in	_	
162-293	32544-32557	schizophrenia	_	
162-294	32557-32558	:	_	
162-295	32559-32560	a	_	
162-296	32561-32571	functional	_	
162-297	32572-32580	magnetic	_	
162-298	32581-32590	resonance	_	
162-299	32591-32598	imaging	_	
162-300	32599-32604	study	_	
162-301	32605-32607	of	_	
162-302	32608-32611	the	_	
162-303	32612-32622	relational	_	
162-304	32623-32626	and	_	
162-305	32627-32640	item-specific	_	
162-306	32641-32649	encoding	_	
162-307	32650-32654	task	_	
162-308	32655-32661	Neural	_	
162-309	32662-32672	mechanisms	_	
162-310	32673-32676	for	_	
162-311	32677-32686	detecting	_	
162-312	32687-32690	and	_	
162-313	32691-32702	remembering	_	
162-314	32703-32708	novel	_	
162-315	32709-32715	events	_	
162-316	32716-32719	Two	_	
162-317	32720-32728	cortical	_	
162-318	32729-32736	systems	_	
162-319	32737-32740	for	_	
162-320	32741-32754	memory-guided	_	
162-321	32755-32764	behaviour	_	
162-322	32765-32768	The	_	
162-323	32769-32778	cognitive	_	
162-324	32779-32791	neuroscience	_	
162-325	32792-32794	of	_	
162-326	32795-32801	memory	_	
162-327	32802-32810	function	_	
162-328	32811-32814	and	_	
162-329	32815-32826	dysfunction	_	
162-330	32827-32829	in	_	
162-331	32830-32843	schizophrenia	_	
162-332	32844-32856	Differential	_	
162-333	32857-32866	targeting	_	
162-334	32867-32869	of	_	
162-335	32870-32873	the	_	
162-336	32874-32877	CA1	_	
162-337	32878-32886	subfield	_	
162-338	32887-32889	of	_	
162-339	32890-32893	the	_	
162-340	32894-32905	hippocampal	_	
162-341	32906-32915	formation	_	
162-342	32916-32918	by	_	
162-343	32919-32932	schizophrenia	_	
162-344	32933-32936	and	_	
162-345	32937-32944	related	_	
162-346	32945-32954	psychotic	_	
162-347	32955-32964	disorders	_	
162-348	32965-32972	Imaging	_	
162-349	32973-32981	patients	_	
162-350	32982-32986	with	_	
162-351	32987-32996	psychosis	_	
162-352	32997-33000	and	_	
162-353	33001-33002	a	_	
162-354	33003-33008	mouse	_	
162-355	33009-33014	model	_	
162-356	33015-33026	establishes	_	
162-357	33027-33028	a	_	
162-358	33029-33038	spreading	_	
162-359	33039-33046	pattern	_	
162-360	33047-33049	of	_	
162-361	33050-33061	hippocampal	_	
162-362	33062-33073	dysfunction	_	
162-363	33074-33077	and	_	
162-364	33078-33088	implicates	_	
162-365	33089-33098	glutamate	_	
162-366	33099-33101	as	_	
162-367	33102-33103	a	_	
162-368	33104-33110	driver	_	
162-369	33111-33124	Event-related	_	
162-370	33125-33129	fMRI	_	
162-371	33130-33137	studies	_	
162-372	33138-33140	of	_	
162-373	33141-33149	episodic	_	
162-374	33150-33158	encoding	_	
162-375	33159-33162	and	_	
162-376	33163-33172	retrieval	_	
162-377	33172-33173	:	_	
162-378	33174-33187	meta-analyses	_	
162-379	33188-33193	using	_	
162-380	33194-33204	activation	_	
162-381	33205-33215	likelihood	_	
162-382	33216-33226	estimation	_	
162-383	33227-33232	Event	_	
162-384	33233-33243	congruency	_	
162-385	33244-33252	enhances	_	
162-386	33253-33261	episodic	_	
162-387	33262-33268	memory	_	
162-388	33269-33277	encoding	_	
162-389	33278-33285	through	_	
162-390	33286-33294	semantic	_	
162-391	33295-33306	elaboration	_	
162-392	33307-33310	and	_	
162-393	33311-33321	relational	_	
162-394	33322-33329	binding	_	
162-395	33330-33342	Dissociating	_	
162-396	33343-33354	intentional	_	
162-397	33355-33363	learning	_	
162-398	33364-33368	from	_	
162-399	33369-33377	relative	_	
162-400	33378-33385	novelty	_	
162-401	33386-33395	responses	_	
162-402	33396-33398	in	_	
162-403	33399-33402	the	_	
162-404	33403-33409	medial	_	
162-405	33410-33418	temporal	_	
162-406	33419-33423	lobe	_	
162-407	33424-33434	Functional	_	
162-408	33435-33447	organization	_	
162-409	33448-33450	of	_	
162-410	33451-33454	the	_	
162-411	33455-33466	hippocampal	_	
162-412	33467-33479	longitudinal	_	
162-413	33480-33484	axis	_	
162-414	33485-33494	Increased	_	
162-415	33495-33506	hippocampal	_	
162-416	33507-33510	CA1	_	
162-417	33511-33519	cerebral	_	
162-418	33520-33525	blood	_	
162-419	33526-33532	volume	_	
162-420	33533-33535	in	_	
162-421	33536-33549	schizophrenia	_	
162-422	33550-33553	The	_	
162-423	33554-33565	hippocampal	_	
162-424	33566-33575	formation	_	
162-425	33576-33578	in	_	
162-426	33579-33592	schizophrenia	_	
162-427	33593-33604	Hippocampal	_	
162-428	33605-33612	novelty	_	
162-429	33613-33624	activations	_	
162-430	33625-33627	in	_	
162-431	33628-33641	schizophrenia	_	
162-432	33641-33642	:	_	
162-433	33643-33650	disease	_	
162-434	33651-33654	and	_	
162-435	33655-33665	medication	_	
162-436	33666-33673	effects	_	
162-437	33674-33684	Transitive	_	
162-438	33685-33694	inference	_	
162-439	33695-33697	in	_	
162-440	33698-33711	schizophrenia	_	
162-441	33711-33712	:	_	
162-442	33713-33724	impairments	_	
162-443	33725-33727	in	_	
162-444	33728-33738	relational	_	
162-445	33739-33745	memory	_	
162-446	33746-33758	organization	_	
162-447	33759-33767	Remember	_	
162-448	33768-33771	and	_	
162-449	33772-33776	know	_	
162-450	33777-33786	judgments	_	
162-451	33787-33793	during	_	
162-452	33794-33805	recognition	_	
162-453	33806-33808	in	_	
162-454	33809-33816	chronic	_	
162-455	33817-33830	schizophrenia	_	
162-456	33831-33839	Impaired	_	
162-457	33840-33851	hippocampal	_	
162-458	33852-33863	recruitment	_	
162-459	33864-33870	during	_	
162-460	33871-33877	normal	_	
162-461	33878-33888	modulation	_	
162-462	33889-33891	of	_	
162-463	33892-33898	memory	_	
162-464	33899-33910	performance	_	
162-465	33911-33913	in	_	
162-466	33914-33927	schizophrenia	_	
162-467	33929-33942	Supplementary	_	
162-468	33943-33947	data	_	
162-469	33948-33961	Supplementary	_	
162-470	33962-33966	data	_	
162-471	33967-33969	to	_	
162-472	33970-33974	this	_	
162-473	33975-33982	article	_	
162-474	33983-33986	can	_	
162-475	33987-33989	be	_	
162-476	33990-33995	found	_	
162-477	33996-34002	online	_	
162-478	34003-34005	at	_	
162-479	34006-34010	http	_	
162-480	34010-34011	:	_	
162-481	34011-34012	/	_	
162-482	34012-34013	/	_	
162-483	34013-34023	dx.doi.org	_	
162-484	34023-34024	/	_	
162-485	34024-34031	10.1016	_	
162-486	34031-34032	/	_	
162-487	34032-34038	j.nicl	_	
162-488	34038-34050	.2016.11.017	_	
162-489	34050-34051	.	_	

#Text=Experimental methods.
163-1	34052-34064	Experimental	_	
163-2	34065-34072	methods	_	
163-3	34072-34073	.	_	

#Text=(A) During encoding, participants viewed scenes for 6 seconds while they received an auditory presentation of a question orienting them to the critical item in the scene.
164-1	34074-34075	(	_	
164-2	34075-34076	A	_	
164-3	34076-34077	)	_	
164-4	34078-34084	During	_	
164-5	34085-34093	encoding	_	
164-6	34093-34094	,	_	
164-7	34095-34107	participants	_	
164-8	34108-34114	viewed	_	
164-9	34115-34121	scenes	_	
164-10	34122-34125	for	_	
164-11	34126-34127	6	_	
164-12	34128-34135	seconds	_	
164-13	34136-34141	while	_	
164-14	34142-34146	they	_	
164-15	34147-34155	received	_	
164-16	34156-34158	an	_	
164-17	34159-34167	auditory	_	
164-18	34168-34180	presentation	_	
164-19	34181-34183	of	_	
164-20	34184-34185	a	_	
164-21	34186-34194	question	_	
164-22	34195-34204	orienting	_	
164-23	34205-34209	them	_	
164-24	34210-34212	to	_	
164-25	34213-34216	the	_	
164-26	34217-34225	critical	_	
164-27	34226-34230	item	_	
164-28	34231-34233	in	_	
164-29	34234-34237	the	_	
164-30	34238-34243	scene	_	
164-31	34243-34244	.	_	

#Text=One of two buttons were used to make a “yes/no” response.
165-1	34245-34248	One	_	
165-2	34249-34251	of	_	
165-3	34252-34255	two	_	
165-4	34256-34263	buttons	_	
165-5	34264-34268	were	_	
165-6	34269-34273	used	_	
165-7	34274-34276	to	_	
165-8	34277-34281	make	_	
165-9	34282-34283	a	_	
165-10	34284-34285	“	_	
165-11	34285-34288	yes	_	
165-12	34288-34289	/	_	
165-13	34289-34291	no	_	
165-14	34291-34292	”	_	
165-15	34293-34301	response	_	
165-16	34301-34302	.	_	

#Text=Following a variable ITI of 2-18 seconds, a visual fixation cross hair appeared for 1 second, alerting to upcoming presentation of the next scene.
166-1	34303-34312	Following	_	
166-2	34313-34314	a	_	
166-3	34315-34323	variable	_	
166-4	34324-34327	ITI	_	
166-5	34328-34330	of	_	
166-6	34331-34332	2	_	
166-7	34332-34333	-	_	
166-8	34333-34335	18	_	
166-9	34336-34343	seconds	_	
166-10	34343-34344	,	_	
166-11	34345-34346	a	_	
166-12	34347-34353	visual	_	
166-13	34354-34362	fixation	_	
166-14	34363-34368	cross	_	
166-15	34369-34373	hair	_	
166-16	34374-34382	appeared	_	
166-17	34383-34386	for	_	
166-18	34387-34388	1	_	
166-19	34389-34395	second	_	
166-20	34395-34396	,	_	
166-21	34397-34405	alerting	_	
166-22	34406-34408	to	_	
166-23	34409-34417	upcoming	_	
166-24	34418-34430	presentation	_	
166-25	34431-34433	of	_	
166-26	34434-34437	the	_	
166-27	34438-34442	next	_	
166-28	34443-34448	scene	_	
166-29	34448-34449	.	_	

#Text=This figure illustrates both a spatial and item orienting question.
167-1	34450-34454	This	_	
167-2	34455-34461	figure	_	
167-3	34462-34473	illustrates	_	
167-4	34474-34478	both	_	
167-5	34479-34480	a	_	
167-6	34481-34488	spatial	_	
167-7	34489-34492	and	_	
167-8	34493-34497	item	_	
167-9	34498-34507	orienting	_	
167-10	34508-34516	question	_	
167-11	34516-34517	.	_	

#Text=(B) During retrieval, participants viewed scenes that had not been seen before (novel), had been repeated and unchanged, had a change in either the critical item (item change) or item location (spatial change), and made a button press to indicate if scenes were changed, unchanged or novel.
168-1	34518-34519	(	_	
168-2	34519-34520	B	_	
168-3	34520-34521	)	_	
168-4	34522-34528	During	_	
168-5	34529-34538	retrieval	_	
168-6	34538-34539	,	_	
168-7	34540-34552	participants	_	
168-8	34553-34559	viewed	_	
168-9	34560-34566	scenes	_	
168-10	34567-34571	that	_	
168-11	34572-34575	had	_	
168-12	34576-34579	not	_	
168-13	34580-34584	been	_	
168-14	34585-34589	seen	_	
168-15	34590-34596	before	_	
168-16	34597-34598	(	_	
168-17	34598-34603	novel	_	
168-18	34603-34604	)	_	
168-19	34604-34605	,	_	
168-20	34606-34609	had	_	
168-21	34610-34614	been	_	
168-22	34615-34623	repeated	_	
168-23	34624-34627	and	_	
168-24	34628-34637	unchanged	_	
168-25	34637-34638	,	_	
168-26	34639-34642	had	_	
168-27	34643-34644	a	_	
168-28	34645-34651	change	_	
168-29	34652-34654	in	_	
168-30	34655-34661	either	_	
168-31	34662-34665	the	_	
168-32	34666-34674	critical	_	
168-33	34675-34679	item	_	
168-34	34680-34681	(	_	
168-35	34681-34685	item	_	
168-36	34686-34692	change	_	
168-37	34692-34693	)	_	
168-38	34694-34696	or	_	
168-39	34697-34701	item	_	
168-40	34702-34710	location	_	
168-41	34711-34712	(	_	
168-42	34712-34719	spatial	_	
168-43	34720-34726	change	_	
168-44	34726-34727	)	_	
168-45	34727-34728	,	_	
168-46	34729-34732	and	_	
168-47	34733-34737	made	_	
168-48	34738-34739	a	_	
168-49	34740-34746	button	_	
168-50	34747-34752	press	_	
168-51	34753-34755	to	_	
168-52	34756-34764	indicate	_	
168-53	34765-34767	if	_	
168-54	34768-34774	scenes	_	
168-55	34775-34779	were	_	
168-56	34780-34787	changed	_	
168-57	34787-34788	,	_	
168-58	34789-34798	unchanged	_	
168-59	34799-34801	or	_	
168-60	34802-34807	novel	_	
168-61	34807-34808	.	_	

#Text=Presentation timing was identical to the encoding condition.
169-1	34809-34821	Presentation	_	
169-2	34822-34828	timing	_	
169-3	34829-34832	was	_	
169-4	34833-34842	identical	_	
169-5	34843-34845	to	_	
169-6	34846-34849	the	_	
169-7	34850-34858	encoding	_	
169-8	34859-34868	condition	_	
169-9	34868-34869	.	_	

#Text=Fig. 1
#Text=Parameter estimates (Beta values) illustrating group differences (controls versus patients) on bilateral fMRI activation during correct detection of item changes (solid lines) and spatial changes (dotted lines) for regions of interest in the anterior hippocampus and posterior hippocampus.
170-1	34870-34873	Fig	_	
170-2	34873-34874	.	_	
170-3	34875-34876	1	_	
170-4	34877-34886	Parameter	_	
170-5	34887-34896	estimates	_	
170-6	34897-34898	(	_	
170-7	34898-34902	Beta	_	
170-8	34903-34909	values	_	
170-9	34909-34910	)	_	
170-10	34911-34923	illustrating	_	
170-11	34924-34929	group	_	
170-12	34930-34941	differences	_	
170-13	34942-34943	(	_	
170-14	34943-34951	controls	_	
170-15	34952-34958	versus	_	
170-16	34959-34967	patients	_	
170-17	34967-34968	)	_	
170-18	34969-34971	on	_	
170-19	34972-34981	bilateral	_	
170-20	34982-34986	fMRI	_	
170-21	34987-34997	activation	_	
170-22	34998-35004	during	_	
170-23	35005-35012	correct	_	
170-24	35013-35022	detection	_	
170-25	35023-35025	of	_	
170-26	35026-35030	item	_	
170-27	35031-35038	changes	_	
170-28	35039-35040	(	_	
170-29	35040-35045	solid	_	
170-30	35046-35051	lines	_	
170-31	35051-35052	)	_	
170-32	35053-35056	and	_	
170-33	35057-35064	spatial	_	
170-34	35065-35072	changes	_	
170-35	35073-35074	(	_	
170-36	35074-35080	dotted	_	
170-37	35081-35086	lines	_	
170-38	35086-35087	)	_	
170-39	35088-35091	for	_	
170-40	35092-35099	regions	_	
170-41	35100-35102	of	_	
170-42	35103-35111	interest	_	
170-43	35112-35114	in	_	
170-44	35115-35118	the	_	
170-45	35119-35127	anterior	_	
170-46	35128-35139	hippocampus	_	
170-47	35140-35143	and	_	
170-48	35144-35153	posterior	_	
170-49	35154-35165	hippocampus	_	
170-50	35165-35166	.	_	

#Text=Statistical analyses revealed significant group by condition interactions for the anterior hippocampus (greater activation for patients than controls for item but not spatial memory), and posterior hippocampus (greater activation for controls than for patients for spatial but not item).
171-1	35167-35178	Statistical	_	
171-2	35179-35187	analyses	_	
171-3	35188-35196	revealed	_	
171-4	35197-35208	significant	_	
171-5	35209-35214	group	_	
171-6	35215-35217	by	_	
171-7	35218-35227	condition	_	
171-8	35228-35240	interactions	_	
171-9	35241-35244	for	_	
171-10	35245-35248	the	_	
171-11	35249-35257	anterior	_	
171-12	35258-35269	hippocampus	_	
171-13	35270-35271	(	_	
171-14	35271-35278	greater	_	
171-15	35279-35289	activation	_	
171-16	35290-35293	for	_	
171-17	35294-35302	patients	_	
171-18	35303-35307	than	_	
171-19	35308-35316	controls	_	
171-20	35317-35320	for	_	
171-21	35321-35325	item	_	
171-22	35326-35329	but	_	
171-23	35330-35333	not	_	
171-24	35334-35341	spatial	_	
171-25	35342-35348	memory	_	
171-26	35348-35349	)	_	
171-27	35349-35350	,	_	
171-28	35351-35354	and	_	
171-29	35355-35364	posterior	_	
171-30	35365-35376	hippocampus	_	
171-31	35377-35378	(	_	
171-32	35378-35385	greater	_	
171-33	35386-35396	activation	_	
171-34	35397-35400	for	_	
171-35	35401-35409	controls	_	
171-36	35410-35414	than	_	
171-37	35415-35418	for	_	
171-38	35419-35427	patients	_	
171-39	35428-35431	for	_	
171-40	35432-35439	spatial	_	
171-41	35440-35443	but	_	
171-42	35444-35447	not	_	
171-43	35448-35452	item	_	
171-44	35452-35453	)	_	
171-45	35453-35454	.	_	

#Text=Fig. 2
#Text=Surface rendering of greater whole brain activation in healthy controls versus patients with schizophrenia during correct responses to spatial change trials minus unchanged trials.
172-1	35455-35458	Fig	_	
172-2	35458-35459	.	_	
172-3	35460-35461	2	_	
172-4	35462-35469	Surface	_	
172-5	35470-35479	rendering	_	
172-6	35480-35482	of	_	
172-7	35483-35490	greater	_	
172-8	35491-35496	whole	_	
172-9	35497-35502	brain	_	
172-10	35503-35513	activation	_	
172-11	35514-35516	in	_	
172-12	35517-35524	healthy	_	
172-13	35525-35533	controls	_	
172-14	35534-35540	versus	_	
172-15	35541-35549	patients	_	
172-16	35550-35554	with	_	
172-17	35555-35568	schizophrenia	_	
172-18	35569-35575	during	_	
172-19	35576-35583	correct	_	
172-20	35584-35593	responses	_	
172-21	35594-35596	to	_	
172-22	35597-35604	spatial	_	
172-23	35605-35611	change	_	
172-24	35612-35618	trials	_	
172-25	35619-35624	minus	_	
172-26	35625-35634	unchanged	_	
172-27	35635-35641	trials	_	
172-28	35641-35642	.	_	

#Text=Top row illustrates lateral, and bottom row illustrates medial surface (left hemisphere on left, right hemisphere on right).
173-1	35643-35646	Top	_	
173-2	35647-35650	row	_	
173-3	35651-35662	illustrates	_	
173-4	35663-35670	lateral	_	
173-5	35670-35671	,	_	
173-6	35672-35675	and	_	
173-7	35676-35682	bottom	_	
173-8	35683-35686	row	_	
173-9	35687-35698	illustrates	_	
173-10	35699-35705	medial	_	
173-11	35706-35713	surface	_	
173-12	35714-35715	(	_	
173-13	35715-35719	left	_	
173-14	35720-35730	hemisphere	_	
173-15	35731-35733	on	_	
173-16	35734-35738	left	_	
173-17	35738-35739	,	_	
173-18	35740-35745	right	_	
173-19	35746-35756	hemisphere	_	
173-20	35757-35759	on	_	
173-21	35760-35765	right	_	
173-22	35765-35766	)	_	
173-23	35766-35767	.	_	

#Text=Hotter colors reflect larger group differences in fronto-parietal and striatal activation (range, z = 2.3–5.0).
174-1	35768-35774	Hotter	_	
174-2	35775-35781	colors	_	
174-3	35782-35789	reflect	_	
174-4	35790-35796	larger	_	
174-5	35797-35802	group	_	
174-6	35803-35814	differences	_	
174-7	35815-35817	in	_	
174-8	35818-35833	fronto-parietal	_	
174-9	35834-35837	and	_	
174-10	35838-35846	striatal	_	
174-11	35847-35857	activation	_	
174-12	35858-35859	(	_	
174-13	35859-35864	range	_	
174-14	35864-35865	,	_	
174-15	35866-35867	z	_	
174-16	35867-35868	 	_	
174-17	35868-35869	=	_	
174-18	35869-35870	 	_	
174-19	35870-35873	2.3	_	
174-20	35873-35874	–	_	
174-21	35874-35877	5.0	_	
174-22	35877-35878	)	_	
174-23	35878-35879	.	_	

#Text=Anatomical labels, Montreal Neurological Institute coordinates, and z-values for significant clusters of within and between groups effects can be found in Table 1 (Supplementary Materials).
175-1	35880-35890	Anatomical	_	
175-2	35891-35897	labels	_	
175-3	35897-35898	,	_	
175-4	35899-35907	Montreal	_	
175-5	35908-35920	Neurological	_	
175-6	35921-35930	Institute	_	
175-7	35931-35942	coordinates	_	
175-8	35942-35943	,	_	
175-9	35944-35947	and	_	
175-10	35948-35956	z-values	_	
175-11	35957-35960	for	_	
175-12	35961-35972	significant	_	
175-13	35973-35981	clusters	_	
175-14	35982-35984	of	_	
175-15	35985-35991	within	_	
175-16	35992-35995	and	_	
175-17	35996-36003	between	_	
175-18	36004-36010	groups	_	
175-19	36011-36018	effects	_	
175-20	36019-36022	can	_	
175-21	36023-36025	be	_	
175-22	36026-36031	found	_	
175-23	36032-36034	in	_	
175-24	36035-36040	Table	_	
175-25	36041-36042	1	_	
175-26	36043-36044	(	_	
175-27	36044-36057	Supplementary	_	
175-28	36058-36067	Materials	_	
175-29	36067-36068	)	_	
175-30	36068-36069	.	_	

#Text=Fig. 3
#Text=Demographic characteristics of research participants.
176-1	36070-36073	Fig	_	
176-2	36073-36074	.	_	
176-3	36075-36076	3	_	
176-4	36077-36088	Demographic	_	
176-5	36089-36104	characteristics	_	
176-6	36105-36107	of	_	
176-7	36108-36116	research	_	
176-8	36117-36129	participants	_	
176-9	36129-36130	.	_	

#Text=Table 1\t \t
#Text=\tHealthy control group (n = 26)\tPatients with schizophrenia (n = 24)\t\t \tMean\tSD\tMean\tSD\tp-Value\t \tAge (years)\t23.1\t3.5\t25.2\t4.2\tns\t \tGender (% male)\t4 F, 22 M\t6 F, 18 M\tns\t \tHandedness\t1 left\t2 left\tns\t \tEducation (years)\t14.8\t1.4\t13.1\t1.9\t< 0.1\t \tParental education (years)\t15.6\t2.9\t14.8\t3.4\tns\t \tBPRS (total)\t\t\t42.7\t13.3\t\t \t
#Text=Note: SANS = Scale for the Assessment of Negative Symptoms; SAPS = Scale for the Assessment of Positive Symptoms; BPRS = Brief Psychiatric Rating Scale; SD = standard deviation; ns = no significant group difference at p < 0.05, two-tailed.
177-1	36131-36136	Table	_	
177-2	36137-36138	1	_	
177-3	36143-36150	Healthy	_	
177-4	36151-36158	control	_	
177-5	36159-36164	group	_	
177-6	36165-36166	(	_	
177-7	36166-36167	n	_	
177-8	36167-36168	 	_	
177-9	36168-36169	=	_	
177-10	36169-36170	 	_	
177-11	36170-36172	26	_	
177-12	36172-36173	)	_	
177-13	36174-36182	Patients	_	
177-14	36183-36187	with	_	
177-15	36188-36201	schizophrenia	_	
177-16	36202-36203	(	_	
177-17	36203-36204	n	_	
177-18	36204-36205	 	_	
177-19	36205-36206	=	_	
177-20	36206-36207	 	_	
177-21	36207-36209	24	_	
177-22	36209-36210	)	_	
177-23	36214-36218	Mean	_	
177-24	36219-36221	SD	_	
177-25	36222-36226	Mean	_	
177-26	36227-36229	SD	_	
177-27	36230-36237	p-Value	_	
177-28	36240-36243	Age	_	
177-29	36244-36245	(	_	
177-30	36245-36250	years	_	
177-31	36250-36251	)	_	
177-32	36252-36256	23.1	_	
177-33	36257-36260	3.5	_	
177-34	36261-36265	25.2	_	
177-35	36266-36269	4.2	_	
177-36	36270-36272	ns	_	
177-37	36275-36281	Gender	_	
177-38	36282-36283	(	_	
177-39	36283-36284	%	_	
177-40	36285-36289	male	_	
177-41	36289-36290	)	_	
177-42	36291-36292	4	_	
177-43	36293-36294	F	_	
177-44	36294-36295	,	_	
177-45	36296-36298	22	_	
177-46	36299-36300	M	_	
177-47	36301-36302	6	_	
177-48	36303-36304	F	_	
177-49	36304-36305	,	_	
177-50	36306-36308	18	_	
177-51	36309-36310	M	_	
177-52	36311-36313	ns	_	
177-53	36316-36326	Handedness	_	
177-54	36327-36328	1	_	
177-55	36329-36333	left	_	
177-56	36334-36335	2	_	
177-57	36336-36340	left	_	
177-58	36341-36343	ns	_	
177-59	36346-36355	Education	_	
177-60	36356-36357	(	_	
177-61	36357-36362	years	_	
177-62	36362-36363	)	_	
177-63	36364-36368	14.8	_	
177-64	36369-36372	1.4	_	
177-65	36373-36377	13.1	_	
177-66	36378-36381	1.9	_	
177-67	36382-36383	<	_	
177-68	36383-36384	 	_	
177-69	36384-36387	0.1	_	
177-70	36390-36398	Parental	_	
177-71	36399-36408	education	_	
177-72	36409-36410	(	_	
177-73	36410-36415	years	_	
177-74	36415-36416	)	_	
177-75	36417-36421	15.6	_	
177-76	36422-36425	2.9	_	
177-77	36426-36430	14.8	_	
177-78	36431-36434	3.4	_	
177-79	36435-36437	ns	_	
177-80	36440-36444	BPRS	_	
177-81	36445-36446	(	_	
177-82	36446-36451	total	_	
177-83	36451-36452	)	_	
177-84	36455-36459	42.7	_	
177-85	36460-36464	13.3	_	
177-86	36469-36473	Note	_	
177-87	36473-36474	:	_	
177-88	36475-36479	SANS	_	
177-89	36479-36480	 	_	
177-90	36480-36481	=	_	
177-91	36481-36482	 	_	
177-92	36482-36487	Scale	_	
177-93	36488-36491	for	_	
177-94	36492-36495	the	_	
177-95	36496-36506	Assessment	_	
177-96	36507-36509	of	_	
177-97	36510-36518	Negative	_	
177-98	36519-36527	Symptoms	_	
177-99	36527-36528	;	_	
177-100	36529-36533	SAPS	_	
177-101	36533-36534	 	_	
177-102	36534-36535	=	_	
177-103	36535-36536	 	_	
177-104	36536-36541	Scale	_	
177-105	36542-36545	for	_	
177-106	36546-36549	the	_	
177-107	36550-36560	Assessment	_	
177-108	36561-36563	of	_	
177-109	36564-36572	Positive	_	
177-110	36573-36581	Symptoms	_	
177-111	36581-36582	;	_	
177-112	36583-36587	BPRS	_	
177-113	36587-36588	 	_	
177-114	36588-36589	=	_	
177-115	36589-36590	 	_	
177-116	36590-36595	Brief	_	
177-117	36596-36607	Psychiatric	_	
177-118	36608-36614	Rating	_	
177-119	36615-36620	Scale	_	
177-120	36620-36621	;	_	
177-121	36622-36624	SD	_	
177-122	36624-36625	 	_	
177-123	36625-36626	=	_	
177-124	36626-36627	 	_	
177-125	36627-36635	standard	_	
177-126	36636-36645	deviation	_	
177-127	36645-36646	;	_	
177-128	36647-36649	ns	_	
177-129	36649-36650	 	_	
177-130	36650-36651	=	_	
177-131	36651-36652	 	_	
177-132	36652-36654	no	_	
177-133	36655-36666	significant	_	
177-134	36667-36672	group	_	
177-135	36673-36683	difference	_	
177-136	36684-36686	at	_	
177-137	36687-36688	p	_	
177-138	36688-36689	 	_	
177-139	36689-36690	<	_	
177-140	36690-36691	 	_	
177-141	36691-36695	0.05	_	
177-142	36695-36696	,	_	
177-143	36697-36707	two-tailed	_	
177-144	36707-36708	.	_	
